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ABSTRACT 
 
Cerebral gliomas of World Health Organization (WHO) grade II and III represent a major 
challenge in terms of histological classification and clinical management. Here, we asked 
whether large-scale genomic and transcriptomic profiling improves the definition of 
prognostically distinct entities. We performed microarray-based genome- and transcriptome-
wide analyses of primary tumor samples from a prospective German Glioma Network cohort 
of 137 patients with cerebral gliomas, including 61 WHO grade II and 76 WHO grade III 
tumors. Integrative bioinformatic analyses were employed to define molecular subgroups, 
which were then related to histology, molecular biomarkers, including isocitrate 
dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q co-deletion and telomerase reverse 
transcriptase (TERT) promoter mutations, and patient outcome. Genomic profiling identified 
five distinct glioma groups, including three IDH1/2 mutant and two IDH1/2 wild-type groups. 
Expression profiling revealed evidence for eight transcriptionally different groups (five 
IDH1/2 mutant, three IDH1/2 wild-type), which were only partially linked to the genomic 
groups. Correlation of DNA-based molecular stratification with clinical outcome allowed to 
define three major prognostic groups with characteristic genomic aberrations. The best 
prognosis was found in patients with IDH1/2 mutant and 1p/19q co-deleted tumors. Patients 
with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, including gain on 
chromosome arm 7q (+7q), loss on chromosome arm 10q (-10q), TERT promoter mutation 
and oncogene amplification, displayed the worst outcome. Intermediate survival was seen in 
patients with IDH1/2 mutant, but 1p/19q intact, mostly astrocytic gliomas, and in patients 
with IDH1/2 wild-type gliomas lacking the +7q/-10q genotype and TERT promoter mutation. 
This molecular subgrouping stratified patients into prognostically distinct groups better than 
histological classification. Addition of gene expression data to this genomic classifier did not 
further improve prognostic stratification. In summary, DNA-based molecular profiling of 
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WHO grade II and III gliomas distinguishes biologically distinct tumor groups and provides 
prognostically relevant information beyond histological classification as well as IDH1/2 
mutation and 1p/19q co-deletion status. 
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INTRODUCTION 
 
The World Health Organization (WHO) classification of tumors of the central nervous system 
[22] separates cerebral gliomas into distinct disease entities based on histological criteria. In 
addition to tumor typing, a malignancy grade ranging from WHO grade I to IV is allocated to 
each tumor considering morphological features of anaplasia, such as mitotic activity, 
microvascular proliferation and necrosis. This serves the overall goal of providing clinicians 
with information on the assumed natural disease course and strongly impacts clinical decision 
making today. In clinical practice, histopathological classification is greatly aided by 
immunohistochemical markers, and, more recently, by an increasing set of molecular 
markers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, co-deletion of 
chromosome arms 1p and 19q, O6-methylguanine DNA-methyltransferase (MGMT) promoter 
methylation, and others [35].  
Combined classification approaches have resulted in a satisfactory segregation of WHO grade 
I pilocytic astrocytoma as a distinct entity characterized by a benign clinical course and 
almost universally driven by mitogen-activated protein kinase (MAPK) pathway activation, 
most commonly caused by fusion of the v-raf murine sarcoma viral oncogene homolog B1 
(BRAF) proto-oncogene to other genes or activating BRAF point mutations [16]. On the other 
end of the glial tumor spectrum, primary glioblastoma has been delineated as a distinct entity 
of highly malignant tumors characterized by the absence of IDH1/2 mutation, gains on 
chromosome 7 and losses on chromosome arm 9p and chromosome 10, frequent mutations in 
the phosphatase and tensin homolog on chromosome 10 (PTEN) gene and the human 
telomerase (TERT) promoter, as well as activation of receptor tyrosine kinase pathways, in 
particular the epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor pathways [17, 25].  
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In contrast, the histologically defined groups of astrocytic, oligodendroglial and 
oligoastrocytic (mixed) gliomas of WHO grades II and III remain a major challenge in 
various ways: (i) there is poor interobserver agreement when diagnoses and grading are made 
by histological criteria alone [30], in particular concerning the classification of 
oligoastrocytomas [10], (ii) the clinical course is highly variable, and (iii) the clinical 
management remains poorly standardized [1, 35]. Current molecular marker-based 
approaches explore the validity of a three-tiered approach delineating (i) IDH1/2-mutant 
tumors with 1p/19q co-deletion which often carry mutations in the Drosophila homolog of 
capicua (CIC) gene as well as the TERT promoter and predominantly include oligodendroglial 
tumors, (ii) IDH1/2 mutant tumors without 1p/19q co-deletion which often carry tumor 
protein p53 (TP53) as well as ATP-dependent X-linked helicase (ATRX) gene mutations and 
predominantly include astrocytic tumors, and (iii) IDH1/2 wild-type tumors that remain 
poorly characterized in terms of other molecular alterations [15, 17, 38]. In addition, recent 
data from exome sequencing of anaplastic astrocytomas suggested a distinct mutation profile 
from primary glioblastomas, including frequent mutations in Notch pathway genes [18]. 
In the present study, we sought to determine whether a molecular profiling approach for 
genomic copy number and mRNA expression changes might help to overcome some of the 
limitations of the current histology-based diagnostic approaches to these tumors and to 
provide better stratification for future clinical trials. Therefore, we performed high-resolution 
array-based comparative genomic hybridization (array-CGH) analyses and Affymetrix gene 
chip expression profiling on 137 cerebral gliomas of WHO grade II or III from patients of the 
German Glioma Network (GGN) with prospectively collected clinical follow-up data. We 
found that molecular profiling distinguishes distinct subtypes among these gliomas that carry 
prognostically relevant information beyond histological classification, grading as well as 
IDH1/2 mutation and 1p/19q co-deletion. 
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PATIENTS AND METHODS 
 
Patients and tumors 
The GGN is a prospective, non-interventional cohort study involving eight clinical centers at 
University Hospitals in Germany (www.gliomnetzwerk.de), and was supported by the 
German Cancer Aid from 2004 to 2012. All patients gave written informed consent for 
participation in the GGN and its translational research projects. For this study, we analyzed 
tumors of 137 patients with WHO grade II or III gliomas by array-CGH analysis, Affymetrix 
chip-based gene expression profiling and candidate gene analyses (Table 1). All tumors were 
subjected to central pathology review (T.P.) and classified according to the WHO 
classification of tumors of the central nervous system [22]. For comparison of molecular 
profiles and prognostic outcome determined for the poor prognosis group of patients in this 
study (group V, see below), we additionally used published molecular and clinical data from 
two previous GGN studies on glioblastoma [26, 34].  
 
Nucleic acid extraction, mutation and promoter methylation analyses 
DNA and RNA were extracted by ultracentrifugation from deep-frozen tumor samples [14]. 
Tumor cell content was histologically estimated as 80% or more in most samples except for 
individual cases with lower tumor cell content but still detectable copy number aberrations by 
array-CGH analysis. High quality of extracted DNA was assured by spectrophotometric 
analysis and agarose gel electrophoresis. RNA quality was determined on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only samples showing a RNA integrity 
number of 7 or more were used for microarray analyses. Mutational analyses of the IDH1, 
IDH2, TERT, BRAF and H3F3A genes were carried out by Sanger sequencing or 
pyrosequencing [9, 12, 19]. The MGMT promoter methylation status was determined by 
methylation-specific PCR [8]. 
 - 7 - 
Weller et al. Molecular profiling of cerebral gliomas 
Array-based comparative genomic hybridization (array-CGH) 
Array-CGH was performed using genomic DNA microarrays with 10,000 large insert clones 
allowing for an average resolution of better than 0.5 Mb. Array assembly, probe labeling, 
array hybridization and scanning were carried out essentially as reported elsewhere [43]. To 
identify amplification events, genomic profiles were generated for each tumor and 
amplifications scored if log2 test/reference ratios were > 1. All other analyses of array-CGH 
data were done using aCGHPipeline [20]. 
 
Affymetrix gene chip analyses 
Gene expression profiles were determined with Affymetrix Gene Chip® Human Genome 
U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Sample preparation was done with 2.5 
µg total tumor RNA using the One Cycle Target Labelling and Controls kit (Affymetrix) [26]. 
Hybridization and scanning of the chips were performed at the Center for Biological and 
Medical Research at Heinrich Heine University Düsseldorf.  
 
Statistical analysis 
Array-CGH data were evaluated as reported before using aCGHPipeline [21]. Gene 
expression data were analyzed after reduction to metagenes using self-organizing map (SOM) 
machine learning [41]. As a result, each tumor tissue is characterized by the expression values 
of 1,600 metagenes that are visualized as expression landscape by color-coding. Metagene-
based clustering using either hierarchical or maximum spanning graph-partitionating methods, 
visualization and downstream analysis of expression data were performed with the program 
OpoSOM after hook calibration of the raw data, quantile normalization and centralization in 
log10-scale [13, 26]. In addition, pairwise testing between groups of samples was carried out 
by regularized t-testing as implemented in OpoSOM [42]. Samples were classified separately 
based either on array-CGH (five groups I to V) or on mRNA expression (eight groups 1 – 8) 
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data as described in the Results section. In addition, both classifications were combined by 
taking the intersections of groups I and 7 and of groups V and 1 to obtain the “integrated 
molecular groups” A and C, respectively. Samples not matching criteria for either groups A or 
C were assigned to group B. 
Progression-free survival (PFS) was calculated from the day of first surgery until tumor 
progression, death, or end of follow-up. Overall survival (OS) was calculated from the day of 
first surgery until death or end of follow-up. Logrank test was used to analyze survival data. 
When more than two groups were compared, we tested for the equality of groups regarding 
PFS or OS and present global p-values indicating that at least two groups were different. Cox 
regression models were built to assess the association of clinical parameters and molecular 
groups defined by array-CGH and expression profiling with OS. The statistic deviance (minus 
twice the logarithm of the maximized likelihood) was used to measure the model fit. All 
statistical analyses were performed with the IBM SPSS Statistics (version 20.0.0) software. 
 
 
RESULTS 
 
Patient characteristics and outcome 
Table 1 summarizes clinical findings and molecular genetic tumor characteristics. Individual 
patient data are provided in Supplementary Table 1. Clinical data, molecular marker 
characteristics, and therapeutic measures over the course of disease until the last follow-up, 
broken down by histology, are summarized in Supplementary Table 2. The median follow-
up was 71.1 months; 92 (67.2%) patients have experienced a progression-free survival (PFS) 
event, 47 (34.3%) patients have died. Histological grading was not associated with PFS, but 
there was a trend towards longer OS with WHO grade II as compared to WHO grade III 
tumors (Supplementary Figure 1A). Astrocytic gliomas were associated with inferior PFS, but 
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not OS, although there were few OS events (Supplementary Figure 1B) (Supplementary Table 
2). WHO grade was prognostic by trend also within histological entities (Supplementary Figs. 
1C,D). IDH1/2 mutation and 1p/19q co-deletion were both associated with prolonged PFS 
and overall survival (OS) (Supplementary Table 3, Supplementary Figs. 1E-F). Among 
IDH1/2 mutant tumors, 1p/19q co-deletion was associated with improved outcome 
(Supplementary Fig. 1G). TERT promoter mutation was linked to outcome neither in the 
entire cohort of 137 patients (Supplementary Fig. 1H) nor in the subgroup of 112 patients 
with IDH1/2 mutant tumors (Supplementary Fig. 1I). The lack of significance for the latter 
comparison likely reflects the low number of events. In oligodendroglial and oligoastrocytic 
gliomas, TERT promoter mutation was more common in cases with than without 1p/19q co-
deletion (27/30 versus 2/19, p<0.001). In patients with 1p/19q non-deleted anaplastic gliomas 
of WHO grade III (n=51), TERT promoter mutation was associated with less favorable 
outcome (median OS: 2.4 versus 8.8 years, p=0.048) (Supplementary Fig. 1K). MGMT 
promoter methylation was associated with prolonged OS, too (Supplementary Table 3, 
Supplementary Fig. 1L). 
 
Genomic copy number profiling 
Unsupervised clustering of the array-CGH data separated the 137 gliomas into three major 
clusters characterized by (a) an oligodendroglial genomic profile with 1p/19q co-deletion, (b) 
an intermediate group consisting mostly of IDH1/2 mutant tumors without 1p/19q co-
deletion, and (c) a glioblastoma-like genomic profile with partial or complete gains on 
chromosome 7, losses on 9p, partial or complete losses on 10, and frequent gene 
amplifications (Fig. 1A). Based on these findings and the well-known differences in tumor 
biology and prognosis between IDH1/2 mutant and wild-type gliomas, we performed 
supervised analyses of the array-CGH data stratified by IDH1/2 status. This analysis revealed 
three distinct tumor groups among the IDH1/2 mutant tumors defined by 1p/19q co-deletion 
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(group I), chromosome arm 7q gain associated with a usually limited number of copy number 
changes on other chromosomes (group II), or gains and losses affecting multiple 
chromosomes (group III). IDH1/2 wild-type tumors were divided into one group with 
relatively few genomic changes variably affecting different chromosomes and TERT promoter 
mutation restricted to a single case (group IV), and another group with primary glioblastoma-
like copy number changes, typically including combined gains on chromosome 7 and losses 
on chromosome 10 affecting at least the long arms of both chromosomes (+7q/-10q; group V) 
(Fig. 1B, Supplementary Table 4). Additional analyses for BRAF-V600E and H3F3A-K27 or -
G34 mutations in 8 of 9 and 7 of 9 group IV tumors did not reveal any mutation (data not 
shown). Tumors in group V often carried TERT promoter mutations (9/13; 75%) as well as 
gene amplifications (11/13; 85%), including TERT amplification in one tumor without TERT 
promoter mutation. Unsupervised analyses of array-CGH data from group V tumors together 
with array-CGH data of primary IDH1/2 wild-type glioblastomas reported elsewhere [26] 
revealed that group V tumors did not form a distinct cluster, but were distributed among the 
glioblastoma cases, indicating that group V tumors carry genomic imbalances typical of 
glioblastoma (Supplementary Fig. 2A).  
Fig. 2A shows the frequency plots of genomic imbalances in each of the five genomic groups 
defined by array-CGH patterns within the subsets of IDH1/2 mutant and wild-type tumors, as 
well as an independent cohort of IDH1/2 wild-type primary glioblastomas reported previously 
[26]. Group V tumors showed a virtually identical genomic aberration pattern as the primary 
glioblastomas. High-level copy number gains indicative of gene amplification occurred at 
similar frequencies in both groups, most commonly affecting epidermal growth factor 
receptor (EGFR) [group V 8/13 (62%) versus primary glioblastoma 26/54 (48%)], murine 
double minute (MDM) 4 [group V 3/13 (23%) versus glioblastoma 6/54 (11%)], cyclin-
dependent kinase (CDK) 4 [group V 2/13 (15%) versus glioblastoma 9/54 (17%)], MDM2 
[group V 1/13 (8%) versus glioblastoma 5/54 (9%)], and platelet-derived growth factor 
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receptor-α (PDGFRA) [group V 0/13 (0%) versus glioblastoma 4/54 (7%] (each comparison: 
p>0.05, Fisher’s exact test). In contrast, amplification of MDM4, EGFR, and CDK4 was less 
common in genomic groups I - IV when compared to group V (Supplementary Table 5), and 
tumors with amplification events were less frequent in groups I – IV versus group V [group I: 
1/37 (3%); group II: 10/31 (32%); group III: 6/47 (13%); group IV: 4/9 (44%); group V: 
11/13 (85%) (groups I - III versus group V: p<0.005, group IV versus group V: p>0.05, 
Fisher’s exact test)].  
Fig. 2B illustrates the association of the array-CGH groups with PFS and OS. Patients with 
IDH1/2 mutant and 1p/19q co-deleted (group I) tumors had the best outcome while patients 
with IDH1/2 wild-type and +7q/-10q (group V) tumors showed the worst prognosis. 
However, compared with a cohort of 270 IDH1/2 wild-type primary glioblastoma from our 
previous GGN study [34], group V patients had a longer median OS (2.4 years versus 1.0 
years, p = 0.008). Patients in groups II - IV demonstrated similar survival, with outcomes 
being intermediate between group I and group V patients. 
 
mRNA expression profiling 
We analysed mRNA expression using the SOM method and identified six major clusters of 
highly correlated tumor samples, two of which closely overlapped with genomic groups I and 
V (Supplementary Figure 3). The individual expression clusters visible in the correlation 
heatmap were characterized by (i) a classical glioblastoma-like profile associated with IDH1/2 
wild-type status and anaplastic astrocytic histology (corresponding to genomic group V 
except for one sample without +7q/-10q status), (ii) a heterogeneous glioblastoma-like profile 
associated with both IDH1/2 wild-type and mutant status and with anaplastic astrocytic and 
oligoastrocytic histology, (iii) a proneural glioblastoma-like profile associated with IDH1/2 
mutation and astrocytic histology, (iv) an expression profile unrelated to known glioblastoma 
signatures and associated with IDH1/2 mutation and predominantly diffuse astrocytoma 
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WHO grade II histology, (v) a proneural glioblastoma-like profile associated with IDH1/2 
mutation, 1p/19q co-deletion and oligodendroglial histology (corresponding to genomic group 
I), and (vi) a normal brain-like profile associated with both IDH1/2 mutant and wild-type 
tumors of predominantly astrocytic histology, but also including a fraction of mixed 
oligoastrocytic tumors (Supplementary Fig. 3). The first expression cluster (i) consisted 
predominantly of IDH1/2 wild-type gliomas whereas the vast majority of tumors in the other 
five expression clusters were IDH1/2 mutant. Therefore, we additionally performed 
supervised analysis of metagene expression data stratified according to IDH1/2 mutation 
status, which separated IDH1/2 wild-type tumors into three major expression groups (groups 
1-3). The IDH1/2 mutant tumors were subdivided into five major expression clusters (groups 
4-8) (Fig. 3A). Metagene expression data of IDH1/2 wild-type gliomas resembled those of 
primary glioblastomas, while expression profiles in IDH1/2 mutant gliomas were shared with 
those of IDH1/2 mutant glioblastomas (Supplementary Fig. 2B). Gene set enrichment analysis 
revealed that the top enriched sets in the lists of up-regulated genes were linked to the 
classical (group 1) and proneural (groups 5 and 7) glioblastoma expression signatures [34], 
immune response processes and increased transcriptional activity (groups 2 and 4), normal 
brain expression signature (groups 3 and 8), astrocytic expression signatures (group 5), 
oxygen transport with high expression levels of hemoglobin and cytoglobin (group 6) and 
concerted transcriptional and mitochondrial activities associated with oligodendroglial tumor 
histology (group 7).  
Clinical and histological correlates of the expression-based classification are summarized in 
Supplementary Table 6 and Fig. 3B. Analysis of patient outcome stratified according to the 
distinct expression groups revealed the best outcome for patients whose tumors carried a 
proneural glioblastoma-like profile, frequently associated with 1p/19q co-deletion 
(corresponding to genomic group I and expression group 7), but also for expression groups 
with brain-like signatures independent of IDH1/2 mutation status (expression groups 3 and 8) 
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and expression group 5 (IDH1/2 mutant), the worst outcome for patients whose tumors 
displayed a classical glioblastoma profile associated with +7q/-10q genomic profile 
(corresponding to genomic group V and expression group 1) and expression group 2 of the 
IDH1/2 wild-type tumors without the +7q/-10q genomic profile and without a brain-like 
expression signature. Patients whose tumors were classified in the remaining two expression 
clusters of the IDH1/2 mutant tumors (group 4 and 6) had intermediate prognoses. Expression 
group 1 tumors had a similarly poor PFS but longer OS when compared to IDH1/2 wild-type 
glioblastoma (Supplementary Table 6, Fig. 3B). 
 
Integration of genomic and expression profiling results 
Next we explored the relationships between the five genomic groups identified by array-CGH 
analyses and the eight clusters obtained by gene expression profiling. Genomic group I 
(IDH1/2 mutant, -1p/-19q) consisted mostly of expression group 7 tumors while genomic 
group V (IDH1/2 wild-type, +7q/-10q) tumors closely overlapped with expression group 1 
tumors (Fig. 3B, Supplementary Table 7). Genomic groups II-IV could not be matched to 
individual expression groups (Supplementary Table 7). Among the IDH1/2 wild-type tumors, 
most genomic group V tumors showed classical glioblastoma-like expression profiles 
(expression group 1), while most genomic group IV tumors showed other expression profiles 
related to immune response processes and increased transcriptional activity (expression group 
2) or a normal brain expression signature (expression group 3). The IDH1/2 mutant genomic 
groups II and III both demonstrated mixed expression profiles without obvious enrichment of 
a certain profile in one of these groups (Fig. 4A, Supplementary Table 7). 
Taken together, genomic and transcriptomic data were compatible with three molecularly 
distinct tumor groups that were primarily defined by genomic features and strongly linked to 
clinical outcome in patients with WHO grade II and III gliomas: a prognostically favorable 
group with IDH1/2 mutation and 1p/19q co-deletion as the characteristic molecular marker, 
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corresponding to genomic group I and including all expression group 7 tumors, a 
prognostically intermediate group mostly containing IDH1/2-mutant tumors without 1p/19q 
co-deletion (genomic groups II-III) and the small group of IDH1/2-wild-type tumors without 
combined gains on 7 and losses on 10 (genomic group IV), and a prognostically unfavorable 
group of exclusively IDH1/2 wild-type tumors with glioblastoma-like genotype characterized 
by +7q/-10q, frequent gene amplification and TERT promoter mutation (genomic group V), 
including mostly expression group 1 tumors (Supplementary Table 8, Fig. 4B). Median PFS 
and OS differed significantly between the groups [group I vs. groups II-IV: PFS 5.9 years vs. 
3.7 years (p=0.046), OS not reached vs. 9.0 years (p=0.028); groups II-IV vs. group V: PFS 
3.7 years vs. 1.5 years (p=0.001), OS 9.0 years vs. 2.4 years (p<0.001)]. Median PFS (1.5 
years) and OS (2.4 years) of the group V patients appeared to be better than PFS and OS of 
unselected glioblastoma patients, as indicated by comparison to survival data from a previous 
study on glioblastoma patients (PFS 0.5 years, p=0.026; OS 1.0 years, p=0.008) [34]. We also 
evaluated the prognostic role of WHO grading within these three tumor groups, which 
revealed that histological grading according to WHO criteria may provide some prognostic 
information within groups I and II-IV, although the differences in these groups were not 
significant presumably because of small samples size (group I, WHO grade II versus III, 
p=0.102 for OS; group II-IV, WHO grade II versus III, p=0.103 for OS) (Fig. 4C). Age at 
diagnosis was a prognostic factor associated with OS in both groups (group I, ≤ 40 years 
versus > 40 years, p=0.076; group II-IV, ≤ 40 years versus > 40 years, p<0.001) (Fig. 4D). In 
group V, WHO grading and age could not be evaluated since these patients were generally 
older than 40 years and except for three patients had WHO grade III tumors. 
We also evaluated the possibility that complementation of the three DNA aberration-based 
prognostic groups by integrating information on mRNA expression groups might further 
improve prognostic stratification. Using this approach, we more strictly defined the best 
prognostic group ("integrated molecular group A", 26 patients) as IDH1/2 mutant, 1p/19q 
 - 15 - 
Weller et al. Molecular profiling of cerebral gliomas 
deleted and group 7 expression profile tumors while the worst prognostic group was 
exclusively composed of IDH1/2 wild-type, +7q/-10q and group 1 expression profile tumors 
("integrated molecular group C", 10 patients). The remaining tumors not falling into either 
group A or group C were compiled in one intermediate prognosis group ("integrated 
molecular group B", 101 patients) (Supplementary Fig. 4A, Supplementary Table 8). This 
integrated molecular stratification again provided three prognostically distinct groups of 
patients (Supplementary Fig. 4B), however, it added no improvement of the three-tiered 
genomic stratification (Fig. 4A). Moreover, the group of patients with intermediate prognosis 
("group B") increased to 101 patients and included patients with molecularly heterogeneous 
tumors lacking a characteristic marker profile, i.e., consisted of IDH1/2 mutant and IDH1/2 
wild-type as well as 1p/19q co-deleted and 1p/19q intact tumors. 
 
Molecular correlates of glioma type and WHO grade 
The genomic aberration profiles determined by array-CGH analysis differed substantially 
between oligodendroglial and astrocytic as well as 1p/19q co-deleted and 1p/19q intact 
tumors (Supplementary Figs. 5A,B), with IDH1/2 mutant and 1p/19q co-deleted tumors 
showing significantly fewer genomic alterations per tumor than IDH1/2 mutant tumors 
without 1p/19q co-deletion (Supplementary Fig. 5C). Comparison of expression profiles in 
the 68 IDH1/2 mutant tumors classified as astrocytic gliomas (AII, AAIII) and the 47 IDH1/2 
mutant tumors containing an oligodendroglial component (OII, OAII, AOIII, AOAIII) 
revealed a set of differentially expressed genes (Fig. 5A; Supplementary Table 9). Similar but 
even more pronounced expression differences were detected when the 37 IDH1/2 mutant 
1p/19q co-deleted tumors were compared with the 78 IDH1/2 mutant but 1p/19q intact tumors 
(Fig. 5B; Supplementary Table 10). In general, oligodendroglial tumors and 1p/19q co-
deleted tumors demonstrated reduced expression of a subset of genes located on 1p or 19q as 
well as genes related to ‘immune response‘ and ‘inflammatory response‘ but showed 
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increased expression of gene signatures related to ‘normal brain‘, synaptic transmission‘ and 
‘brain development‘ (Supplementary Table 11). As expected [15, 21, 38], ATRX was among 
the top genes with higher expression in astrocytic versus oligodendroglial tumors as well as 
1p/19q intact versus 1p/19q co-deleted tumors (Supplementary Tables 9-10).  
Transcriptomic profiles also differed between WHO grade II and WHO grade III gliomas 
(Fig. 5C, Supplementary Table 12). Genes expressed at higher levels in WHO grade II 
gliomas were related to normal brain function, including the gene ontology (GO) terms 
‘normal brain‘ and ‘synaptic transmission’, while genes with higher expression in WHO 
grade III gliomas were related to cell division and transcriptional activity, including the GO 
terms ‘nucleus’, ‘mitotic cell cycle’, ‘DNA repair’, ‘DNA replication’ and ‘nucleic acid 
binding’ (Supplementary Table 11). The overall patterns of genomic aberrations were similar 
in WHO grade III gliomas when compared to WHO grade II gliomas. Moreover, the number 
of genomic aberrations detected per tumor by array-CGH did not significantly differ between 
WHO grade II and III gliomas, except for a trend towards more aberrations per tumor in 
1p/19q co-deleted WHO grade III versus WHO grade II gliomas. Array-CGH analysis did not 
detect any dominant progression-associated genomic aberration according to WHO grade 
(Supplementary Fig. 5).  
 
Multivariate analysis of clinical, histological and molecular parameters 
To analyze the relative impact of clinical and histological parameters (age, histology, WHO 
grade), and molecular tumor groups as defined in Fig. 4, Supplementary Fig. 4 and 
Supplementary Table 8, we performed Cox regression analyses with regard to OS (Table 2). 
We first assessed the genomic classification of groups I, II-IV or V (Fig. 4). In the first model, 
we only considered the most relevant clinical parameters, histology (astrocytic versus 
oligodendroglial), WHO grade (grade III versus II) and age (> 40 years versus < 40 years). 
Compared with the null model (model without any variable) this model reduced the deviance 
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significantly. Higher age had the most significant association with OS (HR=4.4, p<0.001) 
followed by histology (HR=2.59, p=0.007). In the second model, we replaced histology and 
WHO grading by an indicator variable for the three distinct genomic tumor groups I, II-IV or 
V. The tumor group I with the best outcome was defined as the reference group (Fig. 4B). The 
highest hazard ratio (HR) of 8.28 (p<0.001) was seen in group V tumors and the effect for 
tumors in the intermediate group II-IV was of relevant dimension (HR 3.81, p=0.006). 
Relative risk for death was higher for age > 40 years (HR 3.99, p<0.001). This model showed 
a much better model fit than the first model. Adding histology and WHO grade to model 2 
resulted only in insignificant improvements of the model fit (p=0.318). The three genomic 
groups were by far most informative, with age ranking second. Histology and WHO grading 
provided the lowest independent association with OS (HR 1.36, p=0.426 and HR 1.55, 
p=0.175), indicating that much of the information carried in histology and WHO grading has 
been captured by the genomic information.  
When mRNA expression profiling data were introduced, that is integrated molecular profiling 
(Supplementary Fig. 3) considered instead of genomic profiling only, the prognostic 
separation into three distinct groups became less clear (Supplementary Table 13. Conversely, 
when the models were built on IDH1/2 and 1p/19q status alone, some prognostic information 
was lost, with the HR for the poor prognosis group decreasing to 6.82, likely as a 
consequence of including IDH1/2 wild-type tumors without glioblastoma-like genomic 
alteration (Supplementary Table 13). 
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DISCUSSION 
 
Diffusely growing gliomas of WHO grade II and III remain a diagnostic and therapeutic 
challenge. Outcome seems to be determined more by age and molecular genetic features of 
the tumors than by the current treatment options of surgery, radiotherapy and alkylating agent 
chemotherapy. Molecular markers, in particular IDH1/2 mutation/gCIMP and 1p/19q co-
deletion, have been employed to define three major prognostic groups of WHO grade III 
gliomas [39]. The present study explored whether large-scale genomic or transcriptomic 
profiling improves prognostic stratification in comparison to histology and established 
molecular markers like IDH1/2 mutation and 1p/19q co-deletion in WHO grade II and III 
gliomas. 
Genomic and expression profiling each revealed groups of tumors with distinct genetic 
imbalance and gene expression patterns (Figs. 1-3). However, the independently identified 
genomic and transcriptomic groups only partially overlapped. Prognostic evaluation of 
molecular subgrouping revealed the worst survival for patients whose tumors showed a 
glioblastoma-like genomic profile associated with IDH1/2 wild-type status, frequent gains on 
7q and losses on 10q, often a classical glioblastoma-like expression profile, and mostly 
anaplastic astrocytic or oligoastrocytic histology (Fig. 4). Most tumors in this group 
additionally demonstrated gene amplifications and TERT promoter mutations. However, 
despite sharing genomic imbalances and expression signature with primary glioblastomas, 
patients with these tumors may survive longer than IDH1/2 wild-type glioblastoma patients 
(Figs. 2B and 4B), although less than 50% received combined radiochemotherapy as up-front 
treatment (Supplementary Table 8). Our findings thus suggest that the absence of histological 
features of glioblastoma, that is microvascular proliferation and necrosis, in IDH1/2 wild-type 
gliomas with glioblastoma-like genotypes is of prognostic relevance. In line, retrospective 
analyses of the NOA-04 cohort of anaplastic glioma patients and glioblastoma patients of the 
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GGN similarly indicated a longer survival of patients with IDH1/2 wild-type anaplastic 
gliomas compared to patients with IDH1/2 wild-type glioblastomas [11, 39]. However, this 
assumption would need confirmation in an independent larger cohort of patients who ideally 
should have received identical treatment. 
The best outcome was detected in patients whose tumors were characterized by IDH1/2 
mutation, 1p/19q co-deletion and oligodendroglial or oligoastrocytic histology. The majority 
of these tumors demonstrated a proneural glioblastoma-like expression profile, which has 
previously been associated with favorable outcome and oligodendroglial as opposed to 
astrocytic tumors [5, 7]. Moreover, the important role of 1p/19q co-deletion in anaplastic 
glioma patients has been shown in three independent prospective phase III trials [2, 32, 36], 
with recent long-term follow-up data indicating a predictive role of this biomarker for 
favorable response to upfront combined radiochemotherapy [3, 31]. Our present data lend 
further support to the importance of 1p/19q testing for reliable identification of the 
biologically and clinically distinct group of glioma patients showing favorable outcome with 
the current treatment options (genomic group I). Moreover, our data suggest that 1p/19q 
deletion testing is sufficient to define this particular patient group, i.e. no additional tests for 
other chromosomal aberrations, gene mutations or expression profiles appear to be required in 
the diagnostic setting. 450 k methylation bead-array profiling data of the NOA-04 biomarker 
cohort of anaplastic (WHO grade III) glioma patients independently validate the prognostic 
distinction of a gCIMP positive and 1p/19q co-deleted subgroup of patients with favorable 
outcome [39], which essentially corresponds to our IDH1/2 mutant and 1p/19q co-deleted 
genomic group I. 
The other three genomic groups II-IV defined in this study were associated with similar 
prognoses, i.e. patients demonstrated intermediate PFS and OS when compared to genomic 
group I or V patients. Again, this finding fits well to the recent NOA-04 data demonstrating 
intermediate survival for patients with gCIMP positive, 1p/19q intact and ATRX 
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mutant/deficient anaplastic gliomas [39]. However, our intermediate survival group included 
not only patients with IDH1/2 mutant astrocytic or oligoastrocytic gliomas without 1p/19q co-
deletion, but also a small group of patients with IDH1/2 wild-type tumors, i.e. genomic group 
IV. This finding could be clinically important as it suggests that the absence of IDH1/2 hot 
spot mutations in diffuse and anaplastic gliomas may not invariably be linked to less 
favorable outcome when compared to IDH1/2 mutant tumors without 1p/19q co-deletion. Our 
data suggest that the association of IDH1/2 wild-type status with poor survival is mainly 
restricted to those patients whose tumors additionally carry glioblastoma-like genomic 
aberrations, in particular gains on 7q combined with losses on 10q (+7q/-10q). This has 
implications for genetic testing and biomarker-based prognostic stratification, as the sole 
demonstration of IDH1/2 wild-type status may not be sufficient to assume a particularly poor 
outcome. In fact, additional testing for +7q/-10q would be necessary to identify the IDH1/2 
wild-type WHO grade II and III gliomas associated with particularly poor outcome, and 
possibly stratify these patients into a distinct treatment regimen. In addition, these group V 
patients should probably be excluded from future clinical trials on anaplastic glioma patients. 
Admittedly, it is possible that some of these tumors were initially undergraded simply because 
of sampling error although none of the diagnoses in this group were made by biopsy alone. 
Whether the rare patients with IDH1/2 mutant gliomas carrying the +7q/-10q genomic profile 
(6 of 115 patients in our cohort, 5.2%) should be similarly separated from the bulk of patients 
with IDH1/2 mutant gliomas in terms of future trials and clinical management remains to be 
determined. Recent data indicate that IDH1/2 mutation, even in the absence of 1p/19q co-
deletion, may be linked to more favorable response of anaplastic gliomas to procarbazine, 
CCNU and vincristine (PCV) chemotherapy when compared to IDH1/2 wild-type tumors [4]. 
However, the authors did not further stratify the IDH1/2 wild-type tumors in this study 
according to their +7q/-10q status. Conversely, the absence of IDH1/2 mutations has 
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previously been proposed to be linked to a specific predictive value of MGMT promoter 
methylation for benefit from alkylating agent chemotherapy [37]. 
While our study indicates an important role for molecular classification of diffuse and 
anaplastic gliomas, it also supports a role for histological grading according to the WHO 
criteria, since molecular profiling did not allow for reliable distinction of tumor grades. As 
stated above, patients with WHO grade III anaplastic gliomas with glioblastoma-like genetic 
imbalances appear to show better survival than patients with histologically classic WHO 
grade IV glioblastoma. Moreover, our data suggest that WHO grade tends to be 
prognostically relevant in patients with 1p/19q co-deleted (group I) tumors as well as in 
patients with group II-IV tumors. However, these findings would need to be corroborated on 
larger and homogeneously treated patient series. 
In line with previous studies [24, 27, 29], group-wise comparisons of expression profiling 
data revealed sets of genes showing differential expression in oligodendroglial versus 
astrocytic gliomas and/or 1p/19q co-deleted versus 1p/19q intact gliomas. Comparison of the 
sets of differentially expressed genes identified in our cohort (Supplementary Tables 9,10) 
with those reported before [24, 28] revealed considerable overlaps (data not shown). 
Identified candidate genes included published markers such as ATRX [15, 21, 38] and alpha-
internexin (INA) [6], but also novel candidates (Supplementary Tables 7 and 8). The 
diagnostic utility of these candidate genes as surrogate markers for 1p/19q co-deletion, e.g. by 
immunohistochemical analysis, remains to be determined. We also detected sets of genes 
whose expression differed significantly between IDH1/2 mutant gliomas of WHO grade II or 
WHO grade III (Supplementary Table 10). It remains to be demonstrated whether any of 
these candidate genes may serve as a diagnostically useful marker for glioma grading.  
In conclusion, our large-scale molecular profiling of WHO grade II and III cerebral gliomas 
provides important results for improving future classification of these tumors into clinically 
useful categories based on the integration of histological findings and defined molecular 
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markers as recently proposed by the Haarlem Consensus Meeting [23]. Specifically, our 
findings support that patients with IDH1/2 mutant gliomas can be molecularly stratified into 
two prognostically distinct groups corresponding either to patients with 1p/19q co-deleted 
oligodendrogliomas or patient with 1p/19q intact astrocytomas. IDH1/2 mutant 
oligoastrocytomas can be molecular assigned to either of these groups, thus supporting that 
oligoastrocytoma does not constitute a molecularly distinct glioma entity [27]. In patients 
with IDH1/2 wild-type diffuse and anaplastic gliomas, presence of a +7q/-10q glioblastoma-
like genomic signature was linked to poor outcome. However, whether this molecular profile 
is sufficient to switch the histological diagnosis of a WHO grade II or III glioma to WHO 
grade IV glioblastoma is currently unclear and will be a point of discussion for the up-coming 
revision of the WHO classification. In summary, molecular biomarker-based classification of 
diffuse and anaplastic gliomas may not only improve diagnostic accuracy but will also 
facilitate clinical decision making, and needs to be considered for patient stratification in 
future prospective interventional trials. 
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TABLES 
Table 1. Patient characteristics. 
 N=137 
Age (years) 
  Median 
  Range 
 
41 
21-80 
Gender 
  Male 
  Female 
 
84 (61.3%) 
53 (38.7%) 
KPS 
  Median 
  Range 
 
90 
60-100 
  80-100 
  70 or less 
  Unknown 
114 (94.2%) 
    7 (5.8%) 
  16 
Histological diagnosis 
  Diffuse astrocytoma (A2) 
  Oligoastrocytoma (OA2) 
  Oligodendroglioma (O2) 
  Anaplastic astrocytoma (AA3) 
  Anaplastic oligoastrocytoma (AOA3) 
  Anaplastic oligodendroglioma (AO3) 
 
45 (32.8%) 
13 (9.5%) 
  3 (2.2%) 
42 (30.7%) 
31 (22.6%) 
 3 (2.2%) 
IDH1/2 status 
  Mutant 
  Wild-type 
 
115 (83.9%) 
 22 (16.1%) 
1p/19q status 
  1p/19q co-deleted 
  1p/19q non-co-deleted 
 
   37 (27.0%) 
 100 (73.0%) 
MGMT promoter status 
  Unmethylated 
  Weakly methylated 
  Strong methylated 
  Unknown 
 
  25 (18.4%) 
  13 (9.6%) 
  98 (72.1%) 
  1 
TERT promoter status 
  Mutant 
  Wild-type 
  Unknown 
 
  45 (33.8%) 
  88 (66.2%) 
  4 
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Table 2. Multivariate analysis based on clinical and histological parameters as well 
as genomic groups determined by array-CGH analysis and IDH1/2 mutation status 
(groups I – V).  
 
Model Factor HR 95% CI P 
value 
Model fit 
deviance 
Improvement 
1 Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
Age > 40 vs. < 40 (ref) 
2.59 
1.71 
4.40 
1.30 - 5.15 
0.92 - 3.20 
2.21 - 8.79 
0.007 
0.090 
<0.001 
374.02 Model 1 to 
null model:  
p<0.001 
2 Age > 40 vs. < 40 (ref) 
Groups II+ III+ IV vs. group I (ref) 
Group V vs. group I (ref) 
 
3.99 
3.81 
8.28 
 
1.95 - 8.16 
1.46 - 9.93 
2.78 - 24.71 
<0.001 
0.006 
<0.001 
 
366.33 Model 2 to 
null model:  
p<0.001 
3 Age >40 vs. < 40 (ref) 
Groups II+III+IV vs. group I (ref) 
Group V vs. group I (ref) 
Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
4.00 
3.42 
6.45 
1.36 
1.55 
1.94 - 8.25 
1.20 - 9.80 
1.93 - 21.60 
0.64 - 2.91 
0.82 - 2.93 
<0.001 
0.022 
0.002 
0.426 
0.175 
364.03 Model 3 to 2: 
p=0.318 
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FIGURE LEGENDS 
 
Fig. 1. Results of array-CGH analyses. A. Unsupervised analysis of genomic profiles in 137 WHO 
grade II and III gliomas distinguishes three major clusters, one with all 1p/19q co-deleted IDH1/2 
mutant tumors (left), one mostly including IDH1/2 mutant tumors without 1p/19q co-deletion 
(middle), and one mostly including IDH1/2 wildtype tumors with +7q/-10q (right). Shown is a heat 
map indicating genomic losses in green and genomic gains in red. The individual chromosomal bands 
are indicated on the left side of the heat map. The color bars on top of each heat map refer to the 
histological classification (1), as well as the status of MGMT promoter methylation (2), TERT 
promoter mutation (3), 1p/19q co-deletion (4) and IDH1/2 mutation (5) in each tumor. B. Supervised 
analyses of array-CGH data stratified by IDH1/2 status revealed three distinct molecular groups 
among the IDH1/2-mutant gliomas (groups I-III), with group I including all 1p/19q co-deleted tumors, 
while group II and III tumors lacked 1p/19q co-deletion but demonstrated either gains of 7 or 7q 
(group II) or multiple gains on other chromosomes (group III). IDH1/2 wild-type gliomas comprised 
two distinct tumor groups: one characterized by relatively few genomic aberrations affecting diverse 
chromosomes (group IV) while the other (group V) was characterized by a glioblastoma-like genomic 
pattern with gain of 7 or 7q and loss of 10 or 10q as marker lesions. 
 
Fig. 2. Genomic imbalance patterns according to genomic group and relationship to patients outcome. 
A. Frequency plots of genomic imbalances detected in each of the five genomic groups and, for 
reference, a previous series of IDH1/2 wild-type primary glioblastomas [26]. Results are stratified 
according to the IDH1/2 mutation status (left side: IDH1/2 mutant tumor groups; right side: IDH1/2 
wild-type tumor groups). Gains of genomic material are indicated by green bars while losses are 
indicated by red bars. The bar length indicates the percentage of tumors in each group showing gains 
or losses at the respective chromosomal location. The individual chromosomes are indicated on the 
bottom and top of each frequency plot, with markers on each chromosomes being sorted from pter on 
the left to qter on the right. B. Progression-free survival (left) and overall survival (right) of patients 
stratified according to the five genomic groups defined by array-CGH analysis. For reference, survival 
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of a previously published GGN cohort of 270 patients with IDH1/2 wild-type primary glioblastoma 
WHO grade IV (GB IV) is shown [34]. Note that patients with group I tumors (IDH1/2 mutant, 1p/19q 
co-deleted) had the best survival, while patients with group V tumors (IDH1/2 wild-type, +7/-10q) 
showed the worst survival. However, median overall survival of group V patients was still longer 
when compared to primary glioblastoma patients. Patients with group II-IV tumors showed similar 
outcomes, with survival curves running between those of group I and group V patients. 
 
Fig. 3. Results of mRNA expression profiling. A. Pairwise correlation matrices stratified according to 
IDH1/2 status (left, wild-type tumors; right, mutant tumors). Note that 3 distinct expression groups 
(groups 1-3) were delineated in IDH1/2 wild-type tumors while the IDH1/2 mutant tumors were 
stratified in 5 distinct groups (groups 4-8). The color bars on top of each correlation matrix refer to the 
histological classification (1), as well as the status of MGMT promoter methylation (2), TERT 
promoter mutation (3), 1p/19q co-deletion (4), IDH1/2 mutation (5), and the genomic group defined 
by array-CGH analysis for each tumor (6). B. PFS and OS in the 8 patient groups defined by 
expression profiling. Survival curves of an unselected cohort of 270 IDH1/2 wild-type glioblastoma 
patients [34] were added for comparison.  
 
Fig. 4. Molecular classification of WHO grade II and III gliomas based on genomic profiling data. A. 
Supervised pairwise correlation matrix of metagene expression data obtained by SOM analysis 
stratified according to IDH1/2 status and genomic groups I – V identified by array-CGH analysis. The 
color bars on top refer to the histological classification (1), as well as the status of MGMT promoter 
methylation (2), TERT promoter mutation (3), 1p/19q co-deletion (4), expression group (5) IDH1/2 
mutation (6), and genomic group defined by array-CGH analysis (7). Note that genomic group I 
(IDH1/2 mutant, 1p/19q co-deleted) tumors and group V (IDH1/2 wild-type, +7q/-10q) tumors show 
an enrichment for distinct expression profiles, i.e. expression group 7 or expression group 1, further 
strengthening the hypothesis that these two groups reflect biologically distinct tumor entities. Genomic 
groups II – IV show expression profiles distinct from group 1 and group 5, however, cannot be 
separated by distinctive expression profiles from each other. Since these groups shared similar patient 
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outcomes (Fig. 2B), we combined them into a single group II-IV for further prognostic correlations. B. 
Progression-free (PFS) and overall survival (OS) according to the three major genomic groups I, II-IV 
or V. A cohort of patients with IDH1/2 wild-type glioblastoma WHO grade IV (GB IV) published 
previously [34] is included for comparison. C, PFS and OS in the three major genomic groups 
stratified by WHO grade (grade II vs III) in groups I and II-IV. D. PFS and OS in groups I and II-IV 
stratified by patient age (≤ 40 years vs >40 years). Patients in group V were all > 40 years old and 
except for two patients had WHO grade III tumors. Thus, group V was not further stratified according 
to WHO grade and age. 
 
Fig. 5. Expression profiles in 115 IDH1/2 mutant gliomas according to histological classification (A), 
1p/19q status (B) and WHO grade (C). Shown are supervised pairwise correlation matrices based on 
SOM analysis of mRNA expression data for each group-wise comparison. Note distinct expression 
profiles between astrocytic and oligodendroglia/oligoastrocytic tumors (A) as well as 1p/19q intact 
and co-deleted gliomas (B), with differential gene expression differences being more when tumors 
were stratified according to 1p/19q status. Comparison of WHO grade II versus WHO grade III 
gliomas revealed evidence for differential gene expression (C), however, the differences being less 
prominent as compared to those detected between 1p/19q intact versus co-deleted tumors. Lists of 
differentially expressed genes and associated gene ontology terms for each group-wise comparison are 
provided as Supplementary Tables 9-12. 
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SUPPLEMENTARY TABLES 
Supplementary Table 1. Individual patient characteristics: diagnosis, molecular markers, first-line treatment, and outcome. 
Patient Age Gender Diagnosis IDH1/2 
mutation 
1p/19q co-
deletion 
MGMT 
promoter 
methylation 
TERT 
promoter 
mutation 
First-line 
therapy 
PD PFS 
[years] 
OS 
[years] 
P1 37 M AII Mut del strong mut no therapy yes 7.9 9.6 
P2 54 F AII Mut del strong mut no therapy yes 5.4 6.1 
P3 47 M AII Mut del strong mut no therapy no - 3.9 
P4 54 F AII Mut del strong mut CT no - 2.7 
P5 39 M AII Mut no del strong wt no therapy yes 11.7 17.7 
P6 33 M AII Mut no del strong wt no therapy yes 12.6 14.1 
P7 24 M AII Mut no del strong n.d. no therapy yes 6.2 12.1 
P8 25 F AII Mut no del strong wt no therapy yes 9.1 12.0 
P9 35 M AII Mut no del strong wt no therapy yes 5.9 11.4 + 
P10 47 M AII Mut no del strong wt no therapy yes 8.4 9.0 + 
P11 37 F AII Mut no del strong wt no therapy yes 6.1 8.1 
P12 40 F AII Mut no del strong wt no therapy yes 3.4 6.7 
P13 31 M AII Mut no del strong wt no therapy yes 5.6 6.6 + 
P14 44 M AII Mut no del strong wt no therapy yes 2.2 5.9 
P15 36 M AII Mut no del strong wt no therapy yes 5.6 5.6 
P16 36 F AII Mut no del strong wt no therapy yes 1.0 5.3 
P17 30 M AII Mut no del strong wt no therapy yes 3.0 4.5 
P18 43 M AII Mut no del strong wt no therapy yes 1.9 4.2 + 
P19 43 M AII Mut no del strong wt no therapy no - 3.6 
P20 35 M AII Mut no del strong wt no therapy yes 3.2 3.6 
P21 44 M AII Mut no del strong wt no therapy yes 2.3 3.5 
P22 41 F AII Mut no del strong wt no therapy yes 2.4 3.4 + 
P23 42 M AII Mut no del strong n.d. no therapy yes 2.2 3.3 + 
P24 40 M AII Mut no del strong wt no therapy no - 3.1 
 3 
P25 31 M AII Mut no del strong wt RT yes 1.0 2.9 + 
P26 47 M AII Mut no del strong wt no therapy yes 2.0 2.2 + 
P27 41 M AII Mut no del strong wt no therapy no - 1.7 
P28 50 M AII Mut no del strong wt no therapy yes 0.5 1.0 + 
P29 38 F AII Mut no del Weak wt no therapy yes 1.2 6.6 
P30 21 F AII Mut no del Weak wt no therapy yes 1.0 5.7 
P31 30 M AII Mut no del Weak wt no therapy yes 2.2 4.8 
P32 26 M AII Mut no del Weak wt no therapy yes 2.9 3.7 
P33 29 M AII Mut no del Weak wt no therapy yes 1.2 1.2 + 
P34 50 M AII Mut no del No wt RT plus CT yes 10.2 12.6 + 
P35 28 F AII Mut no del No wt no therapy yes 5.8 6.3 
P36 36 M AII Mut no del No wt no therapy yes 0.2 3.9 
P37 23 M AII Mut no del No wt no therapy no - 3.1 
P38 35 F AII Mut no del No wt no therapy no - 2.9 
P39 38 M AII Mut no del No wt no therapy no - 0.6 
P40 67 F AII Wt no del strong mut no therapy yes 2.3 3.0 + 
P41 41 F AII Wt no del No wt no therapy yes 3.3 9.1 + 
P42 54 F AII Wt no del No wt no therapy yes 2.2 3.4 + 
P43 47 M AII Wt no del No wt no therapy yes 1.4 2.2 + 
P44 28 F AII Mut no del No wt no therapy yes 0.4 3.7 + 
P45 35 F AII Mut no del n.d. wt other yes 1.7 1.7 
P46 47 M OAII mut del strong mut no therapy no - 7.4 
P47 41 M OAII mut del strong mut no therapy yes 2.5 6.2 
P48 43 F OAII mut del strong mut no therapy yes 3.6 5.1 
P49 40 F OAII mut del strong mut no therapy no - 3.9 
P50 33 M OAII mut del strong mut no therapy no - 1.0 
P51 59 M OAII mut del No mut no therapy no - 7.5 
P52 56 M OAII mut no del strong wt no therapy yes 7.5 7.5 
P53 30 F OAII mut no del strong wt no therapy yes 2.6 7.1 
P54 24 M OAII mut no del strong wt no therapy no - 6.6 
P55 44 F OAII mut no del strong wt no therapy yes 5.5 6.1 + 
 4 
P56 59 M OAII mut no del strong wt no therapy no - 4.4 
P57 30 M OAII mut no del strong wt no therapy yes 2.0 3.2 + 
P58 39 F OAII wt no del strong wt CT yes 7.3 8.1 
P59 36 M OII mut del strong mut no therapy yes 0.9 9.1 
P60 39 F OII mut del strong mut no therapy yes 1.8 5.8 
P61 49 M OII mut del Weak mut no therapy no - 3.1 
P62 40 F AAIII mut del strong mut RT plus CT yes 1.2 8.3 
P63 74 M AAIII mut del strong mut RT plus CT yes 2.4 5.0 
P64 52 M AAIII mut no del strong wt RT plus CT yes 1.3 8.8 + 
P65 49 F AAIII mut no del strong wt RT no - 8.0 
P66 33 F AAIII mut no del strong wt RT plus CT no - 7.4 
P67 39 M AAIII mut no del strong wt RT plus CT yes 7.3 7.3 
P68 29 F AAIII mut no del strong wt RT yes 4.9 7.3 + 
P69 32 M AAIII mut no del strong wt RT plus CT yes 0.7 6.4 
P70 48 M AAIII mut no del strong wt no therapy no - 5.7 
P71 27 F AAIII mut no del strong wt RT plus CT no - 5.4 
P72 50 F AAIII mut no del strong wt RT plus CT no - 5.1 
P73 30 F AAIII mut no del strong wt no therapy yes 2.8 4.9 
P74 34 M AAIII mut no del strong wt no therapy yes 0.2 4.9 
P75 23 F AAIII mut no del strong wt RT no - 4.1 
P76 30 M AAIII mut no del strong wt RT yes 2.6 4.1 + 
P77 39 M AAIII mut no del strong wt RT plus CT yes 0.4 4.0 + 
P78 51 M AAIII mut no del strong wt RT plus CT yes 2.5 3.9 + 
P79 24 M AAIII mut no del strong wt CT yes 0.2 3.3 
P80 23 F AAIII mut no del strong wt CT yes 0.7 3.3 
P81 29 M AAIII mut no del strong wt CT no - 3.0 
P82 25 F AAIII mut no del strong wt RT yes 1.3 2.4 + 
P83 64 M AAIII mut no del strong wt RT plus CT yes 0.6 2.2 + 
P84 66 M AAIII mut no del strong wt RT no - 2.0 
P85 61 M AAIII mut no del strong wt RT yes 0.7 1.5 + 
P86 37 M AAIII mut no del Weak wt RT plus CT no - 5.4 
 5 
P87 28 M AAIII mut no del Weak mut RT plus CT no - 3.4 
P88 21 M AAIII mut no del No wt no therapy yes 1.7 7.2 
P89 55 F AAIII wt no del strong mut RT plus CT yes 1.5 2.4 + 
P90 66 F AAIII wt no del strong n.d. RT yes 0.5 1.4 + 
P91 55 F AAIII wt no del strong mut RT plus CT yes 0.5 1.2 
P92 49 M AAIII wt no del strong wt RT no - 0.1 + 
P93 29 M AAIII wt no del Weak wt RT yes 4.1 5.8 
P94 50 M AAIII wt no del Weak wt RT plus CT yes 1.9 2.7 + 
P95 46 M AAIII wt no del No wt no therapy yes 5.9 11.0 
P96 44 M AAIII wt no del No mut RT plus CT yes 8.0 9.7 
P97 61 M AAIII wt no del No mut RT plus CT yes 1.6 2.4 + 
P98 72 F AAIII wt no del No wt RT plus CT yes 1.1 1.8 + 
P99 45 M AAIII wt no del No mut RT plus CT yes 0.6 1.6 + 
P100 65 F AAIII wt no del No mut RT yes 0.8 1.2 + 
P101 64 F AAIII wt no del No mut RT plus CT yes 0.8 1.0 + 
P102 55 M AAIII wt no del No mut RT yes 0.8 0.8 + 
P103 47 F AAIII wt no del No wt no therapy no - 0.0 + 
P104 63 F AOAIII mut del strong mut RT no 2.3 4.6 
P105 33 M AOAIII mut del strong wt RT plus CT no - 6.9 
P106 41 M AOAIII mut del strong mut RT no 4.4- 6.7 
P107 57 M AOAIII mut del strong mut RT plus CT yes 4.7 6.5 + 
P108 46 M AOAIII mut del strong mut RT plus CT no - 6.4 
P109 45 F AOAIII mut del strong n.d. RT plus CT no - 6.4 
P110 45 F AOAIII mut del strong mut RT yes 5.9 5.9 
P111 60 F AOAIII mut del strong mut RT yes 5.9 5.9 
P112 38 M AOAIII mut del strong mut CT yes 5.1 5.1 
P113 65 M AOAIII mut del strong mut RT plus CT yes 1.4 4.9 
P114 35 M AOAIII mut del strong mut CT yes 2.7 4.5 
P115 51 F AOAIII mut del strong mut RT yes 2.8 4.4 + 
P116 49 F AOAIII mut del strong mut CT no - 4.4 
P117 32 M AOAIII mut del strong wt CT no - 3.9 
 6 
P118 68 M AOAIII mut del strong mut RT no - 2.3 + 
P119 68 M AOAIII mut del strong mut RT yes 1.3 1.3 + 
P120 37 M AOAIII mut del strong mut RT plus CT no - 0.6 
P121 54 M AOAIII mut del strong mut no therapy yes 0.1 0.1 + 
P122 40 F AOAIII mut del Weak mut RT plus CT no - 9.6 
P123 27 M AOAIII mut del Weak mut RT plus CT no - 6.8 
P124 35 M AOAIII mut no del strong wt RT plus CT yes 7.0 7.0 
P125 50 M AOAIII mut no del strong wt CT yes 5.0 6.6 
P126 68 F AOAIII mut no del strong wt no therapy yes 4.2 4.4 + 
P127 34 M AOAIII mut no del strong wt RT plus CT yes 0.7 3.6 + 
P128 52 M AOAIII mut no del strong wt no therapy no - 3.6 
P129 80 M AOAIII mut no del strong wt CT no - 2.8 + 
P130 41 F AOAIII mut no del strong wt RT plus CT no - 1.2 
P131 51 M AOAIII mut no del Weak mut RT plus CT yes 3.6 4.0 + 
P132 60 M AOAIII mut no del No wt RT plus CT yes 3.7 3.7 + 
P133 26 F AOAIII mut no del No wt no therapy no - 1.7 
P134 40 F AOAIII wt no del No wt RT no - 8.4 
P135 47 F AOIII mut del strong mut RT plus CT no - 7.2 
P136 64 F AOIII mut del strong wt RT no - 4.7 
P137 45 F AOIII wt no del No mut CT yes 1.5 6.3 
n.d. no data; M, male; F, female; mut, mutant; wt, wild-type; RT, radiotherapy; CT, chemotherapy; PD progressive disease; PFS, progression-free 
survival; OS, overall survival; + indicates patients who are deceased; 41 of 47 deceased patients were confirmed to have died of tumor 
progression. For the other 6 patients, diagnoses and survival times were as follows: AII (n=2, P25, 2.9 and P28, 1 year), AAIII (n=2, P98, 1.8 and 
P103, 8 days), AOAIII (n=2, P118, 2.3 and P126, 4.4 years). Five patients were reported to have died from tumor progression, but no timepoint of 
tumor progression was documented: AII (n=1, P33, 1.2 years), AAIII (n=1, P102, 0.8 years), AOAIII (n=3, P119, 1.3, P121, 0.1 and P132, 3.7 
years). Histological diagnoses correspond to: AII, diffuse astrocytoma WHO grade II; OAII, oligoastrocytoma WHO grade II; OII, oligodendroglioma 
WHO grade II; AAIII, anaplastic astrocytoma Who grade III, AOAIII, anaplastic oligoastrocytoma WHO grade III; AOIII, anaplastic 
oligodendroglioma WHO grade III. 
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Supplementary Table 2. Clinical characteristics, molecular markers, treatment and outcome by histology. 
 AII (n=45) OAII (n=13) OII (n=3) AAIII 
(n=42) 
AOAIII (n=31) AOIII (n=3) Total 
(n=137) 
Age (years) 
  Median 
  Range 
 
38 
21-67 
 
41 
24-59 
 
39 
36-49 
 
46 
21-74 
 
46 
26-80 
 
47 
45-64 
 
41 
21-80 
Gender 
  Male 
  Female 
 
29 (64.4%) 
16 (35.6%) 
 
8 (61.5%) 
5 (38.5%) 
 
2 (66.7%) 
1 (33.3%) 
 
25 (59.5%) 
17 (40.5%) 
 
20 (64.5%) 
11 (35.5%) 
 
- 
3 (100%) 
 
84 (61.3%) 
53 (38.7%) 
IDH1/2 
  Mutant 
  Wild-type 
 
41 (91.1%) 
4 (8.9%) 
 
12 (92.3%) 
1 (7.7%) 
 
3 (100%) 
- 
 
27 (64.3%) 
15 (35.7%) 
 
30 (96.8%) 
1 (3.2%) 
 
2 (66.7%) 
1 (33.3%) 
 
115 (83.9%) 
22 (16.1%) 
1p/19q 
  Co-deleted 
  Not co-deleted 
 
4 (8.9%) 
41 (91.1%) 
 
6 (46.2%) 
7 (53.8%) 
 
3 (100%) 
- 
 
2 (4.8%) 
40 (95.2%) 
 
20 (64.5%) 
11 (35.5%) 
 
2 (66.7%) 
1 (33.3%) 
 
  37 (27.0%) 
100 (73.0%) 
MGMT promoter 
  Unmethylated 
  Weakly methylated 
  Strongly methylated 
  Unknown 
 
10 (22.7%) 
5 (11.4%) 
29 (65.9%) 
1  
 
1 (7.7%) 
- 
12 (92.3%) 
 
 
- 
1 (33.3%) 
2 (66.7%) 
 
 
10 (23.8%) 
4 (9.5%) 
28 (66.7%) 
 
 
3 (9.7%) 
3 (9.7%) 
25 (80.6%) 
 
 
1 (33.3%) 
- 
2 (66.7%) 
 
 
25 (18.4%) 
13 (9.6%) 
98 (72.1%) 
1 
TERT promoter 
  Mutant 
  Wild-type 
  Unknown 
 
5 (11.6%) 
38 (88.4%) 
2 
 
6 (46.2%) 
7 (53.8%) 
  
 
3 (100%) 
- 
 
 
11 (26.8%) 
30 (73.2%) 
1 
 
18 (60.0%) 
12 (40.0%) 
1 
 
2 (66.7%) 
1 (33.3%) 
  
 
45 (33.8%) 
88 (66.2%) 
4 
Surgery 
  Gross total resection 
  Subtotal resection (50-99%) 
  Partial resection (<50%) 
  Biopsy 
  Unknown 
 
8 (21.6%) 
16 (43.2%) 
11 (29.7%) 
2 (5.4%) 
8 
 
7 (58.3%) 
4 (33.3%) 
1 (8.3%) 
- 
1 
 
2 (66.7%) 
1 (33.3%) 
- 
- 
 
 
16 (43.2%) 
9 (24.3%) 
12 (32.4%) 
- 
5 
 
11 (40.7%) 
11 (40.7%) 
5 (18.5%) 
- 
4 
 
-  
2 (66.7%)  
1 (33.3%) 
- 
 
 
44 (37.0%) 
43 (36.1%) 
30 (25.2%) 
2 (1.7%) 
18 
Initial postsurgical management 
  Observation 
  Radiotherapy 
  Chemotherapy 
..Radiotherapy plus chemotherapy 
  Other 
 
41 (91.1%) 
1 (2.2%) 
1 (2.2%) 
1 (2.2%) 
1 (2.2%) 
 
12 (92.3%) 
- 
1 (7.7%)  
- 
- 
 
3 (100%) 
- 
- 
- 
- 
 
6 (14.3%) 
12 (28.6%) 
3 (7.1%) 
21 (50.0%) 
- 
 
4 (12.9%) 
8 (25.8%) 
6 (19.4%) 
13 (41.9%) 
- 
 
- 
1 (33.3%) 
1 (33.3%)  
1 (33.3%)   
- 
 
66 (48.2%) 
22 (16.1%) 
12 (8.8%) 
36 (26.3%) 
1 (0.7%) 
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Treatment at first progression 
No treatment 
Surgery only 
Surgery plus radiotherapy 
Surgery plus chemotherapy 
Surgery plus radiotherapy plus Chemoth.   
Radiotherapy only 
Chemotherapy only 
Radiotherapy plus chemotherapy 
 
2 (5.6%) 
8 (22.2%) 
3 (8.3%) 
4 (11.1%) 
11 (30.6%) 
5 (13.9%) 
3 (8.3%) 
- 
 
 1 (14.3%) 
 2 (28.6%) 
 -  
 1 (14.3%) 
 1 (14.3%) 
 1 (14.3%) 
 1 (14.3%) 
 - 
 
- 
1  
- 
- 
- 
- 
1 
- 
 
6 (20.7%) 
2 (6.9%) 
1 (3.4%) 
3 (10.3%) 
4 (13.8%) 
2 (6.9%) 
10 (34.5%) 
1 (3.4%) 
 
 2 (16.7%) 
 4 (33.3%) 
 1 (8.3%) 
 2 (16.7%) 
 1 (8.3%) 
  - 
 1 (8.3%) 
 1 (8.3%) 
 
 
 
1 
 
 
 
11 (12.6%) 
17 (19.5%) 
6 (6.9%) 
10 (11.5%) 
17 (19.5%) 
8 (9.2%) 
16 (18.4%) 
2 (2.3%) 
Outcome data        
  Follow-up (median, range), years 5.7 
(0.6-17.7) 
6.6 ( 
1-8.1) 
5.8  
(3.1-9.1) 
5.7  
(1.2-11) 
5.9  
(0.6-9.6) 
6.3  
(4.7-7.2) 
5.9 
(0.6-17.7) 
  PFS (events) 37/45 7/13 2/3 30/42 15/31 1/3 92/137 
  PFS (median, 95% CI), years 3.2  
(2.1-4.3) 
7.3  
(3.1-11.4) 
- 1.7  
(0.2-3.1) 
5.1  
(3.5-6.7) 
- 3.7 
(2.1-5.3) 
  OS (events) 16/45 2/13 0/3 19/42 10/31 0/3 47/137 
  OS (median, 95% CI), years 11.4  
(7.8-15.1) 
- - 7.3  
(3.5-11.1) 
- - 9.1 
(6.7-11.6) 
  1-year survival rate (%) 97.7  
(93.3-100) 
- - 92.9  
(85.1-100) 
96.8  
(90.6-100) 
- 96.3 
(93.2-99.5) 
  2-year survival rate (%) 95.5  
(89.3-100) 
- - 78.3  
(65.8-90.9) 
93.3  
(84.4-100) 
- 90.3 
(85.2-95.3) 
  3-year survival rate (%) 85.7  
(75.1-96.3) 
- - 65.7  
(51.1-80.3) 
86.1 
(73.5-98.8) 
- 81.6 
(74.9-88.3) 
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Supplementary Table 3. Clinical characteristics, molecular markers, treatment and outcome by molecular marker status. 
 IDH1/2 
mutant 
 
 
(n=115) 
IDH1/2 
Wild-type 
 
 
(n=22) 
1p/19q 
co-deleted 
 
 
(n=37) 
1p/19q 
not co-
deleted 
 
(n=100) 
MGMT 
promoter 
methylated 
 
(n=111) 
MGMT 
promoter 
not 
methylated 
(n=25) 
TERT 
promoter 
mutant  
 
(n=45) 
TERT 
promoter 
wild-type 
 
(n=88) 
Total 
 
 
 
(n=137) 
Age (years) 
  Median 
  Range 
 
40 
21-80 
 
50 
29-72 
 
46 
27-74 
 
40 
21-80 
 
41 
21-80 
 
45 
21-72 
 
47 
27-74 
 
38 
21-80 
 
41 
21-80 
Gender 
  Male 
  Female 
 
75 (65.2%) 
40 (34.8%) 
 
9 (40.9%) 
13 (59.1%) 
 
22 (59.5%) 
15 (40.5%) 
 
62 (62.0%) 
38 (38.0%) 
 
71 (64.0%) 
40 (36.0%) 
 
13 (52.0%) 
12 (48.0%) 
 
26 (57.8%) 
19 (42.2%) 
 
56 (63.6%) 
32 (36.4%) 
 
84 (61.3%) 
53 (38.7%) 
Histological diagnosis 
  AII 
  OAII 
  OII 
  AAIII 
  AOAIII 
  AOIII 
 
41 (35.7%) 
12 (10.4%) 
3 (2.6%) 
27 (23.5%) 
30 (26.1%) 
2 (1.7%) 
 
4 (18.2%) 
1 (4.5%) 
- 
15 (68.2%) 
1 (4.5%) 
1 (4.5%) 
 
4 (10.8%) 
6 (16.2%) 
3 (8.1%) 
2 (5.4%) 
20 (54.1%) 
2 (5.4%) 
 
41 (41.0%) 
7 (7.0%) 
- 
40 (40.0%) 
11 (11.0%) 
1 (1.0%) 
 
34 (30.6%) 
12 (10.8%) 
3 (2.7%) 
32 (28.8%) 
28 (25.2%) 
2 (1.8%) 
 
10 (40.0%) 
1 (4.0%) 
- 
10 (40.0%) 
3 (12.0%) 
1 (4.0%) 
 
5 (11.1%) 
6 (13.3%) 
3 (6.7%) 
11 (24.4%) 
18 (40.0%) 
2 (4.4%) 
 
38 (43.2%) 
7 (8.0%) 
- 
30 (34.1%) 
12 (13.6%) 
1 (1.1%) 
 
45 (32.8%) 
13 (9.5%) 
 3 (2.2%) 
42 (30.7%) 
31 (22.6%) 
 3 (2.2%) 
Surgery 
  Gross total resection 
  Subtotal resection (50-99%) 
  Partial resection (<50%) 
  Biopsy 
  Unknown 
 
36 (36.4%) 
36 (36.4%) 
25 (25.3%) 
2 (2.0%) 
16 
 
8 (40.0%) 
7 (35.0%) 
5 (25.0%) 
- 
2 
 
12 (36.4%) 
15 (45.5%) 
6 (18.2%) 
- 
4 
 
32 (37.2%) 
28 (32.6%) 
24 (27.9%) 
2 (2.3%) 
14 
 
34 (35.4%) 
34 (35.4%) 
26 (27.1%) 
2 (2.1%) 
15 
 
10 (45.5%) 
8 (36.4%) 
4 (18.2%) 
- 
3 
 
15 (38.5%) 
16 (41.0%) 
8 (20.5%) 
- 
6 
 
27 (35.1%) 
27 (35.1%) 
21 (27.3%) 
2 (2.6%) 
11 
 
44 (37.0%) 
43 (36.1%) 
30 (25.2%) 
2 (1.7%) 
18 
Initial postsurgical 
management 
  Observation 
  Radiotherapy 
  Chemotherapy 
  Radiotherapy plus chemoth. 
  Other 
 
 
60 (52.2%) 
16 (13.9%) 
10 (8.7%) 
28 (24.3%) 
1 (0.9%) 
 
 
6 (27.3%) 
6 (27.3%) 
2 (9.1%) 
8 (36.4%) 
- 
 
 
13 (35.1%) 
8 (21.6%) 
5 (13.5%) 
11 (29.7%) 
- 
 
 
53 (53.0%) 
14 (14.0%) 
7 (7.0%) 
25 (25.0%) 
1 (1.0%) 
 
 
52 (46.8%) 
19 (17.1%) 
11 (9.9%) 
29 (26.1%) 
 
 
 
14 (56.0%) 
3 (12.0%) 
1 (4.0%) 
7 (28.0%) 
 
 
 
14 (31.1%) 
9 (20.0%) 
5 (11.1%) 
17 (37.8%) 
- 
 
 
50 (56.8%) 
12 (13.6%) 
7 (8.0%) 
18 (20.5%) 
1 (1.1%) 
 
 
66 (48.2%) 
22 (16.1%) 
12 (8.8%) 
36 (26.3%) 
1 (0.7%) 
Treatment at first progression 
  No treatment 
  Surgery only 
  Surgery plus radiotherapy 
  Surgery plus chemotherapy 
 
 
8 (11.6%) 
16 (23.2%) 
4 (5.8%) 
 
 
3 (16.7%) 
1 (5.6%) 
2 (11.1%) 
 
 
2 (13.3%) 
4 (26.7%) 
1 (6.7%) 
 
 
9 (12.5%) 
13 (18.1%) 
5 (6.9%) 
 
 
9 (12.9%) 
15 (21.4%) 
4 (5.7%) 
 
 
1 (6.2%) 
2 (12.5%) 
2 (12.5%) 
 
 
6 (24.0%) 
5 (20.0%) 
2 (8.0%) 
 
 
5 (8.5%) 
12 (20.3%) 
4 (6.8%) 
 
 
11 (12.6%) 
17 (19.5%) 
6 (6.9%) 
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  Surgery plus radiotherapy plus  
  chemotherapy 
  Radiotherapy only 
  Chemotherapy only 
  Radiotherapy plus chemoth.  
7 (10.1%) 
 
14 (20.3%) 
7 (10.1%) 
11 (15.9%) 
2 (2.9%) 
3 (16.7%) 
 
3 (16.7%) 
1 (5.6%) 
5 (27.8%) 
- 
3 (20.0%) 
 
1 (6.7%) 
1 (6.7%) 
3 (20.0%) 
- 
7 (9.7%) 
 
16 (22.2%) 
7 (9.7%) 
13 (18.1%) 
2 (2.8%) 
9 (12.9%) 
 
13 (18.6%) 
6 (8.6%) 
12 (17.1%) 
2 (2.9%) 
1 (6.2%) 
 
4 (25.0%) 
2 (12.5%) 
4 (25.0%) 
- 
4 (16.0%) 
 
2 (8.0%) 
1 (4.0%) 
5 (20.0%) 
- 
5 (8.5%) 
 
14 (23.7%) 
6 (10.2%) 
11 (18.6%) 
2 (3.4%) 
10 (11.5%) 
 
17 (19.5%) 
8 (9.2%) 
16 (18.4%) 
2 (2.3%) 
Outcome data          
  Follow-up (median, range), 
years 
5.8 
(0.6-17.7) 
8.4 
(1.2-11.0) 
5.9 
(0.6-9.6) 
6.3 
(0.6-17.7) 
5.8 
(0.6-17.7) 
7.2 
(0.6-11.0) 
5.9 
(0.6-9.7) 
5.8 
(0.6-17.7) 
5.9 
(0.6-17.7) 
  PFS (events) 73/115 19/22 17/37 75/100 73/111 18/25 28/45 61/88 92/137 
  PFS (median, 95% CI), years 5.0 
(3.2-6.7) 
1.5 
(1.2-1.8) 
5.9 
(4.7-7.1) 
3.0 
(2.0-4.0) 
4.7 
(3.1-6.3) 
2.2 
(0-4.4) 
3.6 
(0.9-6.2) 
3.7 
(1.7-5.7) 
3.7 
(2.1-5.3) 
  OS (events) 32/115 15/22 5/37 42/100 34/111 13/25 13/45 32/88 47/137 
  OS (median, 95% CI), years 11.4 
(7.6-15.3) 
2.4 
(1.8-3.1) 
- 8.8 
(6.0-11.6) 
11.5 
(7.7-15.2) 
9.1 
(1.0-17.2) 
- 9.0 
(7.3-10.8) 
9.1 
(6.7-11.6) 
  1-year survival rate (%) 98.2 
(95.8-100) 
86.4 
(72.0-100) 
97.3 
(92.1-100) 
96.0 
(92.1-99.8) 
97.3 
(94.3-100) 
91.8 
(81.0-100) 
95.5 
(89.4-100) 
96.6 
(92.8-100) 
96.3 
(93.2-99.5) 
  2-year survival rate (%) 95.5 
(91.8-99.2) 
62.8 
(42.3-83.3) 
94.4 
(86.9-100) 
88.8 
(82.5-95.0) 
93.5 
(88.9-98.2) 
74.9 
(57.5-92.3) 
86.1 
(75.8-96.4) 
93.0 
(87.7-98.4) 
90.3 
(85.2-95.3) 
  3-year survival rate (%) 89.9 
(84.2-95.6) 
38.6 
(17.8-59.5) 
91.6 
(82.4-100) 
77.9 
(69.6-86.3) 
84.9 
(78.1-91.7) 
66.1 
(46.9-85.3) 
76.5 
(63.7-89.3) 
84.5 
(76.7-92.2) 
81.6 
(74.9-88.3) 
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Supplementary Table 4. Clinical characteristics, molecular markers, treatment and outcome by genomic group according to IDH1/2 
mutation status and array-CGH findings. 
Array-CGH class Group I 
IDH1/2 mutant  
-1p/-19q 
(n=37) 
Group II 
IDH1/2 mutant 
+7q 
(n=31) 
Group III 
IDH1/2 mutant 
 
(n=47) 
Group IV 
IDH1/2 wild-type 
 
(n=9) 
Group V 
IDH1/2 wild-
type  
+7q/-10q 
 (n=13) 
Total 
 
 
(n=137) 
Age (years) 
  Median 
  Range 
 
46 
27-74 
 
38 
21-80 
 
36 
21-68 
 
45 
29-72 
 
55 
44-67 
 
41 
21-80 
Gender 
  Male 
  Female 
 
22 (59.5%) 
15 (40.5%) 
 
19 (61.3%) 
12 (38.7%) 
 
34 (72.3%) 
13 (27.7%) 
 
4 (44.4%) 
5 (55.6%) 
 
5 (38.5%) 
8 (61.5%) 
 
84 (61.3%) 
53 (38.7%) 
Histological diagnosis 
  AII 
  OAII 
  OII 
   AAIII 
   AOAIII 
   AOIII 
 
 4 (10.8%) 
 6 (16.2%) 
 3 (8.1%) 
 2 (5.4%) 
 20 (54.1%) 
 2 (5.4%) 
 
18 (58.1%) 
 2 (6.5%) 
 - 
 8 (25.8%) 
 3 (9.7%) 
 - 
 
19 (40.4%) 
 4 (8.5%) 
 - 
 17 (36.2%) 
 7 (14.9%) 
 - 
 
 1 (11.1%) 
 1 (11.1%) 
 - 
 6 (66.7%) 
 1 (11.1%) 
 - 
 
 3 (23.1%) 
 - 
 -  
 9 (69.2%) 
  
 1 (7.7%) 
 
45 (32.8%) 
13 (9.5%) 
 3 (2.2%) 
42 (30.7%) 
31 (22.6%) 
 3 (2.2%) 
IDH1/2 
  Mutant 
  Wild-type 
 
37 (100%) 
- 
 
31 (100%) 
- 
 
47 (100%) 
- 
 
- 
9 (100%) 
 
- 
13 (100%) 
 
115 (83.9%) 
22 (16.1%) 
1p/19q 
  Co-deleted 
  Not co-deleted 
 
37 (100%) 
- 
 
- 
31 (100%) 
 
- 
47 (100%) 
 
- 
9 (100%) 
 
- 
13 (100%) 
 
  37 (27.0%) 
100 (73.0%) 
MGMT promoter 
  Unmethylated 
  Weakly methylated 
  Strongly methylated 
  Unknown 
 
1 (2.7%) 
3 (8.1%) 
33 (89.2%) 
 
5 (16.1%) 
4 (12.9%) 
22 (71.0%) 
 
5 (10.9%) 
4 (8.7%) 
37 (80.4%) 
1 
 
6 (66.7%) 
1 (11.1%) 
2 (22.2%) 
 
8 (61.5%) 
1 (7.7%) 
4 (30.8%) 
 
25 (18.4%) 
13 (9.6%) 
98 (72.1%) 
1 
TERT promoter 
  Mutant 
  Wild-type 
  Unknown 
 
33 (91.7%) 
3 (8.3%) 
1 
 
1 (3.3%) 
29 (96.7%) 
1 
 
1 (2.2%) 
45 (97.8%) 
1 
 
1 (11.1%) 
8 (88.9%) 
 
 
9 (75.0%) 
3 (25.0%) 
1 
 
45 (33.8%) 
88 (66.2%) 
4 
Surgery       
 12 
  Gross total resection 
  Subtotal resection (50-99%) 
  Partial resection (<50%) 
  Biopsy 
  Unknown 
12 (36.4%) 
15 (45.5%) 
6 (18.2%) 
- 
4 
7 (26.9%) 
11 (42.3%) 
7 (26.9%) 
1 (3.8%) 
5 
17 (42.5%) 
10 (25.0%) 
12 (30.0%) 
1 (2.5%) 
7 
4 (50.0%) 
3 (37.5%) 
1 (12.5%) 
- 
1 
4 (33.3%) 
4 (33.3%) 
4 (33.3%) 
- 
1 
44 (37.0%) 
43 (36.1%) 
30 (25.2%) 
2 (1.7%) 
18 
Initial postsurgical management 
  Observation 
  Radiotherapy 
  Chemotherapy 
..Radiotherapy plus chemotherapy 
  Other 
 
 
13 (35.1%) 
8 (21.6%) 
5 (13.5%) 
11 (29.7%) 
  - 
 
 
22 (71.0%) 
2 (6.5%) 
1 (3.2%) 
6 (19.4%) 
- 
 
 
25 (53.2%) 
6 (12.8%) 
4 (8.5%) 
11 (23.4%) 
1 (2.1%) 
 
 
3 (33.3%) 
3 (33.3%) 
1 (11.1%) 
2 (22.2%) 
- 
 
 
3 (23.1%) 
3 (23.1%) 
1 (7.7%) 
6 (46.2%) 
- 
 
 
66 (48.2%) 
22 (16.1%) 
12 (8.8%) 
36 (26.3%) 
1 (0.7%) 
Treatment at first progression 
  No treatment 
  Surgery only 
  Surgery plus radiotherapy 
  Surgery plus chemotherapy 
  Surgery plus radiotherapy plus 
  chemotherapy 
  Radiotherapy only 
  Chemotherapy only 
  Radiotherapy plus chemotherapy 
 
2 (13.3%) 
4 (26.7%) 
1 (6.7%) 
3 (20.0%) 
 
1 (6.7%) 
1 (6.7%) 
3 (20.0%) 
- 
 
2 (11.1%) 
6 (33.3%) 
- 
1 (5.6%) 
 
5 (27.8%) 
3 (16.7%) 
1 (5.6%) 
- 
 
4 (11.1%) 
6 (16.7%) 
3 (8.3%) 
3 (8.3%) 
 
8 (22.2%) 
3 (8.3%) 
7 (19.4%) 
2 (5.6%) 
 
- 
1 (16.7%) 
- 
1 (16.7%) 
 
1 (16.7%) 
1 (16.7%) 
2 (33.3%) 
- 
 
3 (25.0%) 
- 
2 (16.7%) 
2 (16.7%) 
 
2 (16.7%) 
- 
3 (25.0%) 
- 
 
11 (12.6%) 
17 (19.5%) 
6 (6.9%) 
10 (11.5%) 
 
17 (19.5%) 
8 (9.2%) 
16 (18.4%) 
2 (2.3%) 
Outcome data       
  Follow-up (median, range), years 5.9 
(0.6-9.6) 
5.6 
(1.7-7.5) 
6.4 
(0.6-17.7) 
8.4 
(5.8-11.0) 
6.3 
(1.2-9.7) 
5.9 
(0.6-17.7) 
  PFS (events) 17/37 20/31 36/47 6/9 13/13 92/137 
  PFS (median, 95% CI), years 5.9 
(4.7-7.1) 
3.7 
(1.1-6.4) 
3.0 
(0.8-5.1) 
4.1 
(2.0-6.2) 
1.5 
(0.7-2.3) 
3.7 
(2.1-5.3) 
  OS (events) 5/37 11/31 16/47 5/9 10/13 47/137 
  OS (median, 95% CI), years - 8.9 
(4.9-12.7) 
12.6 
(3.4-21.9) 
9.1 
(0-20.2) 
2.4 
(2.0-2.9) 
9.1 
(6.7-11.6) 
  1-year survival rate (%) 97.3 
(92.1-100) 
100 
 
97.8 
(93.6-100) 
 
- 
92.3 
(77.8-100) 
96.3 
(93.2-99.5) 
  2-year survival rate (%) 94.4 
(86.9-100) 
96.8 
(90.6-100) 
95.6 
(89.6-100) 
 
- 
68.4 
(42.6-94.1) 
90.3 
(85.2-95.3) 
  3-year survival rate (%) 91.6 
(82.4-100) 
89.6 
(78.4-100) 
88.8 
(79.5-98.1) 
 
- 
25.6 
(0.8-50.5) 
81.6 
(74.9-88.3) 
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Supplementary Table 5. Frequency of high-level amplifications affecting EGFR, PDGFRA, CDK4, MDM2, MDM4 and other loci by 
genomic group according to array-CGH findings. 
 
Chromosomal sites with 
high-level amplification  
Known cancer 
gene amplified 
Genomic 
group I  
(n=37) 
Genomic 
group II  
(n=31) 
Genomic 
group III 
(n=47) 
Genomic 
group IV  
(n=9) 
Genomic 
group V  
(n=13) 
IDH1/2 wt 
primary 
glioblastoma 
(n=54)* 
1q32.1 MDM4 - - 1 (2%) - 3 (23%) 6 (11%) 
4q12 PDGFRA - - - - - 4 (7%) 
7p11.2 EGFR - 1 (3%) 1 (2%) - 8 (62%) 26 (48%) 
12q14.1 CDK4 - - 1 (2%) 1 (11%) 2 (15%) 9 (17%) 
12q15 MDM2 - - - 1 (11%) 1 (8%) 5 (9%) 
Other chromosomal sites 
(can be >1 per tumor)  1 22 9 10 12 65 
        
Total number of high-level 
amplifications (can be >1 
per tumor)  
1 23 12 12 26 115 
Average number of high-
level amplifications per 
tumor 
 0.03 0.74 0.26 1.33 2 2.13 
Number of tumors with at 
least 1 high-level 
amplification   
1 (3%) 10 (32%) 6 (13%) 4 (44%) 11 (85%) 39 (72%) 
 
*Data from reference [1] 
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Supplementary Table 6. Clinical characteristics, molecular markers, treatment and outcome by gene expression groups. 
Expression group Group 1 
(n=11) 
Group 2 
(n=6) 
Group 3 
(n=5) 
Group 4 
(n=22) 
Group 5 
(n=25) 
Group 6 
(n=15) 
Group 7 
(n=26) 
Group 8 
(n=27) 
Total 
(n=137) 
Age (years) 
  Median 
  Range 
 
55 
44-67 
 
48 
40-72 
 
41 
29-47 
 
45 
24-80 
 
30 
21-51 
 
39 
25-54 
 
48 
27-74 
 
37 
23-59 
 
41 
21-80 
Gender 
  Male 
  Female 
 
4 (36.4%) 
7 (63.6%) 
 
2 (33.3%) 
4 (66.7%) 
 
3 (60.0%) 
2 (40.0%) 
 
15 (68.2%) 
7 (31.8%) 
 
15 (60.0%) 
10 (40.0%) 
 
10 (66.7%) 
5 (33.3%) 
 
13 (50.0%) 
13 (50.0%) 
 
22 (81.5%) 
5 (18.5%) 
 
84 (61.3%) 
53 (38.7%) 
Histological diagnosis 
  AII 
  AOII 
  OII 
   AAIII 
   AOAIII 
   AOIII 
 
2 (18.2%) 
- 
- 
9 (81.8%) 
- 
- 
 
- 
- 
- 
4 (66.7%) 
1 (16.7%) 
1 (16.7%) 
 
2 (40.0%) 
1 (20.0%) 
- 
2 (40.0%) 
- 
- 
 
1 (4.5%) 
2 (9.1%) 
- 
10 (45.5%) 
9 (40.9%) 
- 
 
13 (52.0%) 
1 (4.0%) 
- 
10 (40.0%) 
1 (4.0%) 
- 
 
13 (86.7%) 
- 
- 
1 (6.7%) 
1 (6.7%) 
- 
 
1 (3.8%) 
3 (11.5%) 
3 (11.5%) 
2 (7.7%) 
15 (57.7%) 
2 (7.7%) 
 
13 (48.1%) 
6 (22.2%) 
- 
4 (14.8%) 
4 (14.8%) 
- 
 
45 (32.8%) 
13 (9.5%) 
 3 (2.2%) 
42 (30.7%) 
31 (22.6%) 
 3 (2.2%) 
IDH1/2 
  Mutant 
  Wild-type 
 
- 
11 (100%) 
 
- 
6 (100%) 
 
- 
5 (100%) 
 
22 (100%) 
- 
 
25 (100%) 
- 
 
15 (100%) 
- 
 
26 (100%) 
- 
 
27 (100%) 
- 
 
115 (83.9%) 
22 (16.1%) 
1p/19q 
  Co-deleted 
  Not co-deleted 
 
- 
11 (100%) 
 
- 
6 (100%) 
 
- 
5 (100%) 
 
2 (9.1%) 
20 (90.9%) 
 
- 
25 (100%) 
 
3 (20.0%) 
12 (80.0%) 
 
26 (100%) 
- 
 
6 (22.2%) 
21 (77.8%) 
 
  37 (27.0%) 
100 (73.0%) 
MGMT promoter 
  Unmethylated 
  Weakly methylated 
  Strongly methylated 
  Unknown 
 
6 (54.5%) 
1 (9.1%) 
4 (36.4%) 
 
 
5 (83.3%) 
- 
1 (16.7%) 
 
3 (60.0%) 
1 (20.0%) 
1 (20.0%) 
 
2 (9.1%) 
- 
20 (90.9%) 
 
 
4 (16.0%) 
5 (20.0%) 
16 (64.0%) 
 
 
- 
1 (7.1%) 
13 (92.9%) 
1 
 
1 (3.8%) 
3 (11.5%) 
22 (84.6%) 
 
4 (14.8%) 
2 (7.4%) 
21 (77.8%) 
 
25 (18.4%) 
13 (9.6%) 
98 (72.1%) 
1 
TERT promoter 
  Mutant 
  Wild-type 
  Unknown 
 
8 (80.0%) 
2 (20.0%) 
1 
 
2 (33.3%) 
4 (66.7%) 
 
 
- 
5 (100%) 
 
 
- 
20 (100%) 
2 
 
2 (8.0%) 
23 (92.0%) 
 
 
3 (21.4%) 
11 (78.6%) 
1 
 
25 (96.2%) 
1 (3.8%) 
 
5 (18.5%) 
22 (81.5%) 
 
45 (33.8%) 
88 (66.2%) 
4 
Surgery 
  Gross total resection 
  Subtotal resection (50-99%) 
  Partial resection (<50%) 
  Biopsy 
 
3 (30.0%) 
3 (30.0%) 
4 (40.0%) 
- 
 
2 (40.0%) 
3 (60.0%) 
- 
- 
 
3 (60.0%) 
1 (20.0%) 
1 (20.0%) 
- 
 
8 (40.0%) 
5 (25.0%) 
7 (35.0%) 
- 
 
8 (33.3%) 
9 (37.5%) 
7 (29.2%) 
- 
 
2 (20.0%) 
3 (30.0%) 
3 (30.0%) 
2 (20.0%) 
 
10 (43.5%) 
11 (47.8%) 
2 (8.7%) 
- 
 
8 (36.4%) 
8 (36.4%) 
6 (27.3%) 
- 
 
44 (37.0%) 
43 (36.1%) 
30 (25.2%) 
2 (1.7%) 
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  Unknown 1 1  2 1 5 3 5 18 
Initial postsurgical 
management 
  Observation 
  Radiotherapy 
  Chemotherapy 
..Radiotherapy plus chemotherapy 
  Other 
 
 
2 (18.2%) 
3 (27.3%) 
- 
6 (54.5%) 
- 
 
 
1 (16.7%) 
2 (33.3%) 
1 (16.7%) 
2 (33.3%) 
- 
 
 
3 (60.0%) 
1 (20.0%) 
1 (20.0%) 
- 
- 
 
 
6 (27.3%) 
3 (13.6%) 
4 (18.2%) 
9 (40.9%) 
- 
 
 
17 (68.0%) 
3 (12.0%) 
1 (4.0%) 
4 (16.0%) 
- 
 
 
11 (73.3%) 
1 (6.7%) 
1 (6.7%) 
1 (6.7%) 
1 (6.7%) 
 
 
7 (26.9%) 
8 (30.8%) 
3 (11.5%) 
8 (30.8%) 
- 
 
 
19 (70.4%) 
1 (3.7%) 
1 (3.7%) 
6 (22.2%) 
- 
 
 
66 (48.2%) 
22 (16.1%) 
12 (8.8%) 
36 (26.3%) 
1 (0.7%) 
Treatment at first 
progression 
  No treatment 
  Surgery only 
  Surgery plus radiotherapy 
  Surgery plus chemotherapy 
  Surgery plus radiotherapy plus 
  chemotherapy 
  Radiotherapy only 
  Chemotherapy only 
  Radiotherapy plus chemotherapy  
 
 
3 (30.0%) 
1 (10.0%) 
- 
2 (20.0%) 
 
2 (20.0%) 
- 
2 (20.0%) 
- 
 
 
- 
- 
1 (33.3%) 
- 
 
- 
- 
2 (66.7%) 
- 
 
 
- 
- 
1 (20.0%) 
1 (20.0%) 
 
1 (20.0%) 
1 (20.0%) 
1 (20.0%) 
- 
 
 
2 (16.7%) 
2 (16.7%) 
- 
2 (16.7%) 
 
1 (8.3%) 
1 (8.3%) 
3 (25.0%) 
1 (8.3%) 
 
 
1 (5.9%) 
3 (17.6%) 
1 (5.9%) 
1 (5.9%) 
 
6 (35.3%) 
2 (11.8%) 
2 (11.8%) 
1 (5.9%) 
 
 
2 (13.3%) 
4 (26.7%) 
2 (13.3%) 
2 (13.3%) 
 
4 (26.7%) 
- 
1 (6.7%) 
- 
 
 
1 (10.0%) 
3 (30.0%) 
1 (10.0%) 
2 (20.0%) 
 
- 
- 
3 (30.0%) 
- 
 
 
2 (13.3%) 
4 (26.7%) 
- 
- 
 
3 (20.0%) 
4 (26.7%) 
2 (13.3%) 
- 
 
 
11 (12.6%) 
17 (19.5%) 
6 (6.9%) 
10 (11.5%) 
 
17 (19.5%) 
8 (9.2%) 
16 (18.4%) 
2 (2.3%) 
Outcome data          
  Follow-up (median, range), years 9.7 
(1.2-9.7) 
6.3 
- 
8.1 
- 
6.4 
(1.2-12.1) 
4.8 
(0.6-7.2) 
9.6 
(1.7-17.7) 
5.8 
(0.6-9.6) 
6.3 
(1.0-8.1) 
5.9 
(0.6-17.7) 
  PFS (events) 11/11 3/6 5/5 13/22 17/25 15/15 12/26 16/27 92/137 
  PFS (median, 95% CI), years 0.8 
(0.1-1.6) 
1.5 
(1.0-2.0) 
4.1 
(2.3-5.8) 
4.2 
(1.6-6.8) 
2.9 
(2.1-3.8) 
3.4 
(0-7.4) 
5.9 
(2.6-9.2) 
5.9 
(5.4-6.3) 
3.7 
(2.1-5.3) 
  OS (events) 9/11 4/6 2/5 10/22 5/25 6/15 4/26 7/27 47/137 
  OS (median, 95% CI), years 2.4 
(0.9-3.9) 
1.8 
(0-4.5) 
9.1 
(0-19.2) 
6.1 
(2.8-9.5) 
- 
- 
 
- 
 
- 
11.5 
(4.5-18.4) 
9.1 
(6.7-11.6) 
  1-year survival rate (%) 90.9 
(73.9-100) 
 
- 
 
- 
100 
 
100 
 
93.3 
(80.7-100) 
96.2 
(88.8-100) 
100 
 
96.3 
(93.2-99.5) 
  2-year survival rate (%) 51.9 
(21.2-82.7) 
 
- 
 
- 
95.2 
(86.1-100) 
100 
 
93.3 
(80.7-100) 
92.1 
(81.7-100) 
96.2 
(88.8-100) 
90.3 
(85.2-95.3) 
  3-year survival rate (%) 20.8 
(0-46.3) 
 
- 
 
- 
84.7 
(68.6-100) 
91.3 
(79.8-100) 
86.2 
(68.3-100) 
88.1 
(75.5-100) 
96.2 
(88.8-100) 
81.6 
(74.9-88.3) 
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Supplementary Table 7. Relationships between array-CGH-based genomic and mRNA expression profiling-based groups. 
 Expression 
group 1 
Expression 
group 2 
Expression 
group 3 
Expression 
group 4 
Expression 
group 5 
Expression 
group 6 
Expression 
group 7 
Expression 
group 8 
Total 
Genomic 
group I 
   2  3 26* 6 37 
Genomic 
group II 
   7 12 4  8 31 
Genomic 
group III 
   13 13 8  13 47 
Genomic 
group IV 
1 4 4      9 
Genomic 
group V 
10** 2 1      13 
Total 11 6 5 22 25 15 26 27 137 
 
*Corresponding to "integrated molecular group A" as defined by integration of genomic and transcriptomic classification.**Corresponding to 
"intergrated molecular group C" as defined by integration of genomic and transcriptomic classification. All other tumors were assigned to 
"intergrated molecular group B" (see Supplementary Table 8 and Supplementary Fig. 3) 
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Supplementary Table 8. Clinical characteristics, molecular markers, treatment and outcome by the three-tiered molecular 
classification based on array-CGH findings ("genomic groups") or array-CGH findings combined with mRNA expression data 
("integrated molecular groups"). For further information see also Fig. 4 and Supplementary Fig. 3). 
Array-CGH class Genomic group 
I (n=37) 
Genomic 
groups II-IV 
(n=87) 
Genomic group 
V (n=13) 
Integrated 
molecular 
group A 
(n=26) 
Integrated 
molecular 
group B 
(n=101) 
Integrated 
molecular 
group C 
(n=10) 
Total 
(n=137) 
Age (years) 
  Median 
  Range 
 
46 
27-74 
 
38 
21-80 
 
55 
44-67 
 
48 
27-74 
 
39 
21-80 
 
55 
44-67 
 
41 
21-80 
Gender 
  Male 
  Female 
 
22 (59.5%) 
15 (40.5%) 
 
57 (65.5%) 
30 (34.5%) 
 
5 (38.5%) 
8 (61.5%) 
 
13 (50.0%) 
13 (50.0%) 
 
68 (67.3%) 
33 (32.7%) 
 
3 (30.0%) 
7 (70.0%) 
 
84 (61.3%) 
53 (38.7%) 
Histological diagnosis 
  AII 
  OAII 
  OII 
   AAIII 
   AOAIII 
   AOIII 
 
 4 (10.8%) 
 6 (16.2%) 
 3 (8.1%) 
 2 (5.4%) 
 20 (54.1%) 
 2 (5.4%) 
 
38 (43.7%) 
7 (8.0%) 
- 
31 (35.6%) 
11 (12.6%) 
- 
 
 3 (23.1%) 
 - 
 -  
 9 (69.2%) 
  
 1 (7.7%) 
 
1 (3.8%) 
3 (11.5%) 
3 (11.5%) 
2 (7.7%) 
15 (57.7%) 
2 (7.7%) 
 
42 (41.6%) 
10 (9.9%) 
- 
32 (31.7%) 
16 (15.8%) 
1 (1.0%) 
 
2 (20.0%) 
- 
- 
8 (80.0%) 
- 
- 
 
45 (32.8%) 
13 (9.5%) 
 3 (2.2%) 
42 (30.7%) 
31 (22.6%) 
 3 (2.2%) 
IDH1/2 
  Mutant 
  Wild-type 
 
37 (100%) 
- 
 
78 (89.7%) 
9 (10.3%) 
 
- 
13 (100%) 
 
26 (100%) 
- 
 
89 (88.1%) 
12 (11.9%) 
 
- 
10 (100%) 
 
115 (83.9%) 
22 (16.1%) 
1p/19q 
  Co-deleted 
  Not co-deleted 
 
37 (100%) 
- 
 
- 
87 (100%) 
 
- 
13 (100%) 
 
26 (100%) 
- 
 
11 (10.9%) 
90 (89.1%) 
 
- 
10 (100%) 
 
  37 (27.0%) 
100 (73.0%) 
MGMT promoter 
  Unmethylated 
  Weakly methylated 
  Strongly methylated 
  Unknown 
 
1 (2.7%) 
3 (8.1%) 
33 (89.2%) 
 
16 (18.6%) 
9 (10.5%) 
61 (70.9%) 
 
8 (61.5%) 
1 (7.7%) 
4 (30.8%) 
 
1 (3.8%) 
3 (11.5%) 
22 (84.6%) 
 
 
19 (19.0%) 
9 (9.0%) 
72 (72.0%) 
1 
 
5 (50.0%) 
1 (10.0%) 
4 (40.0%) 
 
 
25 (18.4%) 
13 (9.6%) 
98 (72.1%) 
1 
TERT promoter 
  Mutant 
  Wild-type 
  Unknown 
 
33 (91.7%) 
3 (8.3%) 
1 
 
3 (3.5%) 
82 (96.5%) 
2 
 
9 (75.0%) 
3 (25.0%) 
1 
 
25 (96.2%) 
1 (3.8%) 
 
 
13 (13.3%) 
85 (86.7%) 
3 
 
7 (77.8%) 
2 (22.2%) 
1 
 
45 (33.8%) 
88 (66.2%) 
4 
Surgery        
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  Gross total resection 
  Subtotal resection (50-99%) 
  Partial resection (<50%) 
  Biopsy 
  Unknown 
12 (36.4%) 
15 (45.5%) 
6 (18.2%) 
- 
4 
28 (37.8%) 
24 (32.4%) 
20 (27.0%) 
2 (2.7%) 
13 
4 (33.3%) 
4 (33.3%) 
4 (33.3%) 
- 
1 
10 (43.5%) 
11 (47.8%) 
2 (8.7%) 
- 
3 
31 (35.6%) 
30 (34.5%) 
24 (27.6%) 
2 (2.3%) 
14 
3 (33.3%) 
2 (22.2%) 
4 (44.4%) 
- 
1 
44 (37.0%) 
43 (36.1%) 
30 (25.2%) 
2 (1.7%) 
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Initial postsurgical management 
  Observation 
  Radiotherapy 
  Chemotherapy 
..Radiotherapy plus chemotherapy 
  Other 
 
13 (35.1%) 
8 (21.6%) 
5 (13.5%) 
11 (29.7%) 
  - 
 
50 (57.5%) 
11 (12.6%) 
6 (6.9%) 
19 (21.8%) 
1 (1.1%) 
 
3 (23.1%) 
3 (23.1%) 
1 (7.7%) 
6 (46.2%) 
- 
 
7 (26.9%) 
8 (30.8%) 
3 (11.5%) 
8 (30.8%) 
- 
 
57 (56.4%) 
11 (10.9%) 
9 (8.9%) 
23 (22.8%) 
1 (1.0%) 
 
2 (20.0%) 
3 (30.0%) 
- 
5 (50.0%) 
- 
 
66 (48.2%) 
22 (16.1%) 
12 (8.8%) 
36 (26.3%) 
1 (0.7%) 
Treatment at first progression 
  No treatment 
  Surgery only 
  Surgery plus radiotherapy 
  Surgery plus chemotherapy 
  Surgery plus radiotherapy plus 
  chemotherapy 
  Radiotherapy only 
  Chemotherapy only 
  Radiotherapy plus chemotherapy 
 
2 (13.3%) 
4 (26.7%) 
1 (6.7%) 
3 (20.0%) 
 
1 (6.7%) 
1 (6.7%) 
3 (20.0%) 
- 
 
6 (10.0%) 
13 (21.7%) 
3 (5.0%) 
5 (8.3%) 
 
14 (23.3%) 
7 (11.7%) 
10 (16.7%) 
2 (3.3%) 
 
3 (25.0%) 
- 
2 (16.7%) 
2 (16.7%) 
 
2 (16.7%) 
- 
3 (25.0%) 
- 
 
1 (10.0%) 
3 (30.0%) 
1 (10.0%) 
2 (20.0%) 
 
- 
- 
3 (30.0%) 
- 
 
7 (10.3%) 
14 (20.6%) 
5 (7.4%) 
6 (8.8%) 
 
15 (22.1%) 
8 (11.8%) 
11 (16.2%) 
2 (2.9%) 
 
3 (33.3%) 
- 
- 
2 (22.2%) 
 
2 (22.2%) 
- 
2 (22.2%) 
- 
 
11 (12.6%) 
17 (19.5%) 
6 (6.9%) 
10 (11.5%) 
 
17 (19.5%) 
8 (9.2%) 
16 (18.4%) 
2 (2.3%) 
Outcome data        
  Follow-up (median, range), years 5.9 
(0.6-9.6) 
5.9 
(0.6-17.7) 
6.3 
(1.2-9.7) 
5.8 
(0.6-9.6) 
6.2 
(0.6-17.7) 
9.7 
(1.2-9.7) 
5.9 
(0.6-17.7) 
  PFS (events) 17/37 62/87 13/13 12/26 70/101 10/10 92/137 
  PFS (median, 95% CI), years 5.9 
(4.7-7.1) 
3.7 
(2.0-5.5) 
1.5 
(0.7-2.3) 
5.9 
(2.6-9.2) 
4.2 
(2.5-5.8) 
0.8 
(0-1.8) 
3.7 
(2.1-5.3) 
  OS (events) 5/37 32/87 10/13 4/26 35/101 8/10 47/137 
  OS (median, 95% CI), years - 9.0 
(7.2-10.9) 
2.4 
(2.0-2.9) 
- 
 
9.0 
(8.6-9.5) 
2.4 
(0.7-4.1) 
9.1 
(6.7-11.6) 
  1-year survival rate (%) 97.3 
(92.1-100) 
96.5 
(92.7-100) 
92.3 
(77.8-100) 
96.2 
(88.8-100) 
97.0 
(93.7-100) 
90.0 
(71.4-100) 
96.3 
(93.2-99.5) 
  2-year survival rate (%) 94.4 
(86.9-100) 
91.8 
(85.9-97.6) 
68.4 
(42.6-94.1) 
92.1 
(81.7-100) 
92.9 
(87.8-98.0) 
58.3 
(26.8-89.9) 
90.3 
(85.2-95.3) 
  3-year survival rate (%) 91.6 
(82.4-100) 
85.6 
(78.0-93.1) 
25.6 
(0.8-50.5) 
88.1 
(75.5-100) 
85.4 
(78.4-92.5) 
23.3 
(0-51.4) 
81.6 
(74.9-88.3) 
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Supplementary Table 9. List of genes differentially expressed between IDH1/2 mutant astrocytic and oligodendroglial/oligoastrocytic 
gliomas. 
 
Top 100 genes significantly upregulated in astrocytic (AII+AAIII) versus oligodendroglial/oligoastrocytic (OII/OAII+AOIII/AOAIII) tumors. 
Affymetrix 
probeset ID 
Gene 
location 
Gene symbol Gene description Expression 
fold change 
P-value Local FDR 
226192_at X q12 AR androgen receptor [Source:HGNC Symbol;Acc:644] 10.10 2.22E-16 2.26E-12 
243952_at 22 q11 TPTEP1 transmembrane phosphatase with tensin homology pseudogene 1 
[Source:HGNC Symbol;Acc:43648] 
17.12 8.88E-16 1.58E-10 
205856_at 18 q12 SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 
[Source:HGNC Symbol;Acc:10918] 
6.81 4.73E-11 3.16E-07 
203085_s_at 19 q13 TGFB1 transforming growth factor, beta 1 [Source:HGNC Symbol;Acc:11766] 5.25 1.36E-10 1.03E-06 
213506_at 5 q13 F2RL1 coagulation factor II (thrombin) receptor-like 1 [Source:HGNC 
Symbol;Acc:3538] 
5.59 4.29E-10 5.64E-06 
227300_at 12 q23 TMEM119 transmembrane protein 119 [Source:HGNC Symbol;Acc:27884] 4.72 2.63E-09 1.25E-05 
1553202_at 10 q21 STOX1 storkhead box 1 [Source:HGNC Symbol;Acc:23508] 4.79 7.35E-09 4.02E-05 
205786_s_at 16 p11 ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 
[Source:HGNC Symbol;Acc:6149] 
3.87 1.21E-08 7.57E-05 
243337_at 4 q31 FREM3 FRAS1 related extracellular matrix 3 [Source:HGNC Symbol;Acc:25172] 6.08 1.30E-08 7.57E-05 
228442_at 20 q13 NFATC2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 
[Source:HGNC Symbol;Acc:7776] 
4.52 1.75E-08 7.57E-05 
209879_at 12 q24 SELPLG selectin P ligand [Source:HGNC Symbol;Acc:10722] 3.83 2.36E-08 7.57E-05 
207107_at 1 p31 RPE65 retinal pigment epithelium-specific protein 65kDa [Source:HGNC 
Symbol;Acc:10294] 
4.97 3.60E-08 0.0001 
235783_at 1 p36 MRTO4 mRNA turnover 4 homolog (S. cerevisiae) [Source:HGNC 
Symbol;Acc:18477] 
3.89 3.82E-08 0.0001 
204990_s_at 17 q25 ITGB4 integrin, beta 4 [Source:HGNC Symbol;Acc:6158] 3.92 4.33E-08 0.0001 
202295_s_at 15 q25 CTSH cathepsin H [Source:HGNC Symbol;Acc:2535] 3.86 4.69E-08 0.0002 
213160_at 5 q35 DOCK2 dedicator of cytokinesis 2 [Source:HGNC Symbol;Acc:2988] 3.83 5.65E-08 0.0002 
211105_s_at 18 q23 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
[Source:HGNC Symbol;Acc:7775] 
3.74 8.39E-08 0.0002 
208253_at 19 q13 SIGLEC8 sialic acid binding Ig-like lectin 8 [Source:HGNC Symbol;Acc:10877] 3.73 9.97E-08 0.0002 
203868_s_at 1 p21 VCAM1 vascular cell adhesion molecule 1 [Source:HGNC Symbol;Acc:12663] 4.27 1.04E-07 0.0002 
226909_at 4 p16 ZNF518B zinc finger protein 518B [Source:HGNC Symbol;Acc:29365] 3.92 1.22E-07 0.0002 
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206171_at 1 p13 ADORA3 adenosine A3 receptor [Source:HGNC Symbol;Acc:268] 3.96 1.29E-07 0.0002 
230781_at 4 q21 LINC01088 long intergenic non-protein coding RNA 1088 [Source:HGNC 
Symbol;Acc:49148] 
3.95 1.33E-07 0.0002 
226068_at 9 q22 SYK spleen tyrosine kinase [Source:HGNC Symbol;Acc:11491] 3.83 1.49E-07 0.0002 
231044_at 1 p13 C1orf194 chromosome 1 open reading frame 194 [Source:HGNC 
Symbol;Acc:32331] 
4.31 1.64E-07 0.0002 
204983_s_at X q26 GPC4 glypican 4 [Source:HGNC Symbol;Acc:4452] 3.95 1.92E-07 0.0003 
219256_s_at 4 p16 SH3TC1 SH3 domain and tetratricopeptide repeats 1 [Source:HGNC 
Symbol;Acc:26009] 
4.12 2.39E-07 0.0004 
220005_at 3 q25 P2RY13 purinergic receptor P2Y, G-protein coupled, 13 [Source:HGNC 
Symbol;Acc:4537] 
3.67 2.40E-07 0.0004 
206811_at 8 q24 ADCY8 adenylate cyclase 8 (brain) [Source:HGNC Symbol;Acc:239] 4.34 2.75E-07 0.0004 
205067_at 2 q13 IL1B interleukin 1, beta [Source:HGNC Symbol;Acc:5992] 4.30 2.78E-07 0.0004 
204320_at 1 p21 COL11A1 collagen, type XI, alpha 1 [Source:HGNC Symbol;Acc:2186] 5.06 2.80E-07 0.0004 
219994_at 10 p12 APBB1IP amyloid beta (A4) precursor protein-binding, family B, member 1 
interacting protein [Source:HGNC Symbol;Acc:17379] 
3.74 2.88E-07 0.0004 
227346_at 7 p12 IKZF1 IKAROS family zinc finger 1 (Ikaros) [Source:HGNC Symbol;Acc:13176] 3.62 3.31E-07 0.0004 
232231_at 6 p21 RUNX2 runt-related transcription factor 2 [Source:HGNC Symbol;Acc:10472] 4.11 3.39E-07 0.0004 
239229_at X p22 PHEX phosphate regulating endopeptidase homolog, X-linked [Source:HGNC 
Symbol;Acc:8918] 
3.55 4.09E-07 0.0004 
219235_s_at 1 p35 PHACTR4 phosphatase and actin regulator 4 [Source:HGNC Symbol;Acc:25793] 3.02 4.38E-07 0.0006 
222236_s_at 1 p36 ASAP3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 
[Source:HGNC Symbol;Acc:14987] 
2.86 4.98E-07 0.0006 
232861_at 16 q22 PDP2 pyruvate dehyrogenase phosphatase catalytic subunit 2 [Source:HGNC 
Symbol;Acc:30263] 
3.12 5.06E-07 0.0006 
212873_at 19 p13 HMHA1 histocompatibility (minor) HA-1 [Source:HGNC Symbol;Acc:17102] 3.58 5.06E-07 0.0006 
204192_at 19 q13 CD37 CD37 molecule [Source:HGNC Symbol;Acc:1666] 3.64 6.66E-07 0.0008 
207075_at 1 q44 NLRP3 NLR family, pyrin domain containing 3 [Source:HGNC 
Symbol;Acc:16400] 
3.35 6.76E-07 0.0008 
221900_at 1 p34 COL8A2 collagen, type VIII, alpha 2 [Source:HGNC Symbol;Acc:2216] 3.36 6.92E-07 0.0008 
229435_at 9 p24 GLIS3 GLIS family zinc finger 3 [Source:HGNC Symbol;Acc:28510] 3.25 6.98E-07 0.0008 
229816_at 1 p31 WDR78 WD repeat domain 78 [Source:HGNC Symbol;Acc:26252] 3.82 9.94E-07 0.0008 
215046_at 2 q34 KANSL1L KAT8 regulatory NSL complex subunit 1-like [Source:HGNC 
Symbol;Acc:26310] 
3.59 1.04E-06 0.0009 
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204446_s_at 10 q11 ALOX5 arachidonate 5-lipoxygenase [Source:HGNC Symbol;Acc:435] 3.28 1.08E-06 0.0009 
205168_at 1 q23 DDR2 discoidin domain receptor tyrosine kinase 2 [Source:HGNC 
Symbol;Acc:2731] 
3.41 1.11E-06 0.0009 
218786_at 12 q23 NT5DC3 5'-nucleotidase domain containing 3 [Source:HGNC Symbol;Acc:30826] 3.71 1.16E-06 0.0009 
208130_s_at 7 q34 TBXAS1 thromboxane A synthase 1 (platelet) [Source:HGNC Symbol;Acc:11609] 3.36 1.20E-06 0.0009 
215813_s_at 9 q33 PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase 
and cyclooxygenase) [Source:HGNC Symbol;Acc:9604] 
3.72 1.22E-06 0.001 
228338_at 11 q23 COLCA2 colorectal cancer associated 2 [Source:HGNC Symbol;Acc:26978] 3.71 1.28E-06 0.001 
204174_at 13 q12 ALOX5AP arachidonate 5-lipoxygenase-activating protein [Source:HGNC 
Symbol;Acc:436] 
3.51 1.58E-06 0.001 
202934_at 2 p12 HK2 hexokinase 2 [Source:HGNC Symbol;Acc:4923] 3.02 1.70E-06 0.001 
221860_at 19 q13 HNRNPL heterogeneous nuclear ribonucleoprotein L [Source:HGNC 
Symbol;Acc:5045] 
2.64 1.71E-06 0.001 
219202_at 17 q25 RHBDF2 rhomboid 5 homolog 2 (Drosophila) [Source:HGNC Symbol;Acc:20788] 3.42 1.71E-06 0.001 
205466_s_at 4 p15 HS3ST1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 [Source:HGNC 
Symbol;Acc:5194] 
3.75 1.72E-06 0.001 
204439_at 1 p31 IFI44L interferon-induced protein 44-like [Source:HGNC Symbol;Acc:17817] 3.09 1.74E-06 0.001 
1558101_at 1 p31 NFIA nuclear factor I/A [Source:HGNC Symbol;Acc:7784] 3.58 1.75E-06 0.002 
201693_s_at 5 q31 EGR1 early growth response 1 [Source:HGNC Symbol;Acc:3238] 3.32 2.47E-06 0.002 
238135_at 1 p36 AGTRAP angiotensin II receptor-associated protein [Source:HGNC 
Symbol;Acc:13539] 
3.25 2.51E-06 0.002 
205485_at 19 q13 RYR1 ryanodine receptor 1 (skeletal) [Source:HGNC Symbol;Acc:10483] 3.23 2.67E-06 0.002 
242525_at 1 p36 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 
5 [Source:HGNC Symbol;Acc:11010] 
3.21 2.78E-06 0.002 
207695_s_at X q26 IGSF1 immunoglobulin superfamily, member 1 [Source:HGNC 
Symbol;Acc:5948] 
4.11 2.79E-06 0.003 
210560_at 2 q37 GBX2 gastrulation brain homeobox 2 [Source:HGNC Symbol;Acc:4186] 3.07 3.71E-06 0.003 
230252_at 12 p13 LPAR5 lysophosphatidic acid receptor 5 [Source:HGNC Symbol;Acc:13307] 3.02 3.73E-06 0.003 
210764_s_at 1 p22 CYR61 cysteine-rich, angiogenic inducer, 61 [Source:HGNC Symbol;Acc:2654] 3.37 3.77E-06 0.003 
206283_s_at 1 p33 TAL1 T-cell acute lymphocytic leukemia 1 [Source:HGNC Symbol;Acc:11556] 2.80 3.93E-06 0.004 
203332_s_at 2 q37 INPP5D inositol polyphosphate-5-phosphatase, 145kDa [Source:HGNC 
Symbol;Acc:6079] 
2.82 4.23E-06 0.004 
219747_at 4 q27 NDNF neuron-derived neurotrophic factor [Source:HGNC Symbol;Acc:26256] 3.84 4.53E-06 0.004 
201404_x_at 1 p34 PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 [Source:HGNC 2.78 4.95E-06 0.004 
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Symbol;Acc:9539] 
202957_at 3 q13 HCLS1 hematopoietic cell-specific Lyn substrate 1 [Source:HGNC 
Symbol;Acc:4844] 
2.84 5.27E-06 0.004 
1552365_at 7 p21 SCIN scinderin [Source:HGNC Symbol;Acc:21695] 3.48 5.77E-06 0.005 
203104_at 5 q32 CSF1R colony stimulating factor 1 receptor [Source:HGNC Symbol;Acc:2433] 2.37 6.08E-06 0.005 
206170_at 5 q32 ADRB2 adrenoceptor beta 2, surface [Source:HGNC Symbol;Acc:286] 3.09 6.90E-06 0.005 
235892_at 11 q23 COLCA1 colorectal cancer associated 1 [Source:HGNC Symbol;Acc:33789] 3.56 6.91E-06 0.005 
207085_x_at X p22 CSF2RA colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage) [Source:HGNC Symbol;Acc:2435] 
3.32 7.77E-06 0.005 
202833_s_at 14 q32 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 1 [Source:HGNC Symbol;Acc:8941] 
3.87 8.16E-06 0.005 
220927_s_at 10 q24 HPSE2 heparanase 2 [Source:HGNC Symbol;Acc:18374] 3.57 8.36E-06 0.005 
201124_at 3 q21 ITGB5 integrin, beta 5 [Source:HGNC Symbol;Acc:6160] 3.14 8.78E-06 0.005 
204731_at 1 p22 TGFBR3 transforming growth factor, beta receptor III [Source:HGNC 
Symbol;Acc:11774] 
2.45 9.26E-06 0.008 
1557433_at 1 p13 CLCC1 chloride channel CLIC-like 1 [Source:HGNC Symbol;Acc:29675] 2.65 1.01E-05 0.008 
223958_s_at 14 q24 DNAL1 dynein, axonemal, light chain 1 [Source:HGNC Symbol;Acc:23247] 2.87 1.04E-05 0.008 
218035_s_at 4 p14 RBM47 RNA binding motif protein 47 [Source:HGNC Symbol;Acc:30358] 3.41 1.08E-05 0.008 
236666_s_at 11 q12 LRRC10B leucine rich repeat containing 10B [Source:HGNC Symbol;Acc:37215] 3.01 1.11E-05 0.008 
223737_x_at 18 q11 CHST9 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 
[Source:HGNC Symbol;Acc:19898] 
3.49 1.13E-05 0.008 
204787_at X q12 VSIG4 V-set and immunoglobulin domain containing 4 [Source:HGNC 
Symbol;Acc:17032] 
2.86 1.37E-05 0.008 
213566_at 14 q11 RNASE6 ribonuclease, RNase A family, k6 [Source:HGNC Symbol;Acc:10048] 3.08 1.39E-05 0.008 
218551_at 1 p36 MIIP migration and invasion inhibitory protein [Source:HGNC 
Symbol;Acc:25715] 
2.52 1.41E-05 0.008 
225328_at 8 q24 FBXO32 F-box protein 32 [Source:HGNC Symbol;Acc:16731] 2.70 1.49E-05 0.008 
209521_s_at X q23 AMOT angiomotin [Source:HGNC Symbol;Acc:17810] 2.89 1.53E-05 0.008 
202581_at 6 p21 HSPA1B heat shock 70kDa protein 1B [Source:HGNC Symbol;Acc:5233] 2.73 1.54E-05 0.008 
212103_at 1 p35 KPNA6 karyopherin alpha 6 (importin alpha 7) [Source:HGNC Symbol;Acc:6399] 2.20 1.57E-05 0.008 
210166_at 1 q41 TLR5 toll-like receptor 5 [Source:HGNC Symbol;Acc:11851] 2.90 1.64E-05 0.01 
227376_at 7 p14 GLI3 GLI family zinc finger 3 [Source:HGNC Symbol;Acc:4319] 2.71 1.67E-05 0.01 
206726_at 4 q22 HPGDS hematopoietic prostaglandin D synthase [Source:HGNC 3.31 1.75E-05 0.01 
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Symbol;Acc:17890] 
227645_at 17 p13 PIK3R5 phosphoinositide-3-kinase, regulatory subunit 5 [Source:HGNC 
Symbol;Acc:30035] 
2.96 1.77E-05 0.01 
211742_s_at 17 q11 EVI2B ecotropic viral integration site 2B [Source:HGNC Symbol;Acc:3500] 2.65 1.77E-05 0.01 
202545_at 3 p21 PRKCD protein kinase C, delta [Source:HGNC Symbol;Acc:9399] 3.21 1.78E-05 0.01 
242086_at 1 p33 SPATA6 spermatogenesis associated 6 [Source:HGNC Symbol;Acc:18309] 3.40 2.13E-05 0.01 
220146_at X p22 TLR7 toll-like receptor 7 [Source:HGNC Symbol;Acc:15631] 3.33 2.14E-05 0.01 
244352_at 1 q23 CD84 CD84 molecule [Source:HGNC Symbol;Acc:1704] 2.73 2.25E-05 0.01 
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242774_at 14 q23 SYNE2 spectrin repeat containing, nuclear envelope 2 [Source:HGNC 
Symbol;Acc:17084] 
0.09 2.22E-16 2.26E-12 
211022_s_at X q21 ATRX alpha thalassemia/mental retardation syndrome X-linked 
[Source:HGNC Symbol;Acc:886] 
0.11 2.22E-16 2.26E-12 
209591_s_at 20 q13 BMP7 bone morphogenetic protein 7 [Source:HGNC Symbol;Acc:1074] 0.13 3.77E-14 1.96E-08 
223940_x_at 11 q13 MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein 
coding) [Source:HGNC Symbol;Acc:29665] 
0.19 1.11E-12 1.96E-08 
206984_s_at 18 q12 RIT2 Ras-like without CAAX 2 [Source:HGNC Symbol;Acc:10017] 0.13 5.28E-12 1.49E-07 
230112_at 2 q35 MARCH4 membrane-associated ring finger (C3HC4) 4, E3 ubiquitin protein 
ligase [Source:HGNC Symbol;Acc:29269] 
0.12 1.00E-11 1.49E-07 
235009_at 4 p15 BOD1L1 biorientation of chromosomes in cell division 1-like 1 [Source:HGNC 
Symbol;Acc:31792] 
0.18 1.11E-11 1.52E-07 
209966_x_at 1 q41 ESRRG estrogen-related receptor gamma [Source:HGNC Symbol;Acc:3474] 0.16 1.71E-11 3.16E-07 
1555609_a_at 3 q26 ZMAT3 zinc finger, matrin-type 3 [Source:HGNC Symbol;Acc:29983] 0.18 3.74E-11 3.16E-07 
214464_at 1 q42 CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) [Source:HGNC 
Symbol;Acc:1737] 
0.21 4.07E-11 3.16E-07 
235388_at 16 q12 CHD9 chromodomain helicase DNA binding protein 9 [Source:HGNC 
Symbol;Acc:25701] 
0.22 4.55E-11 3.16E-07 
208065_at 18 q21 ST8SIA3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 
[Source:HGNC Symbol;Acc:14269] 
0.17 8.63E-11 5.58E-07 
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210693_at 19 p13 SPPL2B signal peptide peptidase like 2B [Source:HGNC Symbol;Acc:30627] 0.19 1.32E-10 5.58E-07 
1553415_at 12 q23 SLC17A8 solute carrier family 17 (vesicular glutamate transporter), member 8 
[Source:HGNC Symbol;Acc:20151] 
0.17 1.80E-10 1.69E-06 
229399_at 10 q25 C10orf118 chromosome 10 open reading frame 118 [Source:HGNC 
Symbol;Acc:24349] 
0.20 2.13E-10 3.18E-06 
221683_s_at 12 q21 CEP290 centrosomal protein 290kDa [Source:HGNC Symbol;Acc:29021] 0.22 2.75E-10 5.64E-06 
242665_at 2 q23 FMNL2 formin-like 2 [Source:HGNC Symbol;Acc:18267] 0.24 6.10E-10 1.21E-05 
204840_s_at 12 q22 EEA1 early endosome antigen 1 [Source:HGNC Symbol;Acc:3185] 0.21 1.19E-09 1.21E-05 
206013_s_at 7 q22 ACTL6B actin-like 6B [Source:HGNC Symbol;Acc:160] 0.18 1.33E-09 1.21E-05 
236620_at 2 q23 RIF1 RAP1 interacting factor homolog (yeast) [Source:HGNC 
Symbol;Acc:23207] 
0.25 1.35E-09 1.21E-05 
216375_s_at 3 q27 ETV5 ets variant 5 [Source:HGNC Symbol;Acc:3494] 0.19 1.56E-09 1.25E-05 
219387_at 2 p16 CCDC88A coiled-coil domain containing 88A [Source:HGNC Symbol;Acc:25523] 0.22 2.21E-09 1.25E-05 
233064_at 19 p13 ZFR2 zinc finger RNA binding protein 2 [Source:HGNC Symbol;Acc:29189] 0.17 2.89E-09 1.25E-05 
227608_at 11 q12 HNRNPUL2 heterogeneous nuclear ribonucleoprotein U-like 2 [Source:HGNC 
Symbol;Acc:25451] 
0.29 3.16E-09 1.25E-05 
204035_at 2 q36 SCG2 secretogranin II [Source:HGNC Symbol;Acc:10575] 0.27 3.29E-09 1.86E-05 
234919_s_at 8 q11 SNTG1 syntrophin, gamma 1 [Source:HGNC Symbol;Acc:13740] 0.21 3.66E-09 4.02E-05 
209891_at 2 q31 SPC25 SPC25, NDC80 kinetochore complex component [Source:HGNC 
Symbol;Acc:24031] 
0.22 6.08E-09 4.02E-05 
204584_at X q28 L1CAM L1 cell adhesion molecule [Source:HGNC Symbol;Acc:6470] 0.22 7.47E-09 4.02E-05 
206381_at 2 q24 SCN2A sodium channel, voltage-gated, type II, alpha subunit [Source:HGNC 
Symbol;Acc:10588] 
0.22 1.07E-08 7.57E-05 
220821_at 18 q23 GALR1 galanin receptor 1 [Source:HGNC Symbol;Acc:4132] 0.20 1.46E-08 7.57E-05 
226471_at 20 q11 GGT7 gamma-glutamyltransferase 7 [Source:HGNC Symbol;Acc:4259] 0.27 2.20E-08 7.57E-05 
233357_at 1 q42 TRIM67 tripartite motif containing 67 [Source:HGNC Symbol;Acc:31859] 0.23 2.31E-08 7.57E-05 
1554287_at 7 q22 TRIM4 tripartite motif containing 4 [Source:HGNC Symbol;Acc:16275] 0.25 2.48E-08 9.50E-05 
235343_at 1 q32 VASH2 vasohibin 2 [Source:HGNC Symbol;Acc:25723] 0.24 3.04E-08 9.50E-05 
204737_s_at 14 q11 MYH6 myosin, heavy chain 6, cardiac muscle, alpha [Source:HGNC 
Symbol;Acc:7576] 
0.22 3.25E-08 9.50E-05 
220112_at 5 q11 ANKRD55 ankyrin repeat domain 55 [Source:HGNC Symbol;Acc:25681] 0.24 4.29E-08 0.0001 
234701_at 16 q24 ANKRD11 ankyrin repeat domain 11 [Source:HGNC Symbol;Acc:21316] 0.24 4.47E-08 0.0001 
1569302_at 11 q21 KIAA1731 KIAA1731 [Source:HGNC Symbol;Acc:29366] 0.28 6.83E-08 0.0002 
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237828_at 12 q24 SRRM4 serine/arginine repetitive matrix 4 [Source:HGNC Symbol;Acc:29389] 0.21 7.86E-08 0.0002 
241585_at 11 p12 LRRC4C leucine rich repeat containing 4C [Source:HGNC Symbol;Acc:29317] 0.23 7.94E-08 0.0002 
242319_at 3 q27 DGKG diacylglycerol kinase, gamma 90kDa [Source:HGNC 
Symbol;Acc:2853] 
0.23 8.44E-08 0.0002 
205184_at 1 q42 GNG4 guanine nucleotide binding protein (G protein), gamma 4 
[Source:HGNC Symbol;Acc:4407] 
0.30 9.55E-08 0.0002 
236390_at 20 p12 SLX4IP SLX4 interacting protein [Source:HGNC Symbol;Acc:16225] 0.24 1.00E-07 0.0002 
206137_at 8 q22 RIMS2 regulating synaptic membrane exocytosis 2 [Source:HGNC 
Symbol;Acc:17283] 
0.25 1.06E-07 0.0002 
206849_at 5 q34 GABRG2 gamma-aminobutyric acid (GABA) A receptor, gamma 2 
[Source:HGNC Symbol;Acc:4087] 
0.19 1.37E-07 0.0002 
208427_s_at 9 p21 ELAVL2 ELAV like neuron-specific RNA binding protein 2 [Source:HGNC 
Symbol;Acc:3313] 
0.27 1.44E-07 0.0002 
240841_at 14 q13 INSM2 insulinoma-associated 2 [Source:HGNC Symbol;Acc:17539] 0.24 1.48E-07 0.0002 
238661_at 8 q12 LINC00966 long intergenic non-protein coding RNA 966 [Source:HGNC 
Symbol;Acc:48723] 
0.25 1.49E-07 0.0002 
230475_at 15 q24 C15orf59 chromosome 15 open reading frame 59 [Source:HGNC 
Symbol;Acc:33753] 
0.28 1.56E-07 0.0002 
244170_at 5 q11 RAB3C RAB3C, member RAS oncogene family [Source:HGNC 
Symbol;Acc:30269] 
0.21 1.59E-07 0.0002 
1558747_at 18 p11 SMCHD1 structural maintenance of chromosomes flexible hinge domain 
containing 1 [Source:HGNC Symbol;Acc:29090] 
0.28 1.78E-07 0.0002 
235880_at 7 q11 SRRM3 serine/arginine repetitive matrix 3 [Source:HGNC Symbol;Acc:26729] 0.27 1.82E-07 0.0002 
1552694_at 12 q12 SLC2A13 solute carrier family 2 (facilitated glucose transporter), member 13 
[Source:HGNC Symbol;Acc:15956] 
0.28 2.01E-07 0.0004 
230180_at 22 q13 DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 [Source:HGNC 
Symbol;Acc:2740] 
0.31 2.41E-07 0.0004 
205952_at 2 p23 KCNK3 potassium channel, subfamily K, member 3 [Source:HGNC 
Symbol;Acc:6278] 
0.26 2.58E-07 0.0004 
206343_s_at 8 p12 NRG1 neuregulin 1 [Source:HGNC Symbol;Acc:7997] 0.23 2.92E-07 0.0004 
205481_at 1 q32 ADORA1 adenosine A1 receptor [Source:HGNC Symbol;Acc:262] 0.25 3.20E-07 0.0004 
230217_at 8 q12 CLVS1 clavesin 1 [Source:HGNC Symbol;Acc:23139] 0.26 3.43E-07 0.0004 
1570395_a_at 12 p13 FAM66C family with sequence similarity 66, member C [Source:HGNC 
Symbol;Acc:21644] 
0.29 3.54E-07 0.0004 
1558411_at 3 q26 EGFEM1P EGF-like and EMI domain containing 1, pseudogene [Source:HGNC 
Symbol;Acc:25149] 
0.27 3.59E-07 0.0004 
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1555058_a_at 1 q32 LPGAT1 lysophosphatidylglycerol acyltransferase 1 [Source:HGNC 
Symbol;Acc:28985] 
0.28 3.64E-07 0.0004 
229032_at 12 q23 WSCD2 WSC domain containing 2 [Source:HGNC Symbol;Acc:29117] 0.20 4.06E-07 0.0004 
203699_s_at 14 q31 DIO2 deiodinase, iodothyronine, type II [Source:HGNC Symbol;Acc:2884] 0.20 4.09E-07 0.0004 
1556057_s_at 2 q31 NEUROD1 neuronal differentiation 1 [Source:HGNC Symbol;Acc:7762] 0.27 4.17E-07 0.0006 
233084_s_at 10 q26 SYCE1 synaptonemal complex central element protein 1 [Source:HGNC 
Symbol;Acc:28852] 
0.27 4.82E-07 0.0006 
207210_at X q28 GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3 [Source:HGNC 
Symbol;Acc:4077] 
0.30 4.96E-07 0.0006 
210814_at 4 q27 TRPC3 transient receptor potential cation channel, subfamily C, member 3 
[Source:HGNC Symbol;Acc:12335] 
0.30 6.12E-07 0.0008 
1553654_at 1 q32 SYT14 synaptotagmin XIV [Source:HGNC Symbol;Acc:23143] 0.29 6.26E-07 0.0008 
201291_s_at 17 q21 TOP2A topoisomerase (DNA) II alpha 170kDa [Source:HGNC 
Symbol;Acc:11989] 
0.24 6.37E-07 0.0008 
1555355_a_at 11 q24 ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1 
[Source:HGNC Symbol;Acc:3488] 
0.28 6.40E-07 0.0008 
213957_s_at 1 q25 CEP350 centrosomal protein 350kDa [Source:HGNC Symbol;Acc:24238] 0.31 7.47E-07 0.0008 
229978_at 16 p13 SHISA9 shisa family member 9 [Source:HGNC Symbol;Acc:37231] 0.24 7.64E-07 0.0008 
220675_s_at 22 q13 PNPLA3 patatin-like phospholipase domain containing 3 [Source:HGNC 
Symbol;Acc:18590] 
0.27 7.86E-07 0.0008 
1554633_a_at 2 p25 MYT1L myelin transcription factor 1-like [Source:HGNC Symbol;Acc:7623] 0.25 8.35E-07 0.0008 
228986_at 12 q21 OSBPL8 oxysterol binding protein-like 8 [Source:HGNC Symbol;Acc:16396] 0.30 8.61E-07 0.0008 
232904_at 3 q26 SLC7A14 solute carrier family 7, member 14 [Source:HGNC Symbol;Acc:29326] 0.29 9.16E-07 0.0008 
235957_at 12 q14 GRIP1 glutamate receptor interacting protein 1 [Source:HGNC 
Symbol;Acc:18708] 
0.29 9.29E-07 0.0008 
238784_at 12 q14 DPY19L2 dpy-19-like 2 (C. elegans) [Source:HGNC Symbol;Acc:19414] 0.28 9.51E-07 0.0008 
1555935_s_at 21 q22 HUNK hormonally up-regulated Neu-associated kinase [Source:HGNC 
Symbol;Acc:13326] 
0.28 9.58E-07 0.0008 
205347_s_at X q22 TMSB15A thymosin beta 15a [Source:HGNC Symbol;Acc:30744] 0.26 1.07E-06 0.0009 
210479_s_at 15 q22 RORA RAR-related orphan receptor A [Source:HGNC Symbol;Acc:10258] 0.26 1.11E-06 0.0009 
210807_s_at 12 q14 SLC16A7 solute carrier family 16 (monocarboxylate transporter), member 7 
[Source:HGNC Symbol;Acc:10928] 
0.31 1.20E-06 0.0009 
218994_s_at 7 q11 STAG3L4 stromal antigen 3-like 4 (pseudogene) [Source:HGNC 
Symbol;Acc:33887] 
0.30 1.29E-06 0.001 
203849_s_at 2 q37 KIF1A kinesin family member 1A [Source:HGNC Symbol;Acc:888] 0.29 1.32E-06 0.001 
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1559163_at 7 p14 INHBA-AS1 INHBA antisense RNA 1 [Source:HGNC Symbol;Acc:40303] 0.28 1.33E-06 0.001 
239415_at 4 q32 MAP9 microtubule-associated protein 9 [Source:HGNC Symbol;Acc:26118] 0.31 1.40E-06 0.001 
227860_at 20 p13 CPXM1 carboxypeptidase X (M14 family), member 1 [Source:HGNC 
Symbol;Acc:15771] 
0.25 1.56E-06 0.001 
210319_x_at 5 q35 MSX2 msh homeobox 2 [Source:HGNC Symbol;Acc:7392] 0.26 1.62E-06 0.001 
211094_s_at 17 q11 NF1 neurofibromin 1 [Source:HGNC Symbol;Acc:7765] 0.31 1.72E-06 0.001 
205967_at 6 p22 HIST1H4C histone cluster 1, H4c [Source:HGNC Symbol;Acc:4787] 0.35 2.13E-06 0.002 
236638_at 2 q21 AMER3 APC membrane recruitment protein 3 [Source:HGNC 
Symbol;Acc:26771] 
0.29 2.19E-06 0.002 
235461_at 4 q24 TET2 tet methylcytosine dioxygenase 2 [Source:HGNC Symbol;Acc:25941] 0.29 2.35E-06 0.002 
220345_at 2 p12 LRRTM4 leucine rich repeat transmembrane neuronal 4 [Source:HGNC 
Symbol;Acc:19411] 
0.30 2.50E-06 0.002 
213067_at 17 p13 MYH10 myosin, heavy chain 10, non-muscle [Source:HGNC 
Symbol;Acc:7568] 
0.34 2.53E-06 0.002 
205165_at 3 p21 CELSR3 cadherin, EGF LAG seven-pass G-type receptor 3 [Source:HGNC 
Symbol;Acc:3230] 
0.29 2.61E-06 0.002 
223254_s_at 14 q12 G2E3 G2/M-phase specific E3 ubiquitin protein ligase [Source:HGNC 
Symbol;Acc:20338] 
0.34 2.77E-06 0.002 
221226_s_at 2 q35 ASIC4 acid-sensing (proton-gated) ion channel family member 4 
[Source:HGNC Symbol;Acc:21263] 
0.30 2.78E-06 0.002 
241801_at 2 q33 PGAP1 post-GPI attachment to proteins 1 [Source:HGNC Symbol;Acc:25712] 0.32 2.87E-06 0.003 
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Supplementary Table 10. List of genes differentially expressed between IDH1/2 mutant 1p/19q co-deleted versus 1p/19q intact 
gliomas. 
 
Top 100 genes significantly upregulated in 1p/19q co-deleted versus 1p/19q intact tumors. 
Affymetrix 
probeset ID 
Gene 
location 
Gene symbol Gene description Expression 
fold change 
P-value Local FDR 
230112_at 2 q35 MARCH4 membrane-associated ring finger (C3HC4) 4, E3 ubiquitin protein ligase 
[Source:HGNC Symbol;Acc:29269] 
21,90 2.22E-16 8.34E-14 
233064_at 19 p13 ZFR2 zinc finger RNA binding protein 2 [Source:HGNC Symbol;Acc:29189] 18.51 2.22E-16 8.34E-14 
206984_s_at 18 q12 RIT2 Ras-like without CAAX 2 [Source:HGNC Symbol;Acc:10017] 12.36 2.22E-16 8.34E-14 
241585_at 11 p12 LRRC4C leucine rich repeat containing 4C [Source:HGNC Symbol;Acc:29317] 12.24 2.22E-16 8.34E-14 
216375_s_at 3 q27 ETV5 ets variant 5 [Source:HGNC Symbol;Acc:3494] 10.87 2.22E-16 8.34E-14 
1555230_a_at 10 q24 KCNIP2 Kv channel interacting protein 2 [Source:HGNC Symbol;Acc:15522] 10.77 2.22E-16 8.34E-14 
210319_x_at 5 q35 MSX2 msh homeobox 2 [Source:HGNC Symbol;Acc:7392] 10.24 2.22E-16 8.34E-14 
233357_at 1 q42 TRIM67 tripartite motif containing 67 [Source:HGNC Symbol;Acc:31859] 10.24 2.22E-16 8.34E-14 
203699_s_at 14 q31 DIO2 deiodinase, iodothyronine, type II [Source:HGNC Symbol;Acc:2884] 9.90 2.22E-16 8.34E-14 
229978_at 16 p13 SHISA9 shisa family member 9 [Source:HGNC Symbol;Acc:37231] 9.86 2.22E-16 8.34E-14 
204737_s_at 14 q11 MYH6 myosin, heavy chain 6, cardiac muscle, alpha [Source:HGNC 
Symbol;Acc:7576] 
9.78 2.22E-16 8.34E-14 
206849_at 5 q34 GABRG2 gamma-aminobutyric acid (GABA) A receptor, gamma 2 [Source:HGNC 
Symbol;Acc:4087] 
9.60 2.22E-16 8.34E-14 
1553415_at 12 q23 SLC17A8 solute carrier family 17 (vesicular glutamate transporter), member 8 
[Source:HGNC Symbol;Acc:20151] 
9.35 2.22E-16 8.34E-14 
227614_at 10 q22 HKDC1 hexokinase domain containing 1 [Source:HGNC Symbol;Acc:23302] 9.28 2.22E-16 8.34E-14 
204014_at 8 p12 DUSP4 dual specificity phosphatase 4 [Source:HGNC Symbol;Acc:3070] 8.88 2.22E-16 8.34E-14 
229032_at 12 q23 WSCD2 WSC domain containing 2 [Source:HGNC Symbol;Acc:29117] 8.71 2.22E-16 8.34E-14 
206013_s_at 7 q22 ACTL6B actin-like 6B [Source:HGNC Symbol;Acc:160] 8.56 2.22E-16 8.34E-14 
205952_at 2 p23 KCNK3 potassium channel, subfamily K, member 3 [Source:HGNC Symbol;Acc:6278] 8.41 2.22E-16 8.34E-14 
235343_at 1 q32 VASH2 vasohibin 2 [Source:HGNC Symbol;Acc:25723] 8.41 2.22E-16 8.34E-14 
204584_at X q28 L1CAM L1 cell adhesion molecule [Source:HGNC Symbol;Acc:6470] 8.34 2.22E-16 8.34E-14 
233220_at 9 q31 GRIN3A glutamate receptor, ionotropic, N-methyl-D-aspartate 3A [Source:HGNC 
Symbol;Acc:16767] 
8.26 2.22E-16 8.34E-14 
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209591_s_at 20 q13 BMP7 bone morphogenetic protein 7 [Source:HGNC Symbol;Acc:1074] 8.13 2.22E-16 8.34E-14 
210735_s_at 15 q22 CA12 carbonic anhydrase XII [Source:HGNC Symbol;Acc:1371] 8.07 2.22E-16 8.34E-14 
211022_s_at X q21 ATRX alpha thalassemia/mental retardation syndrome X-linked [Source:HGNC 
Symbol;Acc:886] 
8.04 2.22E-16 8.34E-14 
209966_x_at 1 q41 ESRRG estrogen-related receptor gamma [Source:HGNC Symbol;Acc:3474] 7.90 2.22E-16 8.34E-14 
208065_at 18 q21 ST8SIA3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 [Source:HGNC 
Symbol;Acc:14269] 
7.78 2.22E-16 8.34E-14 
230217_at 8 q12 CLVS1 clavesin 1 [Source:HGNC Symbol;Acc:23139] 7.48 2.22E-16 8.34E-14 
227860_at 20 p13 CPXM1 carboxypeptidase X (M14 family), member 1 [Source:HGNC 
Symbol;Acc:15771] 
7.29 2.22E-16 8.34E-14 
220112_at 5 q11 ANKRD55 ankyrin repeat domain 55 [Source:HGNC Symbol;Acc:25681] 7.27 2.22E-16 8.34E-14 
1554633_a_at 2 p25 MYT1L myelin transcription factor 1-like [Source:HGNC Symbol;Acc:7623] 7.17 2.22E-16 8.34E-14 
229818_at 12 q24 SVOP SV2 related protein homolog (rat) [Source:HGNC Symbol;Acc:25417] 7.14 2.22E-16 8.34E-14 
1555609_a_at 3 q26 ZMAT3 zinc finger, matrin-type 3 [Source:HGNC Symbol;Acc:29983] 7.08 2.22E-16 8.34E-14 
206330_s_at 9 q22 SHC3 SHC (Src homology 2 domain containing) transforming protein 3 
[Source:HGNC Symbol;Acc:18181] 
7.06 2.22E-16 8.34E-14 
207873_x_at 22 q12 SEZ6L seizure related 6 homolog (mouse)-like [Source:HGNC Symbol;Acc:10763] 7.01 2.22E-16 8.34E-14 
240841_at 14 q13 INSM2 insulinoma-associated 2 [Source:HGNC Symbol;Acc:17539] 6.66 2.22E-16 8.34E-14 
224580_at 12 q13 SLC38A1 solute carrier family 38, member 1 [Source:HGNC Symbol;Acc:13447] 6.50 2.22E-16 8.34E-14 
226907_at 6 q25 PPP1R14C protein phosphatase 1, regulatory (inhibitor) subunit 14C [Source:HGNC 
Symbol;Acc:14952] 
6.42 2.22E-16 8.34E-14 
233337_s_at 16 p11 SEZ6L2 seizure related 6 homolog (mouse)-like 2 [Source:HGNC Symbol;Acc:30844] 6.37 2.22E-16 8.34E-14 
206137_at 8 q22 RIMS2 regulating synaptic membrane exocytosis 2 [Source:HGNC Symbol;Acc:17283] 6.29 2.22E-16 8.34E-14 
221489_s_at 5 q31 SPRY4 sprouty homolog 4 (Drosophila) [Source:HGNC Symbol;Acc:15533] 6.22 2.22E-16 8.34E-14 
230788_at 6 p24 GCNT2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) 
[Source:HGNC Symbol;Acc:4204] 
6.20 2.22E-16 8.34E-14 
214954_at 3 p22 SUSD5 sushi domain containing 5 [Source:HGNC Symbol;Acc:29061] 6.10 2.22E-16 8.34E-14 
214495_at 22 q12 CACNG2 calcium channel, voltage-dependent, gamma subunit 2 [Source:HGNC 
Symbol;Acc:1406] 
6.09 2.22E-16 8.34E-14 
236638_at 2 q21 AMER3 APC membrane recruitment protein 3 [Source:HGNC Symbol;Acc:26771] 5.96 2.22E-16 8.34E-14 
223529_at 18 q12 SYT4 synaptotagmin IV [Source:HGNC Symbol;Acc:11512] 5.95 2.22E-16 8.34E-14 
230826_at 7 p22 MMD2 monocyte to macrophage differentiation-associated 2 [Source:HGNC 
Symbol;Acc:30133] 
5.83 2.22E-16 8.34E-14 
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203267_s_at 17 p11 DRG2 developmentally regulated GTP binding protein 2 [Source:HGNC 
Symbol;Acc:3030] 
5.64 2.22E-16 8.34E-14 
1558706_a_at 2 p11 ATOH8 atonal homolog 8 (Drosophila) [Source:HGNC Symbol;Acc:24126] 5.61 2.22E-16 8.34E-14 
1556641_at 3 q26 SLC7A14 solute carrier family 7, member 14 [Source:HGNC Symbol;Acc:29326] 5.40 2.22E-16 8.34E-14 
229550_at 14 q32 UNC79 unc-79 homolog (C. elegans) [Source:HGNC Symbol;Acc:19966] 4.92 2.22E-16 8.34E-14 
229313_at 11 p14 ANO5 anoctamin 5 [Source:HGNC Symbol;Acc:27337] 4.83 2.22E-16 8.34E-14 
204035_at 2 q36 SCG2 secretogranin II [Source:HGNC Symbol;Acc:10575] 4.74 2.22E-16 8.34E-14 
228060_at 6 q22 SLC35F1 solute carrier family 35, member F1 [Source:HGNC Symbol;Acc:21483] 3.97 2.22E-16 8.34E-14 
244435_at 10 q26 FAM196A family with sequence similarity 196, member A [Source:HGNC 
Symbol;Acc:33859] 
5.82 4.44E-16 1.32E-12 
210246_s_at 11 p15 ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 [Source:HGNC 
Symbol;Acc:59] 
5.10 4.44E-16 1.32E-12 
227550_at 10 q25 GFRA1 GDNF family receptor alpha 1 [Source:HGNC Symbol;Acc:4243] 4.35 4.44E-16 1.32E-12 
229029_at 5 q22 CAMK4 calcium/calmodulin-dependent protein kinase IV [Source:HGNC 
Symbol;Acc:1464] 
6.53 1.33E-15 5.65E-12 
1553997_a_at 16 p11 ASPHD1 aspartate beta-hydroxylase domain containing 1 [Source:HGNC 
Symbol;Acc:27380] 
4.67 1.78E-15 5.65E-12 
213676_at 6 p21 TMEM151B transmembrane protein 151B [Source:HGNC Symbol;Acc:21315] 5.52 2.44E-15 5.65E-12 
205165_at 3 p21 CELSR3 cadherin, EGF LAG seven-pass G-type receptor 3 [Source:HGNC 
Symbol;Acc:3230] 
5.56 2.89E-15 5.65E-12 
220727_at 14 q31 KCNK10 potassium channel, subfamily K, member 10 [Source:HGNC Symbol;Acc:6273] 4.79 2.89E-15 5.65E-12 
213201_s_at 19 q13 TNNT1 troponin T type 1 (skeletal, slow) [Source:HGNC Symbol;Acc:11948] 5.68 3.11E-15 1.24E-11 
1554576_a_at 17 q21 ETV4 ets variant 4 [Source:HGNC Symbol;Acc:3493] 6.24 3.55E-15 1.24E-11 
213059_at 11 p11 CREB3L1 cAMP responsive element binding protein 3-like 1 [Source:HGNC 
Symbol;Acc:18856] 
5.23 4.00E-15 1.24E-11 
239580_at 4 q32 GUCY1A3 guanylate cyclase 1, soluble, alpha 3 [Source:HGNC Symbol;Acc:4685] 5.79 5.33E-15 1.46E-11 
225541_at 3 q26 RPL22L1 ribosomal protein L22-like 1 [Source:HGNC Symbol;Acc:27610] 4.41 1.58E-14 5.09E-11 
218994_s_at 7 q11 STAG3L4 stromal antigen 3-like 4 (pseudogene) [Source:HGNC Symbol;Acc:33887] 5.18 2.38E-14 5.30E-11 
204260_at 20 p12 CHGB chromogranin B (secretogranin 1) [Source:HGNC Symbol;Acc:1930] 3.93 3.06E-14 5.30E-11 
238617_at 1 q44 KIF26B kinesin family member 26B [Source:HGNC Symbol;Acc:25484] 4.88 5.28E-14 1.21E-10 
204713_s_at 1 q24 F5 coagulation factor V (proaccelerin, labile factor) [Source:HGNC 
Symbol;Acc:3542] 
8.43 6.82E-14 1.66E-10 
233025_at 5 p13 PDZD2 PDZ domain containing 2 [Source:HGNC Symbol;Acc:18486] 5.23 8.26E-14 1.66E-10 
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219361_s_at 15 q26 AEN apoptosis enhancing nuclease [Source:HGNC Symbol;Acc:25722] 4.79 9.04E-14 1.66E-10 
227522_at 5 p15 CMBL carboxymethylenebutenolidase homolog (Pseudomonas) [Source:HGNC 
Symbol;Acc:25090] 
3.32 9.26E-14 1.66E-10 
237828_at 12 q24 SRRM4 serine/arginine repetitive matrix 4 [Source:HGNC Symbol;Acc:29389] 6.10 1.74E-13 3.59E-10 
208211_s_at 2 p23 ALK anaplastic lymphoma receptor tyrosine kinase [Source:HGNC Symbol;Acc:427] 5.12 1.98E-13 4.24E-10 
229651_at 17 q11 SEZ6 seizure related 6 homolog (mouse) [Source:HGNC Symbol;Acc:15955] 4.15 2.08E-13 4.24E-10 
220821_at 18 q23 GALR1 galanin receptor 1 [Source:HGNC Symbol;Acc:4132] 6.24 2.31E-13 4.24E-10 
228490_at 15 q26 ABHD2 abhydrolase domain containing 2 [Source:HGNC Symbol;Acc:18717] 4.60 3.00E-13 4.24E-10 
235880_at 7 q11 SRRM3 serine/arginine repetitive matrix 3 [Source:HGNC Symbol;Acc:26729] 5.21 3.05E-13 6.28E-10 
205733_at 15 q26 BLM Bloom syndrome, RecQ helicase-like [Source:HGNC Symbol;Acc:1058] 5.80 3.36E-13 6.28E-10 
210814_at 4 q27 TRPC3 transient receptor potential cation channel, subfamily C, member 3 
[Source:HGNC Symbol;Acc:12335] 
4.55 3.46E-13 6.28E-10 
1555958_at 10 q24 CRTAC1 cartilage acidic protein 1 [Source:HGNC Symbol;Acc:14882] 3.93 4.16E-13 6.28E-10 
212279_at 17 q11 TMEM97 transmembrane protein 97 [Source:HGNC Symbol;Acc:28106] 3.02 4.39E-13 6.28E-10 
220345_at 2 p12 LRRTM4 leucine rich repeat transmembrane neuronal 4 [Source:HGNC 
Symbol;Acc:19411] 
4.57 4.52E-13 6.28E-10 
205230_at 12 q24 RPH3A rabphilin 3A homolog (mouse) [Source:HGNC Symbol;Acc:17056] 4.87 4.80E-13 6.28E-10 
206395_at 3 q27 DGKG diacylglycerol kinase, gamma 90kDa [Source:HGNC Symbol;Acc:2853] 4.23 5.29E-13 1.68E-09 
204465_s_at 10 q24 INA internexin neuronal intermediate filament protein, alpha [Source:HGNC 
Symbol;Acc:6057] 
3.75 7.47E-13 1.68E-09 
219668_at 20 q13 GDAP1L1 ganglioside induced differentiation associated protein 1-like 1 [Source:HGNC 
Symbol;Acc:4213] 
4.22 7.64E-13 1.68E-09 
232027_at 6 q25 SYNE1 spectrin repeat containing, nuclear envelope 1 [Source:HGNC 
Symbol;Acc:17089] 
5.38 8.56E-13 1.68E-09 
220675_s_at 22 q13 PNPLA3 patatin-like phospholipase domain containing 3 [Source:HGNC 
Symbol;Acc:18590] 
5.35 9.62E-13 1.68E-09 
1553654_at 1 q32 SYT14 synaptotagmin XIV [Source:HGNC Symbol;Acc:23143] 4.76 1.00E-12 1.68E-09 
230475_at 15 q24 C15orf59 chromosome 15 open reading frame 59 [Source:HGNC Symbol;Acc:33753] 4.38 1.14E-12 1.68E-09 
209891_at 2 q31 SPC25 SPC25, NDC80 kinetochore complex component [Source:HGNC 
Symbol;Acc:24031] 
5.46 1.16E-12 1.68E-09 
205390_s_at 8 p11 ANK1 ankyrin 1, erythrocytic [Source:HGNC Symbol;Acc:492] 4.88 1.16E-12 1.68E-09 
225777_at 9 q34 SAPCD2 suppressor APC domain containing 2 [Source:HGNC Symbol;Acc:28055] 3.96 1.28E-12 1.68E-09 
204870_s_at 20 p12 PCSK2 proprotein convertase subtilisin/kexin type 2 [Source:HGNC Symbol;Acc:8744] 4.81 1.60E-12 1.68E-09 
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221585_at 17 q24 CACNG4 calcium channel, voltage-dependent. gamma subunit 4 [Source:HGNC 
Symbol;Acc:1408] 
4.50 1.90E-12 2.24E-09 
233084_s_at 10 q26 SYCE1 synaptonemal complex central element protein 1 [Source:HGNC 
Symbol;Acc:28852] 
5.28 1.97E-12 2.24E-09 
212768_s_at 13 q14 OLFM4 olfactomedin 4 [Source:HGNC Symbol;Acc:17190] 5.60 2.20E-12 2.24E-09 
1559163_at 7 p14 INHBA-AS1 INHBA antisense RNA 1 [Source:HGNC Symbol;Acc:40303] 5.25 2.45E-12 2.82E-09 
       
Top 100 genes significantly downregulated in 1p/19q co-deleted versus 1p/19q intact tumors 
       
Affymetrix 
probeset ID 
Gene 
location 
Gene symbol Gene description Expression 
fold change 
P-value Local FDR 
243952_at 22 q11 TPTEP1 transmembrane phosphatase with tensin homology pseudogene 1 
[Source:HGNC Symbol;Acc:43648] 
0.01 2.22E-16 8.34E-14 
204320_at 1 p21 COL11A1 collagen, type XI, alpha 1 [Source:HGNC Symbol;Acc:2186] 0.04 2.22E-16 8.34E-14 
226192_at X q12 AR androgen receptor [Source:HGNC Symbol;Acc:644] 0.05 2.22E-16 8.34E-14 
243337_at 4 q31 FREM3 FRAS1 related extracellular matrix 3 [Source:HGNC Symbol;Acc:25172] 0.05 2.22E-16 8.34E-14 
207107_at 1 p31 RPE65 retinal pigment epithelium-specific protein 65kDa [Source:HGNC 
Symbol;Acc:10294] 
0.06 2.22E-16 8.34E-14 
203868_s_at 1 p21 VCAM1 vascular cell adhesion molecule 1 [Source:HGNC Symbol;Acc:12663] 0.08 2.22E-16 8.34E-14 
205466_s_at 4 p15 HS3ST1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 [Source:HGNC 
Symbol;Acc:5194] 
0.08 2.22E-16 8.34E-14 
230561_s_at 2 q34 KANSL1L KAT8 regulatory NSL complex subunit 1-like [Source:HGNC 
Symbol;Acc:26310] 
0.09 2.22E-16 8.34E-14 
229816_at 1 p31 WDR78 WD repeat domain 78 [Source:HGNC Symbol;Acc:26252] 0.09 2.22E-16 8.34E-14 
228504_at 2 q24 SCN7A sodium channel, voltage-gated, type VII, alpha subunit [Source:HGNC 
Symbol;Acc:10594] 
0.09 2.22E-16 8.34E-14 
235201_at 7 q31 FOXP2 forkhead box P2 [Source:HGNC Symbol;Acc:13875] 0.10 2.22E-16 8.34E-14 
213506_at 5 q13 F2RL1 coagulation factor II (thrombin) receptor-like 1 [Source:HGNC 
Symbol;Acc:3538] 
0.10 2.22E-16 8.34E-14 
223737_x_at 18 q11 CHST9 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 [Source:HGNC 
Symbol;Acc:19898] 
0.10 2.22E-16 8.34E-14 
202833_s_at 14 q32 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 1 [Source:HGNC Symbol;Acc:8941] 
0.11 2.22E-16 8.34E-14 
235275_at 1 p34 BMP8B bone morphogenetic protein 8b [Source:HGNC Symbol;Acc:1075] 0.11 2.22E-16 8.34E-14 
219747_at 4 q27 NDNF neuron-derived neurotrophic factor [Source:HGNC Symbol;Acc:26256] 0.12 2.22E-16 8.34E-14 
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227300_at 12 q23 TMEM119 transmembrane protein 119 [Source:HGNC Symbol;Acc:27884] 0.12 2.22E-16 8.34E-14 
231044_at 1 p13 C1orf194 chromosome 1 open reading frame 194 [Source:HGNC Symbol;Acc:32331] 0.13 2.22E-16 8.34E-14 
242086_at 1 p33 SPATA6 spermatogenesis associated 6 [Source:HGNC Symbol;Acc:18309] 0.13 2.22E-16 8.34E-14 
203085_s_at 19 q13 TGFB1 transforming growth factor, beta 1 [Source:HGNC Symbol;Acc:11766] 0.13 2.22E-16 8.34E-14 
1553202_at 10 q21 STOX1 storkhead box 1 [Source:HGNC Symbol;Acc:23508] 0.13 2.22E-16 8.34E-14 
204472_at 8 q22 GEM GTP binding protein overexpressed in skeletal muscle [Source:HGNC 
Symbol;Acc:4234] 
0.13 2.22E-16 8.34E-14 
1552931_a_at 15 q25 PDE8A phosphodiesterase 8A [Source:HGNC Symbol;Acc:8793] 0.14 2.22E-16 8.34E-14 
228442_at 20 q13 NFATC2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 
[Source:HGNC Symbol;Acc:7776] 
0.14 2.22E-16 8.34E-14 
226068_at 9 q22 SYK spleen tyrosine kinase [Source:HGNC Symbol;Acc:11491] 0.14 2.22E-16 8.34E-14 
202295_s_at 15 q25 CTSH cathepsin H [Source:HGNC Symbol;Acc:2535] 0.15 2.22E-16 8.34E-14 
206012_at 1 q42 LEFTY2 left-right determination factor 2 [Source:HGNC Symbol;Acc:3122] 0.15 2.22E-16 8.34E-14 
238135_at 1 p36 AGTRAP angiotensin II receptor-associated protein [Source:HGNC Symbol;Acc:13539] 0.16 2.22E-16 8.34E-14 
211105_s_at 18 q23 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
[Source:HGNC Symbol;Acc:7775] 
0.16 2.22E-16 8.34E-14 
220991_s_at 7 q36 RNF32 ring finger protein 32 [Source:HGNC Symbol;Acc:17118] 0.17 2.22E-16 8.34E-14 
223660_at 1 p13 ADORA3 adenosine A3 receptor [Source:HGNC Symbol;Acc:268] 0.12 4.44E-16 1.32E-12 
1558101_at 1 p31 NFIA nuclear factor I/A [Source:HGNC Symbol;Acc:7784] 0.15 4.44E-16 1.32E-12 
226909_at 4 p16 ZNF518B zinc finger protein 518B [Source:HGNC Symbol;Acc:29365] 0.16 4.44E-16 1.32E-12 
211286_x_at X p22 CSF2RA colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage) [Source:HGNC Symbol;Acc:2435] 
0.16 4.44E-16 1.32E-12 
227091_at 7 q11 CCDC146 coiled-coil domain containing 146 [Source:HGNC Symbol;Acc:29296] 0.19 4.44E-16 1.32E-12 
222236_s_at 1 p36 ASAP3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 [Source:HGNC 
Symbol;Acc:14987] 
0.23 4.44E-16 1.32E-12 
215813_s_at 9 q33 PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and 
cyclooxygenase) [Source:HGNC Symbol;Acc:9604] 
0.15 6.66E-16 5.30E-12 
206432_at 8 q24 HAS2 hyaluronan synthase 2 [Source:HGNC Symbol;Acc:4819] 0.15 6.66E-16 5.30E-12 
220005_at 3 q25 P2RY13 purinergic receptor P2Y, G-protein coupled, 13 [Source:HGNC 
Symbol;Acc:4537] 
0.16 6.66E-16 5.30E-12 
227346_at 7 p12 IKZF1 IKAROS family zinc finger 1 (Ikaros) [Source:HGNC Symbol;Acc:13176] 0.16 6.66E-16 5.30E-12 
207826_s_at 1 p36 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 
[Source:HGNC Symbol;Acc:5362] 
0.27 6.66E-16 5.30E-12 
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206811_at 8 q24 ADCY8 adenylate cyclase 8 (brain) [Source:HGNC Symbol;Acc:239] 0.13 1.11E-15 5.30E-12 
219202_at 17 q25 RHBDF2 rhomboid 5 homolog 2 (Drosophila) [Source:HGNC Symbol;Acc:20788] 0.17 1.33E-15 5.65E-12 
212873_at 19 p13 HMHA1 histocompatibility (minor) HA-1 [Source:HGNC Symbol;Acc:17102] 0.17 1.78E-15 5.65E-12 
204439_at 1 p31 IFI44L interferon-induced protein 44-like [Source:HGNC Symbol;Acc:17817] 0.19 2.00E-15 5.65E-12 
219235_s_at 1 p35 PHACTR4 phosphatase and actin regulator 4 [Source:HGNC Symbol;Acc:25793] 0.22 2.22E-15 5.65E-12 
232231_at 6 p21 RUNX2 runt-related transcription factor 2 [Source:HGNC Symbol;Acc:10472] 0.14 2.44E-15 5.65E-12 
213992_at X q22 COL4A6 collagen, type IV, alpha 6 [Source:HGNC Symbol;Acc:2208] 0.16 2.44E-15 5.65E-12 
220146_at X p22 TLR7 toll-like receptor 7 [Source:HGNC Symbol;Acc:15631] 0.14 2.66E-15 5.65E-12 
1552367_a_at 7 p21 SCIN scinderin [Source:HGNC Symbol;Acc:21695] 0.14 3.11E-15 1.24E-11 
219994_at 10 p12 APBB1IP amyloid beta (A4) precursor protein-binding, family B, member 1 interacting 
protein [Source:HGNC Symbol;Acc:17379] 
0.17 3.11E-15 1.24E-11 
219256_s_at 4 p16 SH3TC1 SH3 domain and tetratricopeptide repeats 1 [Source:HGNC 
Symbol;Acc:26009] 
0.15 4.44E-15 1.24E-11 
202096_s_at 22 q13 TSPO translocator protein (18kDa) [Source:HGNC Symbol;Acc:1158] 0.20 4.44E-15 1.24E-11 
204174_at 13 q12 ALOX5AP arachidonate 5-lipoxygenase-activating protein [Source:HGNC 
Symbol;Acc:436] 
0.16 6.00E-15 1.46E-11 
210895_s_at 3 q13 CD86 CD86 molecule [Source:HGNC Symbol;Acc:1705] 0.16 6.44E-15 1.46E-11 
1553411_s_at 18 q23 SALL3 spalt-like transcription factor 3 [Source:HGNC Symbol;Acc:10527] 0.15 6.66E-15 1.46E-11 
229435_at 9 p24 GLIS3 GLIS family zinc finger 3 [Source:HGNC Symbol;Acc:28510] 0.19 7.11E-15 4.24E-11 
205786_s_at 16 p11 ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 
[Source:HGNC Symbol;Acc:6149] 
0.19 1.18E-14 4.77E-11 
220061_at 16 p12 ACSM5 acyl-CoA synthetase medium-chain family member 5 [Source:HGNC 
Symbol;Acc:26060] 
0.17 1.20E-14 5.09E-11 
209879_at 12 q24 SELPLG selectin P ligand [Source:HGNC Symbol;Acc:10722] 0.19 1.73E-14 5.30E-11 
213160_at 5 q35 DOCK2 dedicator of cytokinesis 2 [Source:HGNC Symbol;Acc:2988] 0.18 1.89E-14 5.30E-11 
226789_at 5 q11 EMB embigin [Source:HGNC Symbol;Acc:30465] 0.16 2.35E-14 5.30E-11 
235783_at 1 p36 MRTO4 mRNA turnover 4 homolog (S. cerevisiae) [Source:HGNC Symbol;Acc:18477] 0.20 3.13E-14 5.30E-11 
213258_at 2 q32 TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
[Source:HGNC Symbol;Acc:11760] 
0.15 3.40E-14 5.83E-11 
206726_at 4 q22 HPGDS hematopoietic prostaglandin D synthase [Source:HGNC Symbol;Acc:17890] 0.16 3.42E-14 1.21E-10 
230252_at 12 p13 LPAR5 lysophosphatidic acid receptor 5 [Source:HGNC Symbol;Acc:13307] 0.20 4.20E-14 1.21E-10 
48659_at 1 p36 MIIP migration and invasion inhibitory protein [Source:HGNC Symbol;Acc:25715] 0.21 4.33E-14 1.21E-10 
204912_at 11 q23 IL10RA interleukin 10 receptor, alpha [Source:HGNC Symbol;Acc:5964] 0.16 4.42E-14 1.21E-10 
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204192_at 19 q13 CD37 CD37 molecule [Source:HGNC Symbol;Acc:1666] 0.18 5.55E-14 1.21E-10 
226219_at 1 q23 ARHGAP30 Rho GTPase activating protein 30 [Source:HGNC Symbol;Acc:27414] 0.17 5.71E-14 1.21E-10 
1555349_a_at 21 q22 ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 
[Source:HGNC Symbol;Acc:6155] 
0.16 6.02E-14 1.21E-10 
1558256_at 19 q11 LINC00662 long intergenic non-protein coding RNA 662 [Source:HGNC 
Symbol;Acc:27122] 
0.22 6.22E-14 1.66E-10 
215017_s_at 1 p22 FNBP1L formin binding protein 1-like [Source:HGNC Symbol;Acc:20851] 0.23 7.59E-14 1.66E-10 
205098_at 3 p21 CCR1 chemokine (C-C motif) receptor 1 [Source:HGNC Symbol;Acc:1602] 0.17 8.02E-14 1.66E-10 
213125_at 1 q23 OLFML2B olfactomedin-like 2B [Source:HGNC Symbol;Acc:24558] 0.17 9.84E-14 1.66E-10 
209716_at 1 p13 CSF1 colony stimulating factor 1 (macrophage) [Source:HGNC Symbol;Acc:2432] 0.25 1.30E-13 3.59E-10 
228462_at 5 p15 IRX2 iroquois homeobox 2 [Source:HGNC Symbol;Acc:14359] 0.14 1.76E-13 3.60E-10 
206011_at 11 q22 CASP1 caspase 1, apoptosis-related cysteine peptidase [Source:HGNC 
Symbol;Acc:1499] 
0.18 2.30E-13 4.24E-10 
218035_s_at 4 p14 RBM47 RNA binding motif protein 47 [Source:HGNC Symbol;Acc:30358] 0.17 2.66E-13 4.24E-10 
230781_at 4 q21 LINC01088 long intergenic non-protein coding RNA 1088 [Source:HGNC 
Symbol;Acc:49148] 
0.17 2.76E-13 4.24E-10 
207145_at 2 q32 MSTN myostatin [Source:HGNC Symbol;Acc:4223] 0.16 2.80E-13 4.24E-10 
236646_at 12 p13 TMEM52B transmembrane protein 52B [Source:HGNC Symbol;Acc:26438] 0.20 2.88E-13 4.24E-10 
204429_s_at 1 p36 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 
[Source:HGNC Symbol;Acc:11010] 
0.20 3.19E-13 6.28E-10 
235802_at 14 q32 PLD4 phospholipase D family, member 4 [Source:HGNC Symbol;Acc:23792] 0.20 4.37E-13 6.28E-10 
204787_at X q12 VSIG4 V-set and immunoglobulin domain containing 4 [Source:HGNC 
Symbol;Acc:17032] 
0.21 4.75E-13 6.28E-10 
213566_at 14 q11 RNASE6 ribonuclease, RNase A family, k6 [Source:HGNC Symbol;Acc:10048] 0.18 4.89E-13 6.28E-10 
212353_at 8 q13 SULF1 sulfatase 1 [Source:HGNC Symbol;Acc:20391] 0.17 5.10E-13 6.28E-10 
203665_at 22 q12 HMOX1 heme oxygenase (decycling) 1 [Source:HGNC Symbol;Acc:5013] 0.15 5.16E-13 6.28E-10 
202545_at 3 p21 PRKCD protein kinase C, delta [Source:HGNC Symbol;Acc:9399] 0.18 7.16E-13 1.68E-09 
204446_s_at 10 q11 ALOX5 arachidonate 5-lipoxygenase [Source:HGNC Symbol;Acc:435] 0.21 1.03E-12 1.68E-09 
1560751_at 18 q11 AQP4-AS1 AQP4 antisense RNA 1 [Source:HGNC Symbol;Acc:26399] 0.20 1.04E-12 1.68E-09 
203591_s_at 1 p34 CSF3R colony stimulating factor 3 receptor (granulocyte) [Source:HGNC 
Symbol;Acc:2439] 
0.22 1.11E-12 1.68E-09 
225384_at 1 p31 DOCK7 dedicator of cytokinesis 7 [Source:HGNC Symbol;Acc:19190] 0.33 1.25E-12 1.68E-09 
203104_at 5 q32 CSF1R colony stimulating factor 1 receptor [Source:HGNC Symbol;Acc:2433] 0.31 1.27E-12 1.68E-09 
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210644_s_at 19 q13 LAIR1 leukocyte-associated immunoglobulin-like receptor 1 [Source:HGNC 
Symbol;Acc:6477] 
0.19 1.31E-12 1.68E-09 
202445_s_at 1 p11 NOTCH2 notch 2 [Source:HGNC Symbol;Acc:7882] 0.23 1.45E-12 1.68E-09 
213425_at 3 p14 WNT5A wingless-type MMTV integration site family, member 5A [Source:HGNC 
Symbol;Acc:12784] 
0.24 1.53E-12 1.68E-09 
204924_at 4 q31 TLR2 toll-like receptor 2 [Source:HGNC Symbol;Acc:11848] 0.17 1.62E-12 2.24E-09 
228885_at 9 q21 MAMDC2 MAM domain containing 2 [Source:HGNC Symbol;Acc:23673] 0.20 1.78E-12 2.24E-09 
203561_at 1 q23 FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) [Source:HGNC 
Symbol;Acc:3616] 
0.18 1.82E-12 2.24E-09 
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Supplementary Table 11. Overview of the major gene ontology terms associated with the gene sets showing differential expression 
between (i) astrocytic versus oligodendroglial/oligoastrocytic gliomas, (ii) 1p/19q co-deleted versus 1p/19q intact gliomas, and (iii) 
WHO grade II versus WHO grade III gliomas. Association strenghts with gene sets were estimated using the gene set enrichment Z-
score (GSZ) of the differential log-expression between the respective condition for all genes studied [2, 4]. The p-values obtained are 
given in parentheses.  
Regulation Astrocytic (AII+AAIII) versus 
oligodendroglial/oligoastrocytic 
(OII/OAII+AOIII/AOAIII) tumors 
1p/19q co-deleted versus 1p/19q intact 
tumors 
WHO grade II versus WHO grade III 
tumors 
Up 1. chromosome 1 (<10-6)  
2. chromosome 19 (<10-6) 
3. inflammatory response (8 10-5) 
4. immune response (2x10-4) 
5. innate immune response (2x10-4) 
1. normal brain (<10-6) 
2. synaptic transmission (<10-6) 
3. chromosome 5 (5x10-5) 
4. chromosome 2 (3x10-4) 
5. nervous system development (3x10-4) 
1. normal brain (<10-6) 
2. synaptic transmission (<10-6) 
3. plasma membrane (9x10-5) 
4. postsynaptic membrane (1x10-4) 
5. chromosome 19 (3x10-4) 
Down 1. normal brain (<10-6) 
2. mitotic cell cycle (2x10-4) 
3. chromosome 2 (2x10-4) 
4. chromosome 5 (3x10-4) 
5. mitochondrion (7x10-4) 
1. chromosome 1 (<10-6) 
2. chromosome 19 (<10-6) 
3. inflammatory response (<10-6) 
4. immune response (<10-6) 
5. innate immune response (5x10-5) 
1. mitotic cell cycle (5x10-5) 
2. nucleic acid binding 1x10-4) 
3. nucleus (1x10-4) 
4. DNA repair (2x10-4) 
5. DNA replication (5x10-4) 
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Supplementary Table 12. List of genes differentially expressed between IDH1/2 mutant gliomas of WHO grade II and III. 
Top 100 genes significantly upregulated in WHO grade II versus WHO grade III tumors. 
Affymetrix 
probeset ID 
Chromosomal 
location 
Gene 
symbol 
Gene description Expression 
fold change 
P-value Local FDR 
206899_at 2 p25 NTSR2 neurotensin receptor 2 [Source:HGNC Symbol;Acc:8040] 5.05 6.70E-10 8.76E-05 
214745_at 3 q25 PLCH1 phospholipase C, eta 1 [Source:HGNC Symbol;Acc:29185] 4.01 4.50E-09 8.76E-05 
219734_at 3 q13 SIDT1 SID1 transmembrane family, member 1 [Source:HGNC 
Symbol;Acc:25967] 
3.61 1.53E-08 0.0002 
208320_at 12 q24 CABP1 calcium binding protein 1 [Source:HGNC Symbol;Acc:1384] 4.55 3.06E-08 0.0002 
206384_at 16 p12 CACNG3 calcium channel, voltage-dependent, gamma subunit 3 
[Source:HGNC Symbol;Acc:1407] 
5.04 3.67E-08 0.0002 
231771_at 13 q12 GJB6 gap junction protein, beta 6, 30kDa [Source:HGNC 
Symbol;Acc:4288] 
4.63 3.79E-08 0.0002 
232010_at 4 q32 FSTL5 follistatin-like 5 [Source:HGNC Symbol;Acc:21386] 4.12 3.94E-08 0.0002 
239275_at 10 q11 FRMPD2 FERM and PDZ domain containing 2 [Source:HGNC 
Symbol;Acc:28572] 
4.04 4.05E-08 0.0002 
233059_at 2 q24 KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3 
[Source:HGNC Symbol;Acc:6264] 
3.95 4.31E-08 0.0008 
214788_x_at 12 q13 DDN dendrin [Source:HGNC Symbol;Acc:24458] 3.63 5.80E-08 0.001 
238697_at X q26 LINC00086 long intergenic non-protein coding RNA 86 [Source:HGNC 
Symbol;Acc:34499] 
3.31 8.60E-08 0.001 
210347_s_at 2 p16 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) [Source:HGNC 
Symbol;Acc:13221] 
4.61 1.15E-07 0.001 
221950_at 10 q26 EMX2 empty spiracles homeobox 2 [Source:HGNC Symbol;Acc:3341] 3.88 1.19E-07 0.001 
210227_at 8 p23 DLGAP2 discs, large (Drosophila) homolog-associated protein 2 
[Source:HGNC Symbol;Acc:2906] 
3.84 1.48E-07 0.001 
223122_s_at 4 q31 SFRP2 secreted frizzled-related protein 2 [Source:HGNC 
Symbol;Acc:10777] 
3.97 1.71E-07 0.001 
210381_s_at 11 p15 CCKBR cholecystokinin B receptor [Source:HGNC Symbol;Acc:1571] 4.12 1.95E-07 0.002 
220927_s_at 10 q24 HPSE2 heparanase 2 [Source:HGNC Symbol;Acc:18374] 3.71 2.59E-07 0.002 
232003_at 19 q13 PNMAL2 paraneoplastic Ma antigen family-like 2 [Source:HGNC 
Symbol;Acc:29206] 
2.91 4.05E-07 0.002 
216452_at 9 q21 TRPM3 transient receptor potential cation channel, subfamily M, member 3 
[Source:HGNC Symbol;Acc:17992] 
3.25 4.23E-07 0.002 
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227217_at 9 q22 WNK2 WNK lysine deficient protein kinase 2 [Source:HGNC 
Symbol;Acc:14542] 
3.37 4.62E-07 0.002 
213636_at 9 p13 KIAA1045 KIAA1045 [Source:HGNC Symbol;Acc:29180] 4.12 5.61E-07 0.003 
235468_at NA RBFOX3 RNA binding protein, fox-1 homolog (C. elegans) 3 [Source:HGNC 
Symbol;Acc:27097] 
4.00 8.20E-07 0.005 
205485_at 19 q13 RYR1 ryanodine receptor 1 (skeletal) [Source:HGNC Symbol;Acc:10483] 2.97 8.24E-07 0.005 
229406_at NA RBFOX3 RNA binding protein, fox-1 homolog (C. elegans) 3 [Source:HGNC 
Symbol;Acc:27097] 
3.47 1.02E-06 0.005 
210408_s_at 14 q11 CPNE6 copine VI (neuronal) [Source:HGNC Symbol;Acc:2319] 3.77 1.24E-06 0.005 
220429_at 4 q26 NDST3 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 
[Source:HGNC Symbol;Acc:7682] 
3.57 1.32E-06 0.005 
215972_at 5 q12 PART1 prostate androgen-regulated transcript 1 (non-protein coding) 
[Source:HGNC Symbol;Acc:17263] 
3.35 1.36E-06 0.005 
239291_at 9 q21 TRPM3 transient receptor potential cation channel, subfamily M, member 3 
[Source:HGNC Symbol;Acc:17992] 
3.38 1.80E-06 0.005 
230255_at 1 p36 GABRD gamma-aminobutyric acid (GABA) A receptor, delta [Source:HGNC 
Symbol;Acc:4084] 
3.40 1.95E-06 0.005 
207695_s_at X q26 IGSF1 immunoglobulin superfamily, member 1 [Source:HGNC 
Symbol;Acc:5948] 
3.62 2.17E-06 0.005 
204229_at 19 q13 SLC17A7 solute carrier family 17 (vesicular glutamate transporter), member 
7 [Source:HGNC Symbol;Acc:16704] 
3.56 2.29E-06 0.005 
205626_s_at 8 q21 CALB1 calbindin 1, 28kDa [Source:HGNC Symbol;Acc:1434] 3.48 2.49E-06 0.005 
206191_at 3 p22 ENTPD3 ectonucleoside triphosphate diphosphohydrolase 3 [Source:HGNC 
Symbol;Acc:3365] 
3.59 3.06E-06 0.007 
228194_s_at 10 q25 SORCS1 sortilin-related VPS10 domain containing receptor 1 
[Source:HGNC Symbol;Acc:16697] 
3.09 3.41E-06 0.007 
208359_s_at 22 q13 KCNJ4 potassium inwardly-rectifying channel, subfamily J, member 4 
[Source:HGNC Symbol;Acc:6265] 
3.24 3.73E-06 0.007 
219671_at 1 p34 HPCAL4 hippocalcin like 4 [Source:HGNC Symbol;Acc:18212] 3.38 4.06E-06 0.007 
207404_s_at 6 q14 HTR1E 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled 
[Source:HGNC Symbol;Acc:5291] 
2.80 4.09E-06 0.007 
222920_s_at 12 q13 TESPA1 thymocyte expressed, positive selection associated 1 
[Source:HGNC Symbol;Acc:29109] 
3.79 4.49E-06 0.007 
215267_s_at 19 q13 SLC8A2 solute carrier family 8 (sodium/calcium exchanger), member 2 
[Source:HGNC Symbol;Acc:11069] 
3.20 4.74E-06 0.007 
1557107_at 7 q22 SLC26A4-
AS1 
SLC26A4 antisense RNA 1 [Source:HGNC Symbol;Acc:22385] 3.14 4.87E-06 0.007 
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236532_at 11 q22 C11orf87 chromosome 11 open reading frame 87 [Source:HGNC 
Symbol;Acc:33788] 
3.43 4.96E-06 0.007 
230238_at 5 q31 SOWAHA sosondowah ankyrin repeat domain family member A 
[Source:HGNC Symbol;Acc:27033] 
3.32 5.09E-06 0.007 
204081_at 11 q24 NRGN neurogranin (protein kinase C substrate, RC3) [Source:HGNC 
Symbol;Acc:8000] 
3.32 5.26E-06 0.007 
205856_at 18 q12 SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood 
group) [Source:HGNC Symbol;Acc:10918] 
3.24 5.45E-06 0.007 
213965_s_at 1 p36 CHD5 chromodomain helicase DNA binding protein 5 [Source:HGNC 
Symbol;Acc:16816] 
3.20 5.82E-06 0.007 
219140_s_at 10 q23 RBP4 retinol binding protein 4, plasma [Source:HGNC Symbol;Acc:9922] 3.16 5.86E-06 0.007 
204718_at 7 q34 EPHB6 EPH receptor B6 [Source:HGNC Symbol;Acc:3396] 3.22 6.22E-06 0.007 
233002_at 14 q32 PPP4R4 protein phosphatase 4, regulatory subunit 4 [Source:HGNC 
Symbol;Acc:23788] 
3.15 6.33E-06 0.007 
210400_at 17 q25 GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 
[Source:HGNC Symbol;Acc:4587] 
2.85 6.41E-06 0.007 
227053_at 6 p21 PACSIN1 protein kinase C and casein kinase substrate in neurons 1 
[Source:HGNC Symbol;Acc:8570] 
3.71 6.82E-06 0.007 
238426_at 7 q22 TMEM130 transmembrane protein 130 [Source:HGNC Symbol;Acc:25429] 3.72 6.83E-06 0.007 
219572_at 7 q31 CADPS2 Ca++-dependent secretion activator 2 [Source:HGNC 
Symbol;Acc:16018] 
2.59 6.86E-06 0.007 
232735_at 1 q21 ANKRD34A ankyrin repeat domain 34A [Source:HGNC Symbol;Acc:27639] 3.14 7.29E-06 0.008 
204230_s_at 19 q13 SLC17A7 solute carrier family 17 (vesicular glutamate transporter), member 
7 [Source:HGNC Symbol;Acc:16704] 
3.48 8.03E-06 0.008 
205625_s_at 8 q21 CALB1 calbindin 1, 28kDa [Source:HGNC Symbol;Acc:1434] 3.49 8.23E-06 0.008 
235128_at 5 q33 SYNPO synaptopodin [Source:HGNC Symbol;Acc:30672] 2.89 8.26E-06 0.008 
227996_at 13 q32 FARP1 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 
(chondrocyte-derived) [Source:HGNC Symbol;Acc:3591] 
2.46 8.56E-06 0.008 
202768_at 19 q13 FOSB FBJ murine osteosarcoma viral oncogene homolog B 
[Source:HGNC Symbol;Acc:3797] 
2.92 8.60E-06 0.008 
204339_s_at 1 q23 RGS4 regulator of G-protein signaling 4 [Source:HGNC 
Symbol;Acc:10000] 
3.64 8.77E-06 0.008 
208457_at 1 p36 GABRD gamma-aminobutyric acid (GABA) A receptor, delta [Source:HGNC 
Symbol;Acc:4084] 
3.14 9.80E-06 0.01 
223121_s_at 4 q31 SFRP2 secreted frizzled-related protein 2 [Source:HGNC 
Symbol;Acc:10777] 
2.97 1.12E-05 0.01 
238600_at 4 p16 JAKMIP1 janus kinase and microtubule interacting protein 1 [Source:HGNC 2.72 1.17E-05 0.01 
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Symbol;Acc:26460] 
218546_at 1 q41 C1orf115 chromosome 1 open reading frame 115 [Source:HGNC 
Symbol;Acc:25873] 
2.92 1.19E-05 0.01 
219308_s_at 1 p31 AK5 adenylate kinase 5 [Source:HGNC Symbol;Acc:365] 3.20 1.43E-05 0.01 
214596_at 1 q43 CHRM3 cholinergic receptor, muscarinic 3 [Source:HGNC 
Symbol;Acc:1952] 
3.53 1.48E-05 0.01 
230973_at 1 p36 SH2D5 SH2 domain containing 5 [Source:HGNC Symbol;Acc:28819] 2.94 1.49E-05 0.01 
241398_at 22 q13 MPPED1 metallophosphoesterase domain containing 1 [Source:HGNC 
Symbol;Acc:1306] 
2.81 1.53E-05 0.01 
241717_at 3 p22 MOBP myelin-associated oligodendrocyte basic protein [Source:HGNC 
Symbol;Acc:7189] 
3.32 1.53E-05 0.01 
206084_at 12 q15 PTPRR protein tyrosine phosphatase, receptor type, R [Source:HGNC 
Symbol;Acc:9680] 
3.38 1.56E-05 0.01 
205551_at 15 q26 SV2B synaptic vesicle glycoprotein 2B [Source:HGNC 
Symbol;Acc:16874] 
3.47 1.59E-05 0.01 
228132_at 4 p16 ABLIM2 actin binding LIM protein family, member 2 [Source:HGNC 
Symbol;Acc:19195] 
2.54 1.59E-05 0.01 
241805_at 4 p12 GABRG1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 
[Source:HGNC Symbol;Acc:4086] 
2.80 1.59E-05 0.01 
236195_x_at 19 q13 PRKCG protein kinase C, gamma [Source:HGNC Symbol;Acc:9402] 2.73 1.60E-05 0.01 
205113_at 8 p21 NEFM neurofilament, medium polypeptide [Source:HGNC 
Symbol;Acc:7734] 
3.73 1.62E-05 0.01 
210181_s_at 12 q24 CABP1 calcium binding protein 1 [Source:HGNC Symbol;Acc:1384] 3.03 1.70E-05 0.01 
207014_at 4 p12 GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 
[Source:HGNC Symbol;Acc:4076] 
3.39 1.70E-05 0.01 
212664_at 19 p13 TUBB4A tubulin, beta 4A class IVa [Source:HGNC Symbol;Acc:20774] 2.42 1.71E-05 0.01 
1552953_a_at 17 q12 NEUROD2 neuronal differentiation 2 [Source:HGNC Symbol;Acc:7763] 2.79 1.74E-05 0.01 
228436_at 1 p13 KCNC4 potassium voltage-gated channel, Shaw-related subfamily, 
member 4 [Source:HGNC Symbol;Acc:6236] 
2.56 1.74E-05 0.01 
208321_s_at 12 q24 CABP1 calcium binding protein 1 [Source:HGNC Symbol;Acc:1384] 3.14 1.78E-05 0.01 
214735_at 6 q25 IPCEF1 interaction protein for cytohesin exchange factors 1 [Source:HGNC 
Symbol;Acc:21204] 
2.54 1.79E-05 0.01 
230972_at 14 q32 ANKRD9 ankyrin repeat domain 9 [Source:HGNC Symbol;Acc:20096] 2.26 1.89E-05 0.02 
207316_at 19 q13 HAS1 hyaluronan synthase 1 [Source:HGNC Symbol;Acc:4818] 2.66 1.90E-05 0.02 
202071_at 20 q13 SDC4 syndecan 4 [Source:HGNC Symbol;Acc:10661] 2.79 2.05E-05 0.02 
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203407_at 16 p13 PPL periplakin [Source:HGNC Symbol;Acc:9273] 3.01 2.12E-05 0.02 
235488_at 17 q12 RASL10B RAS-like, family 10, member B [Source:HGNC Symbol;Acc:30295] 2.70 2.15E-05 0.02 
229770_at 12 q24 GLT1D1 glycosyltransferase 1 domain containing 1 [Source:HGNC 
Symbol;Acc:26483] 
2.81 2.20E-05 0.02 
204337_at 1 q23 RGS4 regulator of G-protein signaling 4 [Source:HGNC 
Symbol;Acc:10000] 
3.20 2.21E-05 0.02 
204505_s_at 8 p21 DMTN dematin actin binding protein [Source:HGNC Symbol;Acc:3382] 2.62 2.22E-05 0.02 
232426_at 15 q26 SV2B synaptic vesicle glycoprotein 2B [Source:HGNC 
Symbol;Acc:16874] 
3.37 2.43E-05 0.02 
206267_s_at 19 p13 MATK megakaryocyte-associated tyrosine kinase [Source:HGNC 
Symbol;Acc:6906] 
2.41 2.45E-05 0.02 
229778_at 12 p12 C12orf39 chromosome 12 open reading frame 39 [Source:HGNC 
Symbol;Acc:28139] 
2.71 2.47E-05 0.02 
220331_at 14 q32 CYP46A1 cytochrome P450, family 46, subfamily A, polypeptide 1 
[Source:HGNC Symbol;Acc:2641] 
2.26 2.47E-05 0.02 
213276_at 7 p13 CAMK2B calcium/calmodulin-dependent protein kinase II beta 
[Source:HGNC Symbol;Acc:1461] 
2.94 2.53E-05 0.02 
229039_at 3 p25 SYN2 synapsin II [Source:HGNC Symbol;Acc:11495] 2.92 2.59E-05 0.02 
1556096_s_at 15 q21 UNC13C unc-13 homolog C (C. elegans) [Source:HGNC Symbol;Acc:23149] 3.29 2.62E-05 0.02 
205635_at 3 q21 KALRN kalirin, RhoGEF kinase [Source:HGNC Symbol;Acc:4814] 2.91 2.63E-05 0.02 
207557_s_at 1 q43 RYR2 ryanodine receptor 2 (cardiac) [Source:HGNC Symbol;Acc:10484] 2.91 2.75E-05 0.02 
228262_at X p22 MAP7D2 MAP7 domain containing 2 [Source:HGNC Symbol;Acc:25899] 3.29 2.84E-05 0.02 
235781_at 9 q34 CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 
[Source:HGNC Symbol;Acc:1389] 
2.92 2.92E-05 0.02 
 
Top 100 genes significantly downregulated in WHO grade II versus WHO grade III tumors. 
Affymetrix 
probeset ID 
Chromosom
al location 
Gene 
symbol 
Gene description Expression 
fold change 
P-value Local FDR 
203474_at 5 q13 IQGAP2 IQ motif containing GTPase activating protein 2 [Source:HGNC 
Symbol;Acc:6111] 
0.20 1.27E-10 2.83E-05 
218883_s_at 4 q35 CENPU centromere protein U [Source:HGNC Symbol;Acc:21348] 0.22 2.99E-09 8.76E-05 
1555564_a_at 4 q25 CFI complement factor I [Source:HGNC Symbol;Acc:5394] 0.21 5.72E-09 0.0002 
201852_x_at 2 q32 COL3A1 collagen, type III, alpha 1 [Source:HGNC Symbol;Acc:2201] 0.19 1.32E-08 0.0002 
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205572_at 8 p23 ANGPT2 angiopoietin 2 [Source:HGNC Symbol;Acc:485] 0.29 4.63E-07 0.003 
211161_s_at 2 q32 COL3A1 collagen, type III, alpha 1 [Source:HGNC Symbol;Acc:2201] 0.28 5.62E-07 0.003 
202291_s_at 12 p12 MGP matrix Gla protein [Source:HGNC Symbol;Acc:7060] 0.27 6.12E-07 0.005 
204162_at 18 p11 NDC80 NDC80 kinetochore complex component [Source:HGNC 
Symbol;Acc:16909] 
0.33 1.04E-06 0.005 
206584_at 8 q21 LY96 lymphocyte antigen 96 [Source:HGNC Symbol;Acc:17156] 0.31 1.23E-06 0.005 
211966_at 13 q34 COL4A2 collagen, type IV, alpha 2 [Source:HGNC Symbol;Acc:2203] 0.29 1.74E-06 0.005 
204146_at 12 p13 RAD51AP
1 
RAD51 associated protein 1 [Source:HGNC Symbol;Acc:16956] 0.34 1.92E-06 0.005 
214467_at 14 q31 GPR65 G protein-coupled receptor 65 [Source:HGNC Symbol;Acc:4517] 0.29 1.96E-06 0.005 
210559_s_at 10 q21 CDK1 cyclin-dependent kinase 1 [Source:HGNC Symbol;Acc:1722] 0.32 2.13E-06 0.005 
242774_at 14 q23 SYNE2 spectrin repeat containing, nuclear envelope 2 [Source:HGNC 
Symbol;Acc:17084] 
0.29 2.35E-06 0.005 
202503_s_at 15 q22 KIAA0101 KIAA0101 [Source:HGNC Symbol;Acc:28961] 0.32 2.62E-06 0.005 
201141_at 7 p15 GPNMB glycoprotein (transmembrane) nmb [Source:HGNC 
Symbol;Acc:4462] 
0.30 2.79E-06 0.005 
211981_at 13 q34 COL4A1 collagen, type IV, alpha 1 [Source:HGNC Symbol;Acc:2202] 0.32 2.82E-06 0.005 
230550_at 11 q12 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
[Source:HGNC Symbol;Acc:13375] 
0.31 2.86E-06 0.005 
215076_s_at 2 q32 COL3A1 collagen, type III, alpha 1 [Source:HGNC Symbol;Acc:2201] 0.29 3.05E-06 0.005 
210052_s_at 20 q11 TPX2 TPX2. microtubule-associated [Source:HGNC Symbol;Acc:1249] 0.33 3.19E-06 0.007 
222680_s_at 1 q32 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) 
[Source:HGNC Symbol;Acc:30288] 
0.33 4.84E-06 0.007 
204822_at 6 q14 TTK TTK protein kinase [Source:HGNC Symbol;Acc:12401] 0.35 5.88E-06 0.007 
219666_at 11 q12 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
[Source:HGNC Symbol;Acc:13375] 
0.32 5.89E-06 0.007 
204006_s_at 1 q23 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 
[Source:HGNC Symbol;Acc:3619] 
0.27 5.94E-06 0.007 
201664_at 3 q25 SMC4 structural maintenance of chromosomes 4 [Source:HGNC 
Symbol;Acc:14013] 
0.37 6.88E-06 0.008 
219918_s_at 1 q31 ASPM asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila) [Source:HGNC Symbol;Acc:19048] 
0.34 7.99E-06 0.008 
209773_s_at 2 p25 RRM2 ribonucleotide reductase M2 [Source:HGNC Symbol;Acc:10452] 0.33 8.01E-06 0.008 
1552862_at 1 q22 RUSC1-
AS1 
RUSC1 antisense RNA 1 [Source:HGNC Symbol;Acc:26680] 0.37 8.89E-06 0.008 
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209138_x_at 22 q11 IGLC2 immunoglobulin lambda constant 2 (Kern-Oz- marker) 
[Source:HGNC Symbol;Acc:5856] 
0.27 8.94E-06 0.008 
203214_x_at 10 q21 CDK1 cyclin-dependent kinase 1 [Source:HGNC Symbol;Acc:1722] 0.35 9.15E-06 0.01 
205394_at 11 q24 CHEK1 checkpoint kinase 1 [Source:HGNC Symbol;Acc:1925] 0.38 1.07E-05 0.01 
219148_at 8 p21 PBK PDZ binding kinase [Source:HGNC Symbol;Acc:18282] 0.33 1.35E-05 0.01 
201291_s_at 17 q21 TOP2A topoisomerase (DNA) II alpha 170kDa [Source:HGNC 
Symbol;Acc:11989] 
0.31 1.40E-05 0.01 
1558411_at 3 q26 EGFEM1P EGF-like and EMI domain containing 1, pseudogene 
[Source:HGNC Symbol;Acc:25149] 
0.35 1.54E-05 0.01 
232724_at 11 q12 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
[Source:HGNC Symbol;Acc:13375] 
0.36 1.55E-05 0.01 
209561_at 1 q22 THBS3 thrombospondin 3 [Source:HGNC Symbol;Acc:11787] 0.40 1.68E-05 0.01 
208368_s_at 13 q13 BRCA2 breast cancer 2, early onset [Source:HGNC Symbol;Acc:1101] 0.41 1.82E-05 0.02 
218542_at 10 q23 CEP55 centrosomal protein 55kDa [Source:HGNC Symbol;Acc:1161] 0.39 1.96E-05 0.02 
201744_s_at 12 q21 LUM lumican [Source:HGNC Symbol;Acc:6724] 0.34 1.99E-05 0.02 
227055_at 12 q13 METTL7B methyltransferase like 7B [Source:HGNC Symbol;Acc:28276] 0.32 2.09E-05 0.02 
218663_at 4 p15 NCAPG non-SMC condensin I complex, subunit G [Source:HGNC 
Symbol;Acc:24304] 
0.37 2.19E-05 0.02 
220132_s_at 12 p13 CLEC2D C-type lectin domain family 2, member D [Source:HGNC 
Symbol;Acc:14351] 
0.38 2.22E-05 0.02 
207165_at 5 q34 HMMR hyaluronan-mediated motility receptor (RHAMM) [Source:HGNC 
Symbol;Acc:5012] 
0.39 2.58E-05 0.02 
220821_at 18 q23 GALR1 galanin receptor 1 [Source:HGNC Symbol;Acc:4132] 0.34 2.59E-05 0.02 
201292_at 17 q21 TOP2A topoisomerase (DNA) II alpha 170kDa [Source:HGNC 
Symbol;Acc:11989] 
0.36 2.79E-05 0.02 
215170_s_at 15 q21 CEP152 centrosomal protein 152kDa [Source:HGNC Symbol;Acc:29298] 0.41 2.85E-05 0.02 
203645_s_at 12 p13 CD163 CD163 molecule [Source:HGNC Symbol;Acc:1631] 0.30 3.31E-05 0.02 
210510_s_at 10 p11 NRP1 neuropilin 1 [Source:HGNC Symbol;Acc:8004] 0.40 3.50E-05 0.02 
223280_x_at 11 q12 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
[Source:HGNC Symbol;Acc:13375] 
0.35 3.63E-05 0.02 
202954_at 20 q13 UBE2C ubiquitin-conjugating enzyme E2C [Source:HGNC 
Symbol;Acc:15937] 
0.37 3.83E-05 0.02 
209040_s_at 6 p21 PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 
[Source:HGNC Symbol;Acc:9545] 
0.38 3.96E-05 0.02 
210260_s_at 5 q23 TNFAIP8 tumor necrosis factor, alpha-induced protein 8 [Source:HGNC 0.40 4.10E-05 0.02 
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Symbol;Acc:17260] 
203213_at 10 q21 CDK1 cyclin-dependent kinase 1 [Source:HGNC Symbol;Acc:1722] 0.38 4.37E-05 0.02 
214677_x_at 22 q11 IGLL5 immunoglobulin lambda-like polypeptide 5 [Source:HGNC 
Symbol;Acc:38476] 
0.30 4.47E-05 0.02 
211864_s_at 10 q23 MYOF myoferlin [Source:HGNC Symbol;Acc:3656] 0.38 4.61E-05 0.03 
227860_at 20 p13 CPXM1 carboxypeptidase X (M14 family), member 1 [Source:HGNC 
Symbol;Acc:15771] 
0.35 5.25E-05 0.03 
219978_s_at 15 q15 NUSAP1 nucleolar and spindle associated protein 1 [Source:HGNC 
Symbol;Acc:18538] 
0.37 5.26E-05 0.03 
203854_at 4 q25 CFI complement factor I [Source:HGNC Symbol;Acc:5394] 0.36 5.35E-05 0.03 
207714_s_at 11 q13 SERPINH
1 
serpin peptidase inhibitor, clade H (heat shock protein 47), 
member 1, (collagen binding protein 1) [Source:HGNC 
Symbol;Acc:1546] 
0.40 5.69E-05 0.03 
209642_at 2 q13 BUB1 BUB1 mitotic checkpoint serine/threonine kinase [Source:HGNC 
Symbol;Acc:1148] 
0.41 6.57E-05 0.05 
231725_at 5 q31 PCDHB2 protocadherin beta 2 [Source:HGNC Symbol;Acc:8687] 0.33 7.61E-05 0.05 
218755_at 5 q31 KIF20A kinesin family member 20A [Source:HGNC Symbol;Acc:9787] 0.42 8.06E-05 0.05 
226936_at 6 q22 CENPW centromere protein W [Source:HGNC Symbol;Acc:21488] 0.43 8.22E-05 0.05 
208309_s_at 18 q21 MALT1 mucosa associated lymphoid tissue lymphoma translocation 
gene 1 [Source:HGNC Symbol;Acc:6819] 
0.41 8.28E-05 0.05 
204846_at 3 q25 CP ceruloplasmin (ferroxidase) [Source:HGNC Symbol;Acc:2295] 0.34 8.69E-05 0.05 
202589_at 18 p11 TYMS thymidylate synthetase [Source:HGNC Symbol;Acc:12441] 0.42 8.79E-05 0.05 
241981_at 17 q24 FAM20A family with sequence similarity 20, member A [Source:HGNC 
Symbol;Acc:23015] 
0.42 8.93E-05 0.05 
230205_at 19 p13 ZNF561 zinc finger protein 561 [Source:HGNC Symbol;Acc:28684] 0.44 9.17E-05 0.05 
225646_at 11 q14 CTSC cathepsin C [Source:HGNC Symbol;Acc:2528] 0.39 9.19E-05 0.05 
223922_x_at 11 q12 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
[Source:HGNC Symbol;Acc:13375] 
0.39 9.76E-05 0.05 
224356_x_at 11 q12 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
[Source:HGNC Symbol;Acc:13375] 
0.37 9.93E-05 0.05 
218710_at 2 p22 TTC27 tetratricopeptide repeat domain 27 [Source:HGNC 
Symbol;Acc:25986] 
0.42 0.00010762 0.05 
244434_at X p11 GPR82 G protein-coupled receptor 82 [Source:HGNC Symbol;Acc:4533] 0.40 0.0001131 0.05 
1563629_a_at 16 p13 ERVK13-1 endogenous retrovirus group K13, member 1 [Source:HGNC 
Symbol;Acc:27548] 
0.44 0.00011507 0.05 
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241726_at 21 q22 SIM2 single-minded family bHLH transcription factor 2 [Source:HGNC 
Symbol;Acc:10883] 
0.33 0.00012188 0.05 
212865_s_at 8 q24 COL14A1 collagen, type XIV. alpha 1 [Source:HGNC Symbol;Acc:2191] 0.40 0.00012353 0.05 
222848_at 5 q12 CENPK centromere protein K [Source:HGNC Symbol;Acc:29479] 0.42 0.00012921 0.05 
229551_x_at 9 q22 ZNF367 zinc finger protein 367 [Source:HGNC Symbol;Acc:18320] 0.44 0.00013057 0.05 
215044_s_at 2 q23 STAM2 signal transducing adaptor molecule (SH3 domain and ITAM 
motif) 2 [Source:HGNC Symbol;Acc:11358] 
0.44 0.00013589 0.05 
215121_x_at 22 q11 IGLC2 immunoglobulin lambda constant 2 (Kern-Oz- marker) 
[Source:HGNC Symbol;Acc:5856] 
0.34 0.00013899 0.05 
213975_s_at 12 q15 LYZ lysozyme [Source:HGNC Symbol;Acc:6740] 0.36 0.00014084 0.05 
213415_at X q28 CLIC2 chloride intracellular channel 2 [Source:HGNC Symbol;Acc:2063] 0.43 0.00014336 0.05 
1555247_a_at 5 q31 RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 [Source:HGNC 
Symbol;Acc:20655] 
0.43 0.00014361 0.05 
236034_at 8 p23 ANGPT2 angiopoietin 2 [Source:HGNC Symbol;Acc:485] 0.41 0.0001472 0.05 
239413_at 15 q21 CEP152 centrosomal protein 152kDa [Source:HGNC Symbol;Acc:29298] 0.45 0.00014832 0.05 
1554696_s_at 18 p11 TYMS thymidylate synthetase [Source:HGNC Symbol;Acc:12441] 0.43 0.00015068 0.05 
237261_at 8 p23 ANGPT2 angiopoietin 2 [Source:HGNC Symbol;Acc:485] 0.42 0.00015342 0.05 
225303_at 1 q23 KIRREL kin of IRRE like (Drosophila) [Source:HGNC Symbol;Acc:15734] 0.44 0.00015439 0.05 
204962_s_at 2 p23 CENPA centromere protein A [Source:HGNC Symbol;Acc:1851] 0.45 0.00015741 0.05 
225107_at 7 p15 HNRNPA2
B1 
heterogeneous nuclear ribonucleoprotein A2/B1 [Source:HGNC 
Symbol;Acc:5033] 
0.47 0.00016264 0.05 
201890_at 2 p25 RRM2 ribonucleotide reductase M2 [Source:HGNC Symbol;Acc:10452] 0.38 0.00016272 0.05 
201508_at 17 q21 IGFBP4 insulin-like growth factor binding protein 4 [Source:HGNC 
Symbol;Acc:5473] 
0.40 0.00016281 0.05 
232898_at 5 p13 DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2 
(Drosophila) [Source:HGNC Symbol;Acc:2662] 
0.44 0.00016298 0.05 
201663_s_at 3 q25 SMC4 structural maintenance of chromosomes 4 [Source:HGNC 
Symbol;Acc:14013] 
0.44 0.0001695 0.05 
214770_at 8 p22 MSR1 macrophage scavenger receptor 1 [Source:HGNC 
Symbol;Acc:7376] 
0.38 0.00017371 0.05 
228144_at 5 q33 ZNF300 zinc finger protein 300 [Source:HGNC Symbol;Acc:13091] 0.47 0.00017614 0.07 
223381_at 1 q23 NUF2 NUF2, NDC80 kinetochore complex component [Source:HGNC 
Symbol;Acc:14621] 
0.44 0.00017663 0.08 
225681_at 8 q22 CTHRC1 collagen triple helix repeat containing 1 [Source:HGNC 
Symbol;Acc:18831] 
0.42 0.00018948 0.09 
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210609_s_at 2 p23 TP53I3 tumor protein p53 inducible protein 3 [Source:HGNC 
Symbol;Acc:19373] 
0.43 0.00019882 0.09 
218802_at 4 q25 CCDC109
B 
coiled-coil domain containing 109B [Source:HGNC 
Symbol;Acc:26076] 
0.43 0.00020151 0.09 
 
 
 48 
Supplementary Table 13. Multivariate analyses based on clinical and histological  
parameters as well as array-CGH analysis without or with consideration of mRNA 
expression profiling (integrated molecular groups A-C), or based on IDH1/2 and 
1p/19q status alone. 
 
 Modeling with mRNA expression 
profiling 
     
Model Factor HR 95% CI P 
value 
Model fit 
deviance 
Improvement 
1 Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
Age > 40 vs. < 40 (ref) 
2.59 
1.71 
4.40 
1.30 - 5.15 
0.92 - 3.20 
2.21 - 8.79 
0.007 
0.090 
<0.001 
374.02 Model 1 to 
null model:  
p<0.001 
2 Age > 40 vs. < 40 (ref) 
Group B vs. group A (ref) 
Group C vs. group A (ref) 
 
3.79 
2.92 
8.08 
 
1.87 - 7.68 
1.03 - 8.31 
2.38 - 27.49 
<0.001 
0.045 
0.001 
 
371.45 Model 2 to 
null model:  
p<0.001 
3 Age >40 vs. < 40 (ref) 
Group B vs.group A (ref) 
Group C vs. group A (ref) 
Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
3.96 
2.59 
5.43 
1.60 
1.66 
1.93 - 8.10 
0.83 - 8.05 
1.36 - 21.64 
0.74 - 3.46 
0.88 - 3.14 
<0.001 
0.100 
0.016 
0.230 
0.118 
367.78 Model 3 to 2: 
p=0.167 
 Modeling based on IDH1/2 and 1p/19q 
status alone 
     
Model Factor HR 95% CI P 
value 
Model fit 
deviance 
Improvement 
1 Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
Age > 40 vs. < 40 (ref) 
 
2.59 
1.71 
4.40 
1.30 - 5.15 
0.92 - 3.20 
2.21 - 8.79 
0.007 
0.090 
<0.001 
374.02 Model 1 to 
null model:  
p<0.001 
2 Age > 40 vs. < 40 (ref) 
IDH mut/1p/19q non- co-deleted vs.  
                                 1p/19q co-deleted (ref) 
IDH wt vs. 
                                 1p/19q-co-deleted (ref) 
 
4.06 
 
3.67 
 
6.82 
 
2.00 - 8.25 
 
1.34 - 9.71 
 
2.44 - 19.08 
<0.001 
 
0.009 
 
<0.001 
 
366.87 Model 2 to 
null model:  
p<0.001 
3 Age >40 vs. <  40 (ref) 
IDH mut/1p/19q non-co-deleted vs.  
                                 1p/19q co-deleted (ref) 
IDH wt vs. 
                                 1p/19q co-deleted (ref) 
Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
 
4.05 
3.38 
 
5.52 
 
1.34 
1.56 
1.97 - 8.30 
1.17 - 9.80 
 
1.74 - 17.46 
 
0.62 - 2.87 
0.83 - 2.95 
<0.001 
0.025 
 
0.004 
 
0.456 
0.167 
364.57 Model 3 to 2: 
p=0.316 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1. Prognostic associations of WHO grade, tumor type and 
established molecular markers in the study cohort of 137 glioma patients. A. WHO grade II 
vs. WHO grade III. B. Astrocytic histology (AII / AAIII) vs. oligodendroglial or oligoastrocytic 
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histology (O II / AO III / OA II / AOA III). C. WHO grade II vs. WHO grade III for astrocytic 
tumors. D. WHO grade II vs. WHO grade III for oligodendroglial tumors. E. IDH1/2 mutant vs. 
IDH1/2 wild-type. F. 1p/19q co-deleted vs. 1p/19q intact. G. 1p/19q co-deleted vs. 1p/19q 
intact in the subgroup of patients with IDH1/2 mutant tumors. H. TERT promoter mutant vs. 
wild-type in the entire patient cohort. I. TERT promoter mutant vs. wild-type in the subgroup 
of patients with IDH1/2 mutant tumors. K. TERT promoter mutant vs. wild-type in the 
subgroup of patients with 1p/19q intact anaplastic gliomas of WHO grade III. L. MGMT 
promoter methylated vs. unmethylated. For each marker, associations with PFS (left) and OS 
(right) are depicted. 
 
 
 
Supplementary Figure 2. A. Comparison of genomic aberrations in group V gliomas with 
those in primary IDH1/2 wild-type glioblastomas. Unsupervised analysis of the 13 group V 
gliomas together with 54 primary glioblastomas investigated before on the same array-CGH 
platform [1] revealed that the group V gliomas are loosely distributed among the primary 
glioblastomas without forming a separate cluster. This indicates that group V tumors share a 
primary glioblastoma-associated genomic aberration profile. B. Comparison of expression 
profiles in the 137 WHO grade II and III gliomas of the present patient cohort with expression 
profiles previously obtained in 70 glioblastomas [1]. The supervised pairwise correlation 
matrix is based on SOM analysis and stratified according to the IDH1/2 mutation status. Note 
that IDH1/2 wild-type gliomas of WHO grade II or III share similar expression profiles with 
IDH1/2 wild-type glioblastomas while IDH1/2 mutant gliomas of WHO grade II or III share 
similar expression profiles with IDH1/2 mutant glioblastomas.  
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Supplementary Figure 3. Pairwise correlation matrix based on SOM analysis of mRNA 
expression data of the 137 investigated gliomas. Samples were clustered by means of maximum 
spanning graph partitioning. In total, 6 major transcriptional subgroups of gliomas (i - vi) become 
evident. The color bars on top of each correlation matrix refer to the histological classification (1), as 
well as the status of MGMT promoter methylation (2), TERT promoter mutation (3), 1p/19q co-
deletion (4), IDH1/2 mutation (5), and the genomic group defined by array-CGH analysis for each 
tumor (6). 
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Supplementary Figure 4. Molecular subgroups defined by integrating mRNA and genomic 
profiling data of WHO grade II and III gliomas. A. Supervised pairwise correlation matrix of 
metagene expression data obtained by SOM analysis stratified according to three groups of 
tumors defined by combining genomic and transcriptomic classification (“intergrated 
molecular goups” A, B and C). The color bars on top refer to the histological classification (1), 
MGMT promoter methylation status (2), TERT promoter mutation status (3), 1p/19q co-
deletion (4), expression group (5) IDH1/2 mutation (6), genomic group defined by array-CGH 
analysis (7), and “integrated molecular group” (8). Group A consists only of genomic group I 
(IDH1/2 mutant, 1p/19q co-deleted) tumors with an expression group 7 profile, while group C 
consists only of group V (IDH1/2 wild-type, +7q/-10q) tumors with expression group 1 profile. 
All the remaining tumors with were compiled in group B. B. Progression-free (PFS) and 
overall survival (OS) according to these three “integrated molecular groups A, B and C”. An 
IDH1/2 wild-type glioblastoma cohort published previously [3] is included for comparison. C, 
PFS and OS in groups A and B stratified by WHO grade (grade II vs III). D. PFS and OS in 
groups A and B stratified by patient age (≤ 40 years vs >40 years). Patients in group C were 
all > 40 years old and except for two patients had WHO grade III tumors. Thus, group C was 
not further stratified according to WHO grade and age. 
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Supplementary Figure 5. Genomic changes detected by array-CGH in (A) IDH1/2 mutant 
astrocytic (A II and AA III) versus oligodendroglial/oligoastrocytic (O II, OA II, AO III, AOA III) 
and (B) 1p/19q intact versus 1p/19q co-deleted gliomas. Shown are frequency plots of 
genomic imbalances detected in each tumor group. Gains of genomic material are indicated 
by green bars while losses are indicated by red bars. The bar length indicates the 
percentage of tumors in each group showing gains or losses at the respective chromosomal 
location. The individual chromosomes are indicated on the bottom and top of each frequency 
plot, with markers on each chromosomes being sorted from pter on the left to qter on the 
right. Most commonly detectable imbalances in oligodendroglial tumors are losses on 1p and 
19q, followed by losses on chromosomes 4, 13, 14 and 15. Most common changes in 
astrocytic gliomas are gains on 7 or 7q, followed by gains on 8q, 10p and 11q as well as 
losses on 9p, 10q, 11p, 12, 13, 14 and 19q (A). These patterns of genomic aberrations 
become even more clear when tumors are stratified according to 1p/19q co-deletion status 
(B). Overall, 1p/19q co-deleted (oligodendroglial) gliomas show significantly fewer genomic 
aberrations per tumor (average number of aberrant genomic regions/tumor: 5) as 1p/19q 
intact (astrocytic) gliomas (average number of aberrant genomic regions/tumor: 15), 
indicating a lower degree of genomic instability in 1p/19q co-deleted tumors (C). 
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 Supplementary Figure 6. Genomic changes associated with WHO grade in IDH1/2 mutant 
gliomas. Shown are frequency plots of genomic imbalances detected in WHO grade II or III 
gliomas as well as plots illustrating genomic differences between the WHO grades. Gains of 
genomic material are indicated by green bars while losses are indicated by red bars. The bar 
length indicates the percentage of tumors in each group showing gains or losses at the 
respective chromosomal location. The individual chromosomes are indicated on the bottom 
and top of each frequency plot, with markers on each chromosomes being sorted from pter 
on the left to qter on the right. To compare the incidence of copy number aberrations 
between subgroups, we performed a clone-wise comparison of copy number gains and 
losses using Fisher’s exact test. For visualization, the p-values were transformed to the 
negative log10 scale in which 2 corresponds to a nominal p-value of 0.01 and 1.3 to a p-
value of 0.05 (third row). (A) WHO grade II versus III in all 115 IDH1/2 mutant gliomas. (B) 
WHO grade II versus III in the 1p/19q co-deleted gliomas (left) and the 1p/19q intact gliomas 
(right). There is no dominant aberration that may drive progression in the majority of cases. 
In 1p/19q co-deleted tumors, gain of chromosome 7 occurs little more frequently in WHO 
grade III tumors, while losses on 9p, 11p, 14q and the sex chromosomes are little more 
common in WHO grade III tumors with the 1p/19q intact genotype. (C) Box plots indicating 
the number of aberrant genomic regions per tumor in WHO grade II versus III tumors in all 
115 IDH1/2 mutant gliomas (left), the subgroup of 1p/19q co-deleted gliomas (middle) and 
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the subgroup of 1p/19q intact gliomas (right). In general, WHO grade III gliomas do not 
appear to carry significantly more genomic aberrations per tumor as WHO grade II gliomas. 
In 1p/19q co-deleted tumors (middle) the number of aberrations per tumor is generally lower 
and tends to increase with WHO grade. 
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Attn: 
Werner Paulus, MD 
Editor-in-Chief, Acta Neuropathologica 
 
03 March 2015 
 
 
Dear Dr Paulus 
 
Please find enclosed the revised version of our manuscript ANEU-D-15-00029. In order to point out 
more clearly the main message of our paper, we have slightly modified the title of the manuscript to: 
 
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and 
transcriptome-wide profiling improves stratification of prognostically distinct patient groups. 
 
We have considered the reviewers’ valuable comments and revised our manuscript accordingly as 
detailed below. Revisions in the manuscript have been highlighted in yellow. The statistical analyses 
were performed by B. Hentschel and M. Löffler at the Institute for Medical Informatics, Statistics and 
Epidemiology, University of Leipzig, Leipzig, Germany. 
 
We hope that our revised manuscript is now suitable for publication in Acta Neuropathologica.  
 
Thank you very much for your interest in our work. 
 
Kind regards 
 
Michael Weller, MD 
 
 
RESPONSES TO THE REVIEWERS 
 
Reviewer #1: The authors performed microarray-based genome- and transcriptome-wide molecular 
profiling of primary tumor samples from 137 patients with grade II-III cerebral gliomas, define 
molecular subgroups, which were then related to histology, molecular biomarkers, and patient 
outcome. They find five distinct glioma groups, including three IDH1/2 mutant and two IDH1/2 wild-
type groups. Expression profiling revealed evidence for eight transcriptionally different tumor groups 
(five IDH1/2 mutant, three IDH1/2 wild-type), which were only partially linked to the genomic 
groups. Correlation of DNA-based molecular stratification with clinical outcome allowed definition of 
three major prognostic groups with characteristic genomic aberrations.  
 
COMMENT 1.  This is clearly an important study that brings relevant markers closer to clinical 
implementation and at the same time represents an improvement over histologic-based 
classification 
 
RESPONSE 
We appreciate the reviewer`s feedback. 
 
COMMENT 2. Genomic group IV is clearly of interest, as these tumors do not have IDH mutations, 
but prognosis-wise, fit into the IDHmut, non-codeleted tumors. As shown in Fig 1B, group IV tumors 
do not have the gain of 7/loss of 10 pattern, although some of them and gain of 7 and others have 
loss of 10.  Are there additional, positive markers that could be employed to more definitively 
encompass these tumors?  Are there differences identifiable on 450k profiling between group IV and 
response to reviewer's comments
Click here to download response to reviewer's comments: ANEU-D-15-00029_Letter_to_the_Editor.docx 
group V tumors? Could some of these group IV tumors have the genetics of circumscribed gliomas 
(for example BRAF mutation) that are histologically masquerading as a diffuse glioma? 
 
RESPONSE 
We have performed some further analyses on the group IV tumors as requested by the reviewer. 
Specifically, we sequenced the mutation hotspots in BRAF in 8 and H3F3A in 7 of the nine cases (due 
to used up DNA, we could not sequence all 9 cases). None of the investigated tumors demonstrated a 
BRAF (V600E) or H3F3A (K27 or G34) mutation. These new data have been added in the revised 
manuscript on page 11. The absence of BRAF mutations does not support the hypothesis that the 
group IV tumors might be circumscribed gliomas masquerading as diffuse gliomas. Concerning the 
reviewer’s suggestion of performing additional 450 k bead array analyses, we believe that this 
approach is beyond the scope of the present manuscript.  
 
COMMENT 3. The improvement in outcome between group V tumors versus IDHwt GBM is of 
interest, since genomically group V tumors look like GBM despite the fact that presumably as a whole 
received less aggressive therapy (as compared to GBM) in the adjuvant setting.  Obviously 
microvascular proliferation and necrosis would be one way to distinguish group V cases from GBM, 
but some cases have limited sampling.  Can the authors examine the differences between group V 
and GBM on a genomic level?  Do the authors wish to comment on the possible value how to 
molecularly "grade" +7/-10 IDHwt glioma? 
 
RESPONSE 
We would like to refer to Supplementary Figure 2A in which we already performed an unsupervised 
comparison between group V tumors and glioblastomas based on genomic aberration profiles. As 
shown in this figure, there is no distinctive genomic aberration detectable between both groups, that 
is group V tumors are not forming a separate cluster on their own but intermingle with 
glioblastomas. We take these data as evidence that group V tumors share the genomic profile with 
glioblastomas, at least at the resolution of array-CGH. Additional studies based on whole genome or 
whole methylome sequencing would be necessary to screen for more subtle genomic/epigenomic 
aberrations that could possibly distinguish both groups and help to molecularly grade the IDH 
wildtype +7/-10 glioma group. For the time being, we agree that we are restricted to the classic 
histological features of microvascular proliferation and necrosis, which admittedly may be missed in 
some patients due to limited sampling.  
 
COMMENT 4. As the authors are aware, the issue of MGMT methylation is a bit confounded by the 
presence of CIMP.  Could the authors comment of the relative value of MGMT methylation testing as 
a prognostic/predictive marker in CIMP-positive versus -negative diffuse glioma? 
 
RESPONSE 
We have recently reported that indeed the IDH mutation status (which closely correlates with the 
gCIMP status) determines whether MGMT promoter methylation is prognostic only or predictive of 
benefit from alkylating chemotherapy (Wick et al. Neurology 2013;81:1515-1522). In the present 
series, we have only 14 IDH wildtype tumors without MGMT promoter methylation and 8 IDH 
wildtype tumors with MGMT promoter methylation. These small numbers plus the heterogeneous 
treatment preclude meaningful analyses of this question. However, as requested, we have now 
inserted one sentence on this topic in the discussion on page 21 and referred to the above 
mentioned paper (reference 37). 
 
 
Reviewer #2: The authors studied 137 WHO grade 2 and 3 tumors for microarray-based copy number 
and transcriptome analysis as well as mutations in several key genes including IDH1/2 and TERT. They 
defined 5 groups according to copy number profile and 8 groups by expression profiling. Copy-
number and expression groups were only partially associated with each other. In addition to the IDH 
and 1p19q status, which are considered to be a molecular diagnostic marker for adult gliomas, gain 
of 7q and/or loss of 10q as well as TERT promoter mutation was a potentially useful prognostic 
marker when combined. Expression profiling was not found to improve the prognostic stratification 
defined by genomic/genetic findings.  
 
The prospective WHO classification will most certainly employ a combination of IDH and 1p19q 
status (or a surrogate of the latter). The question is that whether these are sufficient to identify all 
major subgroups, whatever they may be called, or additional markers could identify an independent 
entity. The efficacy of their genomic/transcriptomic analysis may be discussed from this view point.  
 
COMMENT 1 
Although their genomic groups correspond to this classification, molecular system proposed in the 
Haarlem Consensus meeting could be more explicitly referred to. 
 
RESPONSE 
We have referred to the proposal of the Haarlem consensus meeting at the end of the discussion on 
page 22-23 and elucidated how our data may fit to this concept and could refine future integrated 
glioma classification.  
 
COMMENT 2 
Does genomic grouping have an independent value on classification?  
 
RESPONSE 
Yes, we believe that the +7/-10 genotype adds to the classifier provided by IDH and 1p/19q status 
alone, as is discussed on page 21.  
 
COMMENT 3 
Would the genomic Group V be a separate entity? Or will they still be astrocytomas even if IDH is 
wild-type and survival obviously worse than IDH-mutated tumors? Are IDH-wt grade 3 tumors with 
7q+/10q- separate entity? 
 
RESPONSE 
Such decisions remain to be taken by the taskforce for the next revision of the WHO classification. 
We have provided some thoughts on this at the end of the Discussion on page 23. There certainly is 
evidence that IDH1/2 wildtype +7/-10 tumors clinically behave similar to bona fide glioblastomas, 
especially in older patients. However, whether presence of this molecular profile is generally 
sufficient to switch a grade III histology with absence of microvascular proliferation and necrosis to a 
grade IV histology of glioblastoma remains to be decided by the WHO group.   
 
COMMENT 4 
The fact that transcriptomic profiling did not have additional value for molecular classification 
somehow reminisces that of glioblastoma, in which only proneural group, a mixture of IDH1-wt 
(worst prognosis) and mutated tumors (best), had an impact on survival. The authors may wish to 
state their view on the validity of transcriptomic analysis in molecular diagnosis. 
 
RESPONSE 
We have done that. Yet, we can only state that transcriptomic characterization at the level done here 
adds little to what IDH1/2 mutation, 1p/19q co-deletion and genomic analyses or their combination 
provide in terms of defining prognostic subgroups. However, we agree with the reviewer’s statement 
that our findings in WHO grade II and III gliomas are reminiscent to those in glioblastomas where 
expression classes also are of limited prognostic significance. Moreover, recent findings indicating 
that expression classes might be regionally heterogeneous within a single tumor or may change from 
primary to recurrent tumors add further evidence that transcriptomic profiles may be less reliable as 
diagnostic or prognostic markers compared to genetic and epigenetic profiles. 
 
COMMENT 5 
It is intriguing that a subgroup of IDH-wt tumors (Genomic group IV) appear to show relatively better 
prognosis than group V (other IDH-wt tumors). An information as to whether the group IV tumors 
have G-CIMP would be very useful, as well as re-examination of the IDH status, to confirm the 
peculiar nature of this group.  
 
RESPONSE 
We agree and have addressed this issue as outlined in comment 2 of referee 1. The IDH status had 
been re-confirmed even prior to first submission.  
 
 
COMMENT 6 
The Kaplan-Meir curve of Fig.3 is uninformative. Which groups contributed significant difference in 
survival (p<0.001) need to be identified. 
 
RESPONSE 
Our intention was to describe the courses of PFS and OS without pairwise testing according to an 
explorative objective. The given p-value is the result of a global test that checks the equality of 
groups regarding OS or PFS.  We presented the global p-value to show that at least two groups are 
different. We have added a new sentence explaining this issue on page 9. 
In fact, pairwise testing of individual groups, as suggested by the reviewer, is associated with the 
problem of multiple testing. Here, we exemplary list which groups are significantly different in Figure 
3 at 5% level after Bonferroni adjustment: PFS differed between group 1 vs. group 7 or group 8 as 
well as between glioblastoma vs. groups 4, 5, 6, 7 or 8; OS differed between group 1 vs groups 4, 5, 6, 
7 or 8, as well as between glioblastoma vs. groups 3, 4, 5, 6, 7 or 8. However, as the expression 
classes were only partially overlapping with the genomic classes and did not add much additional 
prognostic information to genomic stratification, we believe that presentation of all these group-wise 
comparisons in the actual manuscript would be rather confusing and have therefore only added 
information for the group-wise comparisons of genomic group I vs group II-IV and group V vs group 
II-IV on page 15. 
 
 
COMMENT 7 
Among the IDH-mutated tumors, presence of TERT promoter mutation is almost equivalent to that of 
1p/19q co-deletion. It is curious that TERT mutation was not prognostic among IDH-mutated tumors 
(Suppl Fig 1I). This may reflect the fact that not all tumors were examined for TERT mutation. The 
author may wish to comment on this point.  
 
RESPONSE 
To clarify this, we have now included – in the revised Supplementary Figure 1 - a similar analysis as 
for TERT mutation in IDH1/2 mutant tumors also for 1p/19q co-deletion. For both analyses, the trend 
for improved outcome is similar, but significance is only reached for 1p/19q co-deletion but not TERT 
promoter mutation,  (a) because the patient numbers are small and (b) the number of events for 
overall survival is small. This may lead to differences in statistical evaluations due to only individual 
tumors that were 1p/19q co-deleted but lacked TERT promoter mutation. This has now been clarified 
and addressed in the Results section on page 10. 
 
 
COMMENT 8 
Perhaps the two most information in this paper are the possibility that the 7q/10q status could help 
further stratify IDH-wt astrocytomas, and that astrocytomas with GBM-like genotype could still may 
survive longer than bona fide GBM. This may be more explicitly expressed. Although logically well 
structured, the manuscript is overly long and highly descriptive, which might make it difficult for 
some authors to find out the main points of the manuscript.  
 
RESPONSE 
We have condensed some sections of the manuscript. We do agree that the 7q/10q status could help 
to further stratify IDH1/2 wildtype astrocytomas and have stressed this in several parts of the 
discussion on pages 21-22. Our data also suggest that grade II or III gliomas with a glioblastoma-like 
genotype survive longer than bona fide glioblastomas. However, we also acknowledged the fact that 
it is difficult to draw a definite conclusion from the comparison of two prospectively studied, but not 
matched or otherwise controlled cohorts. Thus, we are hesitant to change our careful wording here. 
 
 
Reviewer #3: Weller et al. describe comprehensive genome copy number and expression profiling 
analyses of 137 grade II and III gliomas.   The paper attempts to stratify patients into molecular 
groups that have distinct clinical features as well as acquired genetic alterations.   The paper has 
many merits - most especially that it will complement the efforts of The Cancer Genome Atlas (TCGA) 
in the molecular classification of grade II and III gliomas.  The paper will also provide important 
information as the WHO neuropathology working group moves forward with a revision of the criteria 
for glioma diagnosis.  Several relatively minor points should be addressed by the authors. 
 
COMMENT 1)  The authors should be more explicit in their description of the grade IV glioma 
comparison group(s). These groups are included throughout the paper and the apparent focus on 
grade II-III gliomas is lost. The explicit inclusion of these gliomas into the Title, Introduction and 
Methods would help the flow of the manuscript. 
 
RESPONSE 
The focus of our manuscript clearly is on WHO grade II and III gliomas. We have now stressed this 
also in the revised manuscript title. The WHO grade IV glioblastoma groups have been published and 
characterized elsewhere (see references 26 and 34) and serve only as comparators for the worst 
outcome group of the WHO grade II and III population identified in the present study. Thus, we 
would not like to change the main focus of our manuscript by the inclusion of glioblastoma in the 
title. The fact that we only used the glioblastoma groups for comparisons with IDH1/2 wildtype and 
+7/-10 gliomas identified as group V in the present manuscript, has been mentioned in a new 
sentence in the Methods on page 7. 
 
COMMENT 2)  The distinction between the group II and III copy number groups was made by +7q/-
10q and "genome complexity" status.  While such groups are generally apparent in Figure 1, at the 
individual tumor level it isn't clear how these distinctions were made.  E.g. There are tumors with +7, 
-10, and +19 etc. in group II that look like they should be in group III and vice versa.   The group III 
tumors were ony marginally more "complex" than the group II tumors.  How as "complexity" 
determined? 
 
RESPONSE 
We assume that the reviewer refers to Figure 1A and we agree that we introduced a bias when 
describing this classifier. This part of the manuscript has been simplified and now follows the results 
of the unsupervised clustering which revealed in fact three major clusters. Figure 1A has been 
correspondingly modified. 
 
COMMENT 3)  The expression profiling section in the Results was interesting but long and hard to 
follow.   This reviwer wondered if the data shown in Figure 3A was necessary.  E.g. the stratification 
of the expression data should begin with IDH status.  This would simplify the description of the 
expression results.  This will also simplify the profusion of the various groups (see next). 
 
RESPONSE 
We agree, see response to COMMENT 4 below and to COMMENT 8 of reviewer 2. 
 
COMMENT 4)  There are five (I-V) copy number groups, six (i-vi) expression groups using one scheme, 
eight (1-8) expression groups by another scheme, and three (A, B and C) integrated molecular 
groups.   This is a lot of groups (and symbols) to keep straight.   While this complexity may be 
important, there would seem to be opportunities to simplify the scheme(s).   Can the grouping be 
simplified? 
 
RESPONSE 
We agree and have shifted Figure 3A to the Supplement. This removes one set of labels (i-vi) from 
the main manuscript.  
 
COMMENT 5)  The outcome studies are important and interesting.  This reviewer appreciated the 
work involved in generating the models.  However, it is not clear that the various mulitvariate models 
have any real meaning - especially given the relatively small number of patients.  Can the different 
models shown in Table 2 really be compared?  A statistician might be worried about over-fitting.  
Table 2 should be moved to the Supplement and a simplifed version of the table provided in the main 
document. 
 
RESPONSE 
It is correct that the sample size is relatively small. With the available sample set, we built Cox 
models to get more information about the association of molecular markers and histological 
parameters, adjusted for age, with overall survival. Our analysis indicated that molecular parameters 
are at least as relevant as histological parameters. The effect difference quantified by the estimated 
hazard ratio for genomic groups for OS was more pronounced (8.28) than for groups defined by 
IDH1/2 and 1p19q co-deletion status alone (6.82). The models were built in an explorative sense and 
have to be confirmed in further independent data sets. The deviance as a statistical measure is 
suitable to compare the different models. All models were built using the same sample, which allows 
to compare them. The statistical analyses were done by B.H. and M.L. at the Institute for Medical 
Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. To simplify the 
presentation of data in the manuscript, we have reduced Table 2 to the most relevant results of the 
multivariate analyses. The additional data are now provided as supplementary information in 
Supplementary Table 13. 
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ABSTRACT 
 
Cerebral gliomas of World Health Organization (WHO) grade II and III represent a major 
challenge in terms of histological classification and clinical management. Here, we asked 
whether large-scale genomic and transcriptomic profiling improves the definition of 
prognostically distinct entities. We performed microarray-based genome- and transcriptome-
wide analyses of primary tumor samples from a prospective German Glioma Network cohort 
of 137 patients with cerebral gliomas, including 61 WHO grade II and 76 WHO grade III 
tumors. Integrative bioinformatic analyses were employed to define molecular subgroups, 
which were then related to histology, molecular biomarkers, including isocitrate 
dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q co-deletion and telomerase reverse 
transcriptase (TERT) promoter mutations, and patient outcome. Genomic profiling identified 
five distinct glioma groups, including three IDH1/2 mutant and two IDH1/2 wild-type groups. 
Expression profiling revealed evidence for eight transcriptionally different groups (five 
IDH1/2 mutant, three IDH1/2 wild-type), which were only partially linked to the genomic 
groups. Correlation of DNA-based molecular stratification with clinical outcome allowed to 
define three major prognostic groups with characteristic genomic aberrations. The best 
prognosis was found in patients with IDH1/2 mutant and 1p/19q co-deleted tumors. Patients 
with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, including gain on 
chromosome arm 7q (+7q), loss on chromosome arm 10q (-10q), TERT promoter mutation 
and oncogene amplification, displayed the worst outcome. Intermediate survival was seen in 
patients with IDH1/2 mutant, but 1p/19q intact, mostly astrocytic gliomas, and in patients 
with IDH1/2 wild-type gliomas lacking the +7q/-10q genotype and TERT promoter mutation. 
This molecular subgrouping stratified patients into prognostically distinct groups better than 
histological classification. Addition of gene expression data to this genomic classifier did not 
further improve prognostic stratification. In summary, DNA-based molecular profiling of 
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WHO grade II and III gliomas distinguishes biologically distinct tumor groups and provides 
prognostically relevant information beyond histological classification as well as IDH1/2 
mutation and 1p/19q co-deletion status. 
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INTRODUCTION 
 
The World Health Organization (WHO) classification of tumors of the central nervous system 
[22] separates cerebral gliomas into distinct disease entities based on histological criteria. In 
addition to tumor typing, a malignancy grade ranging from WHO grade I to IV is allocated to 
each tumor considering morphological features of anaplasia, such as mitotic activity, 
microvascular proliferation and necrosis. This serves the overall goal of providing clinicians 
with information on the assumed natural disease course and strongly impacts clinical decision 
making today. In clinical practice, histopathological classification is greatly aided by 
immunohistochemical markers, and, more recently, by an increasing set of molecular 
markers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, co-deletion of 
chromosome arms 1p and 19q, O
6
-methylguanine DNA-methyltransferase (MGMT) promoter 
methylation, and others [35].  
Combined classification approaches have resulted in a satisfactory segregation of WHO grade 
I pilocytic astrocytoma as a distinct entity characterized by a benign clinical course and 
almost universally driven by mitogen-activated protein kinase (MAPK) pathway activation, 
most commonly caused by fusion of the v-raf murine sarcoma viral oncogene homolog B1 
(BRAF) proto-oncogene to other genes or activating BRAF point mutations [16]. On the other 
end of the glial tumor spectrum, primary glioblastoma has been delineated as a distinct entity 
of highly malignant tumors characterized by the absence of IDH1/2 mutation, gains on 
chromosome 7 and losses on chromosome arm 9p and chromosome 10, frequent mutations in 
the phosphatase and tensin homolog on chromosome 10 (PTEN) gene and the human 
telomerase (TERT) promoter, as well as activation of receptor tyrosine kinase pathways, in 
particular the epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor pathways [17, 25].  
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In contrast, the histologically defined groups of astrocytic, oligodendroglial and 
oligoastrocytic (mixed) gliomas of WHO grades II and III remain a major challenge in 
various ways: (i) there is poor interobserver agreement when diagnoses and grading are made 
by histological criteria alone [30], in particular concerning the classification of 
oligoastrocytomas [10], (ii) the clinical course is highly variable, and (iii) the clinical 
management remains poorly standardized [1, 35]. Current molecular marker-based 
approaches explore the validity of a three-tiered approach delineating (i) IDH1/2-mutant 
tumors with 1p/19q co-deletion which often carry mutations in the Drosophila homolog of 
capicua (CIC) gene as well as the TERT promoter and predominantly include oligodendroglial 
tumors, (ii) IDH1/2 mutant tumors without 1p/19q co-deletion which often carry tumor 
protein p53 (TP53) as well as ATP-dependent X-linked helicase (ATRX) gene mutations and 
predominantly include astrocytic tumors, and (iii) IDH1/2 wild-type tumors that remain 
poorly characterized in terms of other molecular alterations [15, 17, 38]. In addition, recent 
data from exome sequencing of anaplastic astrocytomas suggested a distinct mutation profile 
from primary glioblastomas, including frequent mutations in Notch pathway genes [18]. 
In the present study, we sought to determine whether a molecular profiling approach for 
genomic copy number and mRNA expression changes might help to overcome some of the 
limitations of the current histology-based diagnostic approaches to these tumors and to 
provide better stratification for future clinical trials. Therefore, we performed high-resolution 
array-based comparative genomic hybridization (array-CGH) analyses and Affymetrix gene 
chip expression profiling on 137 cerebral gliomas of WHO grade II or III from patients of the 
German Glioma Network (GGN) with prospectively collected clinical follow-up data. We 
found that molecular profiling distinguishes distinct subtypes among these gliomas that carry 
prognostically relevant information beyond histological classification, grading as well as 
IDH1/2 mutation and 1p/19q co-deletion. 
 
Weller et al. Molecular profiling of cerebral gliomas 
 - 7 - 
PATIENTS AND METHODS 
 
Patients and tumors 
The GGN is a prospective, non-interventional cohort study involving eight clinical centers at 
University Hospitals in Germany (www.gliomnetzwerk.de), and was supported by the 
German Cancer Aid from 2004 to 2012. All patients gave written informed consent for 
participation in the GGN and its translational research projects. For this study, we analyzed 
tumors of 137 patients with WHO grade II or III gliomas by array-CGH analysis, Affymetrix 
chip-based gene expression profiling and candidate gene analyses (Table 1). All tumors were 
subjected to central pathology review (T.P.) and classified according to the WHO 
classification of tumors of the central nervous system [22]. For comparison of molecular 
profiles and prognostic outcome determined for the poor prognosis group of patients in this 
study (group V, see below), we additionally used published molecular and clinical data from 
two previous GGN studies on glioblastoma [26, 34].  
 
Nucleic acid extraction, mutation and promoter methylation analyses 
DNA and RNA were extracted by ultracentrifugation from deep-frozen tumor samples [14]. 
Tumor cell content was histologically estimated as 80% or more in most samples except for 
individual cases with lower tumor cell content but still detectable copy number aberrations by 
array-CGH analysis. High quality of extracted DNA was assured by spectrophotometric 
analysis and agarose gel electrophoresis. RNA quality was determined on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only samples showing a RNA integrity 
number of 7 or more were used for microarray analyses. Mutational analyses of the IDH1, 
IDH2, TERT, BRAF and H3F3A genes were carried out by Sanger sequencing or 
pyrosequencing [9, 12, 19]. The MGMT promoter methylation status was determined by 
methylation-specific PCR [8]. 
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Array-based comparative genomic hybridization (array-CGH) 
Array-CGH was performed using genomic DNA microarrays with 10,000 large insert clones 
allowing for an average resolution of better than 0.5 Mb. Array assembly, probe labeling, 
array hybridization and scanning were carried out essentially as reported elsewhere [43]. To 
identify amplification events, genomic profiles were generated for each tumor and 
amplifications scored if log2 test/reference ratios were > 1. All other analyses of array-CGH 
data were done using aCGHPipeline [20]. 
 
Affymetrix gene chip analyses 
Gene expression profiles were determined with Affymetrix Gene Chip
®
 Human Genome 
U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Sample preparation was done with 2.5 
µg total tumor RNA using the One Cycle Target Labelling and Controls kit (Affymetrix) [26]. 
Hybridization and scanning of the chips were performed at the Center for Biological and 
Medical Research at Heinrich Heine University Düsseldorf.  
 
Statistical analysis 
Array-CGH data were evaluated as reported before using aCGHPipeline [21]. Gene 
expression data were analyzed after reduction to metagenes using self-organizing map (SOM) 
machine learning [41]. As a result, each tumor tissue is characterized by the expression values 
of 1,600 metagenes that are visualized as expression landscape by color-coding. Metagene-
based clustering using either hierarchical or maximum spanning graph-partitionating methods, 
visualization and downstream analysis of expression data were performed with the program 
OpoSOM after hook calibration of the raw data, quantile normalization and centralization in 
log10-scale [13, 26]. In addition, pairwise testing between groups of samples was carried out 
by regularized t-testing as implemented in OpoSOM [42]. Samples were classified separately 
based either on array-CGH (five groups I to V) or on mRNA expression (eight groups 1 – 8) 
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data as described in the Results section. In addition, both classifications were combined by 
taking the intersections of groups I and 7 and of groups V and 1 to obtain the “integrated 
molecular groups” A and C, respectively. Samples not matching criteria for either groups A or 
C were assigned to group B. 
Progression-free survival (PFS) was calculated from the day of first surgery until tumor 
progression, death, or end of follow-up. Overall survival (OS) was calculated from the day of 
first surgery until death or end of follow-up. Logrank test was used to analyze survival data. 
When more than two groups were compared, we tested for the equality of groups regarding 
PFS or OS and present global p-values indicating that at least two groups were different. Cox 
regression models were built to assess the association of clinical parameters and molecular 
groups defined by array-CGH and expression profiling with OS. The statistic deviance (minus 
twice the logarithm of the maximized likelihood) was used to measure the model fit. All 
statistical analyses were performed with the IBM SPSS Statistics (version 20.0.0) software. 
 
 
RESULTS 
 
Patient characteristics and outcome 
Table 1 summarizes clinical findings and molecular genetic tumor characteristics. Individual 
patient data are provided in Supplementary Table 1. Clinical data, molecular marker 
characteristics, and therapeutic measures over the course of disease until the last follow-up, 
broken down by histology, are summarized in Supplementary Table 2. The median follow-up 
was 71.1 months; 92 (67.2%) patients have experienced a progression-free survival (PFS) 
event, 47 (34.3%) patients have died. Histological grading was not associated with PFS, but 
there was a trend towards longer OS with WHO grade II as compared to WHO grade III 
tumors (Supplementary Figure 1A). Astrocytic gliomas were associated with inferior PFS, but 
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not OS, although there were few OS events (Supplementary Figure 1B) (Supplementary Table 
2). WHO grade was prognostic by trend also within histological entities (Supplementary Figs. 
1C,D). IDH1/2 mutation and 1p/19q co-deletion were both associated with prolonged PFS 
and overall survival (OS) (Supplementary Table 3, Supplementary Figs. 1E-F). Among 
IDH1/2 mutant tumors, 1p/19q co-deletion was associated with improved outcome 
(Supplementary Fig. 1G). TERT promoter mutation was linked to outcome neither in the 
entire cohort of 137 patients (Supplementary Fig. 1H) nor in the subgroup of 112 patients 
with IDH1/2 mutant tumors (Supplementary Fig. 1I). The lack of significance for the latter 
comparison likely reflects the low number of events. In oligodendroglial and oligoastrocytic 
gliomas, TERT promoter mutation was more common in cases with than without 1p/19q co-
deletion (27/30 versus 2/19, p<0.001). In patients with 1p/19q non-deleted anaplastic gliomas 
of WHO grade III (n=51), TERT promoter mutation was associated with less favorable 
outcome (median OS: 2.4 versus 8.8 years, p=0.048) (Supplementary Fig. 1K). MGMT 
promoter methylation was associated with prolonged OS, too (Supplementary Table 3, 
Supplementary Fig. 1L). 
 
Genomic copy number profiling 
Unsupervised clustering of the array-CGH data separated the 137 gliomas into three major 
clusters characterized by (a) an oligodendroglial genomic profile with 1p/19q co-deletion, (b) 
an intermediate group consisting mostly of IDH1/2 mutant tumors without 1p/19q co-
deletion, and (c) a glioblastoma-like genomic profile with partial or complete gains on 
chromosome 7, losses on 9p, partial or complete losses on 10, and frequent gene 
amplifications (Fig. 1A). Based on these findings and the well-known differences in tumor 
biology and prognosis between IDH1/2 mutant and wild-type gliomas, we performed 
supervised analyses of the array-CGH data stratified by IDH1/2 status. This analysis revealed 
three distinct tumor groups among the IDH1/2 mutant tumors defined by 1p/19q co-deletion 
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(group I), chromosome arm 7q gain associated with a usually limited number of copy number 
changes on other chromosomes (group II), or gains and losses affecting multiple 
chromosomes (group III). IDH1/2 wild-type tumors were divided into one group with 
relatively few genomic changes variably affecting different chromosomes and TERT promoter 
mutation restricted to a single case (group IV), and another group with primary glioblastoma-
like copy number changes, typically including combined gains on chromosome 7 and losses 
on chromosome 10 affecting at least the long arms of both chromosomes (+7q/-10q; group V) 
(Fig. 1B, Supplementary Table 4). Additional analyses for BRAF-V600E and H3F3A-K27 or -
G34 mutations in 8 of 9 and 7 of 9 group IV tumors did not reveal any mutation (data not 
shown). Tumors in group V often carried TERT promoter mutations (9/13; 75%) as well as 
gene amplifications (11/13; 85%), including TERT amplification in one tumor without TERT 
promoter mutation. Unsupervised analyses of array-CGH data from group V tumors together 
with array-CGH data of primary IDH1/2 wild-type glioblastomas reported elsewhere [26] 
revealed that group V tumors did not form a distinct cluster, but were distributed among the 
glioblastoma cases, indicating that group V tumors carry genomic imbalances typical of 
glioblastoma (Supplementary Fig. 2A).  
Fig. 2A shows the frequency plots of genomic imbalances in each of the five genomic groups 
defined by array-CGH patterns within the subsets of IDH1/2 mutant and wild-type tumors, as 
well as an independent cohort of IDH1/2 wild-type primary glioblastomas reported previously 
[26]. Group V tumors showed a virtually identical genomic aberration pattern as the primary 
glioblastomas. High-level copy number gains indicative of gene amplification occurred at 
similar frequencies in both groups, most commonly affecting epidermal growth factor 
receptor (EGFR) [group V 8/13 (62%) versus primary glioblastoma 26/54 (48%)], murine 
double minute (MDM) 4 [group V 3/13 (23%) versus glioblastoma 6/54 (11%)], cyclin-
dependent kinase (CDK) 4 [group V 2/13 (15%) versus glioblastoma 9/54 (17%)], MDM2 
[group V 1/13 (8%) versus glioblastoma 5/54 (9%)], and platelet-derived growth factor 
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receptor- (PDGFRA) [group V 0/13 (0%) versus glioblastoma 4/54 (7%] (each comparison: 
p>0.05, Fisher’s exact test). In contrast, amplification of MDM4, EGFR, and CDK4 was less 
common in genomic groups I - IV when compared to group V (Supplementary Table 5), and 
tumors with amplification events were less frequent in groups I – IV versus group V [group I: 
1/37 (3%); group II: 10/31 (32%); group III: 6/47 (13%); group IV: 4/9 (44%); group V: 
11/13 (85%) (groups I - III versus group V: p<0.005, group IV versus group V: p>0.05, 
Fisher’s exact test)].  
Fig. 2B illustrates the association of the array-CGH groups with PFS and OS. Patients with 
IDH1/2 mutant and 1p/19q co-deleted (group I) tumors had the best outcome while patients 
with IDH1/2 wild-type and +7q/-10q (group V) tumors showed the worst prognosis. 
However, compared with a cohort of 270 IDH1/2 wild-type primary glioblastoma from our 
previous GGN study [34], group V patients had a longer median OS (2.4 years versus 1.0 
years, p = 0.008). Patients in groups II - IV demonstrated similar survival, with outcomes 
being intermediate between group I and group V patients. 
 
mRNA expression profiling 
We analysed mRNA expression using the SOM method and identified six major clusters of 
highly correlated tumor samples, two of which closely overlapped with genomic groups I and 
V (Supplementary Figure 3). The individual expression clusters visible in the correlation 
heatmap were characterized by (i) a classical glioblastoma-like profile associated with IDH1/2 
wild-type status and anaplastic astrocytic histology (corresponding to genomic group V 
except for one sample without +7q/-10q status), (ii) a heterogeneous glioblastoma-like profile 
associated with both IDH1/2 wild-type and mutant status and with anaplastic astrocytic and 
oligoastrocytic histology, (iii) a proneural glioblastoma-like profile associated with IDH1/2 
mutation and astrocytic histology, (iv) an expression profile unrelated to known glioblastoma 
signatures and associated with IDH1/2 mutation and predominantly diffuse astrocytoma 
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WHO grade II histology, (v) a proneural glioblastoma-like profile associated with IDH1/2 
mutation, 1p/19q co-deletion and oligodendroglial histology (corresponding to genomic group 
I), and (vi) a normal brain-like profile associated with both IDH1/2 mutant and wild-type 
tumors of predominantly astrocytic histology, but also including a fraction of mixed 
oligoastrocytic tumors (Supplementary Fig. 3). The first expression cluster (i) consisted 
predominantly of IDH1/2 wild-type gliomas whereas the vast majority of tumors in the other 
five expression clusters were IDH1/2 mutant. Therefore, we additionally performed 
supervised analysis of metagene expression data stratified according to IDH1/2 mutation 
status, which separated IDH1/2 wild-type tumors into three major expression groups (groups 
1-3). The IDH1/2 mutant tumors were subdivided into five major expression clusters (groups 
4-8) (Fig. 3A). Metagene expression data of IDH1/2 wild-type gliomas resembled those of 
primary glioblastomas, while expression profiles in IDH1/2 mutant gliomas were shared with 
those of IDH1/2 mutant glioblastomas (Supplementary Fig. 2B). Gene set enrichment analysis 
revealed that the top enriched sets in the lists of up-regulated genes were linked to the 
classical (group 1) and proneural (groups 5 and 7) glioblastoma expression signatures [34], 
immune response processes and increased transcriptional activity (groups 2 and 4), normal 
brain expression signature (groups 3 and 8), astrocytic expression signatures (group 5), 
oxygen transport with high expression levels of hemoglobin and cytoglobin (group 6) and 
concerted transcriptional and mitochondrial activities associated with oligodendroglial tumor 
histology (group 7).  
Clinical and histological correlates of the expression-based classification are summarized in 
Supplementary Table 6 and Fig. 3B. Analysis of patient outcome stratified according to the 
distinct expression groups revealed the best outcome for patients whose tumors carried a 
proneural glioblastoma-like profile, frequently associated with 1p/19q co-deletion 
(corresponding to genomic group I and expression group 7), but also for expression groups 
with brain-like signatures independent of IDH1/2 mutation status (expression groups 3 and 8) 
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and expression group 5 (IDH1/2 mutant), the worst outcome for patients whose tumors 
displayed a classical glioblastoma profile associated with +7q/-10q genomic profile 
(corresponding to genomic group V and expression group 1) and expression group 2 of the 
IDH1/2 wild-type tumors without the +7q/-10q genomic profile and without a brain-like 
expression signature. Patients whose tumors were classified in the remaining two expression 
clusters of the IDH1/2 mutant tumors (group 4 and 6) had intermediate prognoses. Expression 
group 1 tumors had a similarly poor PFS but longer OS when compared to IDH1/2 wild-type 
glioblastoma (Supplementary Table 6, Fig. 3B). 
 
Integration of genomic and expression profiling results 
Next we explored the relationships between the five genomic groups identified by array-CGH 
analyses and the eight clusters obtained by gene expression profiling. Genomic group I 
(IDH1/2 mutant, -1p/-19q) consisted mostly of expression group 7 tumors while genomic 
group V (IDH1/2 wild-type, +7q/-10q) tumors closely overlapped with expression group 1 
tumors (Fig. 3B, Supplementary Table 7). Genomic groups II-IV could not be matched to 
individual expression groups (Supplementary Table 7). Among the IDH1/2 wild-type tumors, 
most genomic group V tumors showed classical glioblastoma-like expression profiles 
(expression group 1), while most genomic group IV tumors showed other expression profiles 
related to immune response processes and increased transcriptional activity (expression group 
2) or a normal brain expression signature (expression group 3). The IDH1/2 mutant genomic 
groups II and III both demonstrated mixed expression profiles without obvious enrichment of 
a certain profile in one of these groups (Fig. 4A, Supplementary Table 7). 
Taken together, genomic and transcriptomic data were compatible with three molecularly 
distinct tumor groups that were primarily defined by genomic features and strongly linked to 
clinical outcome in patients with WHO grade II and III gliomas: a prognostically favorable 
group with IDH1/2 mutation and 1p/19q co-deletion as the characteristic molecular marker, 
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corresponding to genomic group I and including all expression group 7 tumors, a 
prognostically intermediate group mostly containing IDH1/2-mutant tumors without 1p/19q 
co-deletion (genomic groups II-III) and the small group of IDH1/2-wild-type tumors without 
combined gains on 7 and losses on 10 (genomic group IV), and a prognostically unfavorable 
group of exclusively IDH1/2 wild-type tumors with glioblastoma-like genotype characterized 
by +7q/-10q, frequent gene amplification and TERT promoter mutation (genomic group V), 
including mostly expression group 1 tumors (Supplementary Table 8, Fig. 4B). Median PFS 
and OS differed significantly between the groups [group I vs. groups II-IV: PFS 5.9 years vs. 
3.7 years (p=0.046), OS not reached vs. 9.0 years (p=0.028); groups II-IV vs. group V: PFS 
3.7 years vs. 1.5 years (p=0.001), OS 9.0 years vs. 2.4 years (p<0.001)]. Median PFS (1.5 
years) and OS (2.4 years) of the group V patients appeared to be better than PFS and OS of 
unselected glioblastoma patients, as indicated by comparison to survival data from a previous 
study on glioblastoma patients (PFS 0.5 years, p=0.026; OS 1.0 years, p=0.008) [34]. We also 
evaluated the prognostic role of WHO grading within these three tumor groups, which 
revealed that histological grading according to WHO criteria may provide some prognostic 
information within groups I and II-IV, although the differences in these groups were not 
significant presumably because of small samples size (group I, WHO grade II versus III, 
p=0.102 for OS; group II-IV, WHO grade II versus III, p=0.103 for OS) (Fig. 4C). Age at 
diagnosis was a prognostic factor associated with OS in both groups (group I,  40 years 
versus > 40 years, p=0.076; group II-IV,  40 years versus > 40 years, p<0.001) (Fig. 4D). In 
group V, WHO grading and age could not be evaluated since these patients were generally 
older than 40 years and except for three patients had WHO grade III tumors. 
We also evaluated the possibility that complementation of the three DNA aberration-based 
prognostic groups by integrating information on mRNA expression groups might further 
improve prognostic stratification. Using this approach, we more strictly defined the best 
prognostic group ("integrated molecular group A", 26 patients) as IDH1/2 mutant, 1p/19q 
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deleted and group 7 expression profile tumors while the worst prognostic group was 
exclusively composed of IDH1/2 wild-type, +7q/-10q and group 1 expression profile tumors 
("integrated molecular group C", 10 patients). The remaining tumors not falling into either 
group A or group C were compiled in one intermediate prognosis group ("integrated 
molecular group B", 101 patients) (Supplementary Fig. 4A, Supplementary Table 8). This 
integrated molecular stratification again provided three prognostically distinct groups of 
patients (Supplementary Fig. 4B), however, it added no improvement of the three-tiered 
genomic stratification (Fig. 4A). Moreover, the group of patients with intermediate prognosis 
("group B") increased to 101 patients and included patients with molecularly heterogeneous 
tumors lacking a characteristic marker profile, i.e., consisted of IDH1/2 mutant and IDH1/2 
wild-type as well as 1p/19q co-deleted and 1p/19q intact tumors. 
 
Molecular correlates of glioma type and WHO grade 
The genomic aberration profiles determined by array-CGH analysis differed substantially 
between oligodendroglial and astrocytic as well as 1p/19q co-deleted and 1p/19q intact 
tumors (Supplementary Figs. 5A,B), with IDH1/2 mutant and 1p/19q co-deleted tumors 
showing significantly fewer genomic alterations per tumor than IDH1/2 mutant tumors 
without 1p/19q co-deletion (Supplementary Fig. 5C). Comparison of expression profiles in 
the 68 IDH1/2 mutant tumors classified as astrocytic gliomas (AII, AAIII) and the 47 IDH1/2 
mutant tumors containing an oligodendroglial component (OII, OAII, AOIII, AOAIII) 
revealed a set of differentially expressed genes (Fig. 5A; Supplementary Table 9). Similar but 
even more pronounced expression differences were detected when the 37 IDH1/2 mutant 
1p/19q co-deleted tumors were compared with the 78 IDH1/2 mutant but 1p/19q intact tumors 
(Fig. 5B; Supplementary Table 10). In general, oligodendroglial tumors and 1p/19q co-
deleted tumors demonstrated reduced expression of a subset of genes located on 1p or 19q as 
well as genes related to ‘immune response‘ and ‘inflammatory response‘ but showed 
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increased expression of gene signatures related to ‘normal brain‘, synaptic transmission‘ and 
‘brain development‘ (Supplementary Table 11). As expected [15, 21, 38], ATRX was among 
the top genes with higher expression in astrocytic versus oligodendroglial tumors as well as 
1p/19q intact versus 1p/19q co-deleted tumors (Supplementary Tables 9-10).  
Transcriptomic profiles also differed between WHO grade II and WHO grade III gliomas 
(Fig. 5C, Supplementary Table 12). Genes expressed at higher levels in WHO grade II 
gliomas were related to normal brain function, including the gene ontology (GO) terms 
‘normal brain‘ and ‘synaptic transmission’, while genes with higher expression in WHO 
grade III gliomas were related to cell division and transcriptional activity, including the GO 
terms ‘nucleus’, ‘mitotic cell cycle’, ‘DNA repair’, ‘DNA replication’ and ‘nucleic acid 
binding’ (Supplementary Table 11). The overall patterns of genomic aberrations were similar 
in WHO grade III gliomas when compared to WHO grade II gliomas. Moreover, the number 
of genomic aberrations detected per tumor by array-CGH did not significantly differ between 
WHO grade II and III gliomas, except for a trend towards more aberrations per tumor in 
1p/19q co-deleted WHO grade III versus WHO grade II gliomas. Array-CGH analysis did not 
detect any dominant progression-associated genomic aberration according to WHO grade 
(Supplementary Fig. 5).  
 
Multivariate analysis of clinical, histological and molecular parameters 
To analyze the relative impact of clinical and histological parameters (age, histology, WHO 
grade), and molecular tumor groups as defined in Fig. 4, Supplementary Fig. 4 and 
Supplementary Table 8, we performed Cox regression analyses with regard to OS (Table 2). 
We first assessed the genomic classification of groups I, II-IV or V (Fig. 4). In the first model, 
we only considered the most relevant clinical parameters, histology (astrocytic versus 
oligodendroglial), WHO grade (grade III versus II) and age (> 40 years versus < 40 years). 
Compared with the null model (model without any variable) this model reduced the deviance 
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significantly. Higher age had the most significant association with OS (HR=4.4, p<0.001) 
followed by histology (HR=2.59, p=0.007). In the second model, we replaced histology and 
WHO grading by an indicator variable for the three distinct genomic tumor groups I, II-IV or 
V. The tumor group I with the best outcome was defined as the reference group (Fig. 4B). The 
highest hazard ratio (HR) of 8.28 (p<0.001) was seen in group V tumors and the effect for 
tumors in the intermediate group II-IV was of relevant dimension (HR 3.81, p=0.006). 
Relative risk for death was higher for age > 40 years (HR 3.99, p<0.001). This model showed 
a much better model fit than the first model. Adding histology and WHO grade to model 2 
resulted only in insignificant improvements of the model fit (p=0.318). The three genomic 
groups were by far most informative, with age ranking second. Histology and WHO grading 
provided the lowest independent association with OS (HR 1.36, p=0.426 and HR 1.55, 
p=0.175), indicating that much of the information carried in histology and WHO grading has 
been captured by the genomic information.  
When mRNA expression profiling data were introduced, that is integrated molecular profiling 
(Supplementary Fig. 3) considered instead of genomic profiling only, the prognostic 
separation into three distinct groups became less clear (Supplementary Table 13. Conversely, 
when the models were built on IDH1/2 and 1p/19q status alone, some prognostic information 
was lost, with the HR for the poor prognosis group decreasing to 6.82, likely as a 
consequence of including IDH1/2 wild-type tumors without glioblastoma-like genomic 
alteration (Supplementary Table 13). 
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DISCUSSION 
 
Diffusely growing gliomas of WHO grade II and III remain a diagnostic and therapeutic 
challenge. Outcome seems to be determined more by age and molecular genetic features of 
the tumors than by the current treatment options of surgery, radiotherapy and alkylating agent 
chemotherapy. Molecular markers, in particular IDH1/2 mutation/gCIMP and 1p/19q co-
deletion, have been employed to define three major prognostic groups of WHO grade III 
gliomas [39]. The present study explored whether large-scale genomic or transcriptomic 
profiling improves prognostic stratification in comparison to histology and established 
molecular markers like IDH1/2 mutation and 1p/19q co-deletion in WHO grade II and III 
gliomas. 
Genomic and expression profiling each revealed groups of tumors with distinct genetic 
imbalance and gene expression patterns (Figs. 1-3). However, the independently identified 
genomic and transcriptomic groups only partially overlapped. Prognostic evaluation of 
molecular subgrouping revealed the worst survival for patients whose tumors showed a 
glioblastoma-like genomic profile associated with IDH1/2 wild-type status, frequent gains on 
7q and losses on 10q, often a classical glioblastoma-like expression profile, and mostly 
anaplastic astrocytic or oligoastrocytic histology (Fig. 4). Most tumors in this group 
additionally demonstrated gene amplifications and TERT promoter mutations. However, 
despite sharing genomic imbalances and expression signature with primary glioblastomas, 
patients with these tumors may survive longer than IDH1/2 wild-type glioblastoma patients 
(Figs. 2B and 4B), although less than 50% received combined radiochemotherapy as up-front 
treatment (Supplementary Table 8). Our findings thus suggest that the absence of histological 
features of glioblastoma, that is microvascular proliferation and necrosis, in IDH1/2 wild-type 
gliomas with glioblastoma-like genotypes is of prognostic relevance. In line, retrospective 
analyses of the NOA-04 cohort of anaplastic glioma patients and glioblastoma patients of the 
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GGN similarly indicated a longer survival of patients with IDH1/2 wild-type anaplastic 
gliomas compared to patients with IDH1/2 wild-type glioblastomas [11, 39]. However, this 
assumption would need confirmation in an independent larger cohort of patients who ideally 
should have received identical treatment. 
The best outcome was detected in patients whose tumors were characterized by IDH1/2 
mutation, 1p/19q co-deletion and oligodendroglial or oligoastrocytic histology. The majority 
of these tumors demonstrated a proneural glioblastoma-like expression profile, which has 
previously been associated with favorable outcome and oligodendroglial as opposed to 
astrocytic tumors [5, 7]. Moreover, the important role of 1p/19q co-deletion in anaplastic 
glioma patients has been shown in three independent prospective phase III trials [2, 32, 36], 
with recent long-term follow-up data indicating a predictive role of this biomarker for 
favorable response to upfront combined radiochemotherapy [3, 31]. Our present data lend 
further support to the importance of 1p/19q testing for reliable identification of the 
biologically and clinically distinct group of glioma patients showing favorable outcome with 
the current treatment options (genomic group I). Moreover, our data suggest that 1p/19q 
deletion testing is sufficient to define this particular patient group, i.e. no additional tests for 
other chromosomal aberrations, gene mutations or expression profiles appear to be required in 
the diagnostic setting. 450 k methylation bead-array profiling data of the NOA-04 biomarker 
cohort of anaplastic (WHO grade III) glioma patients independently validate the prognostic 
distinction of a gCIMP positive and 1p/19q co-deleted subgroup of patients with favorable 
outcome [39], which essentially corresponds to our IDH1/2 mutant and 1p/19q co-deleted 
genomic group I. 
The other three genomic groups II-IV defined in this study were associated with similar 
prognoses, i.e. patients demonstrated intermediate PFS and OS when compared to genomic 
group I or V patients. Again, this finding fits well to the recent NOA-04 data demonstrating 
intermediate survival for patients with gCIMP positive, 1p/19q intact and ATRX 
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mutant/deficient anaplastic gliomas [39]. However, our intermediate survival group included 
not only patients with IDH1/2 mutant astrocytic or oligoastrocytic gliomas without 1p/19q co-
deletion, but also a small group of patients with IDH1/2 wild-type tumors, i.e. genomic group 
IV. This finding could be clinically important as it suggests that the absence of IDH1/2 hot 
spot mutations in diffuse and anaplastic gliomas may not invariably be linked to less 
favorable outcome when compared to IDH1/2 mutant tumors without 1p/19q co-deletion. Our 
data suggest that the association of IDH1/2 wild-type status with poor survival is mainly 
restricted to those patients whose tumors additionally carry glioblastoma-like genomic 
aberrations, in particular gains on 7q combined with losses on 10q (+7q/-10q). This has 
implications for genetic testing and biomarker-based prognostic stratification, as the sole 
demonstration of IDH1/2 wild-type status may not be sufficient to assume a particularly poor 
outcome. In fact, additional testing for +7q/-10q would be necessary to identify the IDH1/2 
wild-type WHO grade II and III gliomas associated with particularly poor outcome, and 
possibly stratify these patients into a distinct treatment regimen. In addition, these group V 
patients should probably be excluded from future clinical trials on anaplastic glioma patients. 
Admittedly, it is possible that some of these tumors were initially undergraded simply because 
of sampling error although none of the diagnoses in this group were made by biopsy alone. 
Whether the rare patients with IDH1/2 mutant gliomas carrying the +7q/-10q genomic profile 
(6 of 115 patients in our cohort, 5.2%) should be similarly separated from the bulk of patients 
with IDH1/2 mutant gliomas in terms of future trials and clinical management remains to be 
determined. Recent data indicate that IDH1/2 mutation, even in the absence of 1p/19q co-
deletion, may be linked to more favorable response of anaplastic gliomas to procarbazine, 
CCNU and vincristine (PCV) chemotherapy when compared to IDH1/2 wild-type tumors [4]. 
However, the authors did not further stratify the IDH1/2 wild-type tumors in this study 
according to their +7q/-10q status. Conversely, the absence of IDH1/2 mutations has 
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previously been proposed to be linked to a specific predictive value of MGMT promoter 
methylation for benefit from alkylating agent chemotherapy [37]. 
While our study indicates an important role for molecular classification of diffuse and 
anaplastic gliomas, it also supports a role for histological grading according to the WHO 
criteria, since molecular profiling did not allow for reliable distinction of tumor grades. As 
stated above, patients with WHO grade III anaplastic gliomas with glioblastoma-like genetic 
imbalances appear to show better survival than patients with histologically classic WHO 
grade IV glioblastoma. Moreover, our data suggest that WHO grade tends to be 
prognostically relevant in patients with 1p/19q co-deleted (group I) tumors as well as in 
patients with group II-IV tumors. However, these findings would need to be corroborated on 
larger and homogeneously treated patient series. 
In line with previous studies [24, 27, 29], group-wise comparisons of expression profiling 
data revealed sets of genes showing differential expression in oligodendroglial versus 
astrocytic gliomas and/or 1p/19q co-deleted versus 1p/19q intact gliomas. Comparison of the 
sets of differentially expressed genes identified in our cohort (Supplementary Tables 9,10) 
with those reported before [24, 28] revealed considerable overlaps (data not shown). 
Identified candidate genes included published markers such as ATRX [15, 21, 38] and alpha-
internexin (INA) [6], but also novel candidates (Supplementary Tables 7 and 8). The 
diagnostic utility of these candidate genes as surrogate markers for 1p/19q co-deletion, e.g. by 
immunohistochemical analysis, remains to be determined. We also detected sets of genes 
whose expression differed significantly between IDH1/2 mutant gliomas of WHO grade II or 
WHO grade III (Supplementary Table 10). It remains to be demonstrated whether any of 
these candidate genes may serve as a diagnostically useful marker for glioma grading.  
In conclusion, our large-scale molecular profiling of WHO grade II and III cerebral gliomas 
provides important results for improving future classification of these tumors into clinically 
useful categories based on the integration of histological findings and defined molecular 
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markers as recently proposed by the Haarlem Consensus Meeting [23]. Specifically, our 
findings support that patients with IDH1/2 mutant gliomas can be molecularly stratified into 
two prognostically distinct groups corresponding either to patients with 1p/19q co-deleted 
oligodendrogliomas or patient with 1p/19q intact astrocytomas. IDH1/2 mutant 
oligoastrocytomas can be molecular assigned to either of these groups, thus supporting that 
oligoastrocytoma does not constitute a molecularly distinct glioma entity [27]. In patients 
with IDH1/2 wild-type diffuse and anaplastic gliomas, presence of a +7q/-10q glioblastoma-
like genomic signature was linked to poor outcome. However, whether this molecular profile 
is sufficient to switch the histological diagnosis of a WHO grade II or III glioma to WHO 
grade IV glioblastoma is currently unclear and will be a point of discussion for the up-coming 
revision of the WHO classification. In summary, molecular biomarker-based classification of 
diffuse and anaplastic gliomas may not only improve diagnostic accuracy but will also 
facilitate clinical decision making, and needs to be considered for patient stratification in 
future prospective interventional trials. 
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TABLES 
Table 1. Patient characteristics. 
 N=137 
Age (years) 
  Median 
  Range 
 
41 
21-80 
Gender 
  Male 
  Female 
 
84 (61.3%) 
53 (38.7%) 
KPS 
  Median 
  Range 
 
90 
60-100 
  80-100 
  70 or less 
  Unknown 
114 (94.2%) 
    7 (5.8%) 
  16 
Histological diagnosis 
  Diffuse astrocytoma (A2) 
  Oligoastrocytoma (OA2) 
  Oligodendroglioma (O2) 
  Anaplastic astrocytoma (AA3) 
  Anaplastic oligoastrocytoma (AOA3) 
  Anaplastic oligodendroglioma (AO3) 
 
45 (32.8%) 
13 (9.5%) 
  3 (2.2%) 
42 (30.7%) 
31 (22.6%) 
 3 (2.2%) 
IDH1/2 status 
  Mutant 
  Wild-type 
 
115 (83.9%) 
 22 (16.1%) 
1p/19q status 
  1p/19q co-deleted 
  1p/19q non-co-deleted 
 
   37 (27.0%) 
 100 (73.0%) 
MGMT promoter status 
  Unmethylated 
  Weakly methylated 
  Strong methylated 
  Unknown 
 
  25 (18.4%) 
  13 (9.6%) 
  98 (72.1%) 
  1 
TERT promoter status 
  Mutant 
  Wild-type 
  Unknown 
 
  45 (33.8%) 
  88 (66.2%) 
  4 
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Table 2. Multivariate analysis based on clinical and histological parameters as well 
as genomic groups determined by array-CGH analysis and IDH1/2 mutation status 
(groups I – V).  
 
Model Factor HR 95% CI P 
value 
Model fit 
deviance 
Improvement 
1 Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
Age > 40 vs. < 40 (ref) 
2.59 
1.71 
4.40 
1.30 - 5.15 
0.92 - 3.20 
2.21 - 8.79 
0.007 
0.090 
<0.001 
374.02 Model 1 to 
null model:  
p<0.001 
2 Age > 40 vs. < 40 (ref) 
Groups II+ III+ IV vs. group I (ref) 
Group V vs. group I (ref) 
 
3.99 
3.81 
8.28 
 
1.95 - 8.16 
1.46 - 9.93 
2.78 - 24.71 
<0.001 
0.006 
<0.001 
 
366.33 Model 2 to 
null model:  
p<0.001 
3 Age >40 vs. < 40 (ref) 
Groups II+III+IV vs. group I (ref) 
Group V vs. group I (ref) 
Astrocytic vs. oligodendroglial (ref) 
WHO grade III vs. WHO grade II (ref) 
4.00 
3.42 
6.45 
1.36 
1.55 
1.94 - 8.25 
1.20 - 9.80 
1.93 - 21.60 
0.64 - 2.91 
0.82 - 2.93 
<0.001 
0.022 
0.002 
0.426 
0.175 
364.03 Model 3 to 2: 
p=0.318 
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FIGURE LEGENDS 
 
Fig. 1. Results of array-CGH analyses. A. Unsupervised analysis of genomic profiles in 137 WHO 
grade II and III gliomas distinguishes three major clusters, one with all 1p/19q co-deleted IDH1/2 
mutant tumors (left), one mostly including IDH1/2 mutant tumors without 1p/19q co-deletion 
(middle), and one mostly including IDH1/2 wildtype tumors with +7q/-10q (right). Shown is a heat 
map indicating genomic losses in green and genomic gains in red. The individual chromosomal bands 
are indicated on the left side of the heat map. The color bars on top of each heat map refer to the 
histological classification (1), as well as the status of MGMT promoter methylation (2), TERT 
promoter mutation (3), 1p/19q co-deletion (4) and IDH1/2 mutation (5) in each tumor. B. Supervised 
analyses of array-CGH data stratified by IDH1/2 status revealed three distinct molecular groups 
among the IDH1/2-mutant gliomas (groups I-III), with group I including all 1p/19q co-deleted tumors, 
while group II and III tumors lacked 1p/19q co-deletion but demonstrated either gains of 7 or 7q 
(group II) or multiple gains on other chromosomes (group III). IDH1/2 wild-type gliomas comprised 
two distinct tumor groups: one characterized by relatively few genomic aberrations affecting diverse 
chromosomes (group IV) while the other (group V) was characterized by a glioblastoma-like genomic 
pattern with gain of 7 or 7q and loss of 10 or 10q as marker lesions. 
 
Fig. 2. Genomic imbalance patterns according to genomic group and relationship to patients outcome. 
A. Frequency plots of genomic imbalances detected in each of the five genomic groups and, for 
reference, a previous series of IDH1/2 wild-type primary glioblastomas [26]. Results are stratified 
according to the IDH1/2 mutation status (left side: IDH1/2 mutant tumor groups; right side: IDH1/2 
wild-type tumor groups). Gains of genomic material are indicated by green bars while losses are 
indicated by red bars. The bar length indicates the percentage of tumors in each group showing gains 
or losses at the respective chromosomal location. The individual chromosomes are indicated on the 
bottom and top of each frequency plot, with markers on each chromosomes being sorted from pter on 
the left to qter on the right. B. Progression-free survival (left) and overall survival (right) of patients 
stratified according to the five genomic groups defined by array-CGH analysis. For reference, survival 
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of a previously published GGN cohort of 270 patients with IDH1/2 wild-type primary glioblastoma 
WHO grade IV (GB IV) is shown [34]. Note that patients with group I tumors (IDH1/2 mutant, 1p/19q 
co-deleted) had the best survival, while patients with group V tumors (IDH1/2 wild-type, +7/-10q) 
showed the worst survival. However, median overall survival of group V patients was still longer 
when compared to primary glioblastoma patients. Patients with group II-IV tumors showed similar 
outcomes, with survival curves running between those of group I and group V patients. 
 
Fig. 3. Results of mRNA expression profiling. A. Pairwise correlation matrices stratified according to 
IDH1/2 status (left, wild-type tumors; right, mutant tumors). Note that 3 distinct expression groups 
(groups 1-3) were delineated in IDH1/2 wild-type tumors while the IDH1/2 mutant tumors were 
stratified in 5 distinct groups (groups 4-8). The color bars on top of each correlation matrix refer to the 
histological classification (1), as well as the status of MGMT promoter methylation (2), TERT 
promoter mutation (3), 1p/19q co-deletion (4), IDH1/2 mutation (5), and the genomic group defined 
by array-CGH analysis for each tumor (6). B. PFS and OS in the 8 patient groups defined by 
expression profiling. Survival curves of an unselected cohort of 270 IDH1/2 wild-type glioblastoma 
patients [34] were added for comparison.  
 
Fig. 4. Molecular classification of WHO grade II and III gliomas based on genomic profiling data. A. 
Supervised pairwise correlation matrix of metagene expression data obtained by SOM analysis 
stratified according to IDH1/2 status and genomic groups I – V identified by array-CGH analysis. The 
color bars on top refer to the histological classification (1), as well as the status of MGMT promoter 
methylation (2), TERT promoter mutation (3), 1p/19q co-deletion (4), expression group (5) IDH1/2 
mutation (6), and genomic group defined by array-CGH analysis (7). Note that genomic group I 
(IDH1/2 mutant, 1p/19q co-deleted) tumors and group V (IDH1/2 wild-type, +7q/-10q) tumors show 
an enrichment for distinct expression profiles, i.e. expression group 7 or expression group 1, further 
strengthening the hypothesis that these two groups reflect biologically distinct tumor entities. Genomic 
groups II – IV show expression profiles distinct from group 1 and group 5, however, cannot be 
separated by distinctive expression profiles from each other. Since these groups shared similar patient 
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outcomes (Fig. 2B), we combined them into a single group II-IV for further prognostic correlations. B. 
Progression-free (PFS) and overall survival (OS) according to the three major genomic groups I, II-IV 
or V. A cohort of patients with IDH1/2 wild-type glioblastoma WHO grade IV (GB IV) published 
previously [34] is included for comparison. C, PFS and OS in the three major genomic groups 
stratified by WHO grade (grade II vs III) in groups I and II-IV. D. PFS and OS in groups I and II-IV 
stratified by patient age (≤ 40 years vs >40 years). Patients in group V were all > 40 years old and 
except for two patients had WHO grade III tumors. Thus, group V was not further stratified according 
to WHO grade and age. 
 
Fig. 5. Expression profiles in 115 IDH1/2 mutant gliomas according to histological classification (A), 
1p/19q status (B) and WHO grade (C). Shown are supervised pairwise correlation matrices based on 
SOM analysis of mRNA expression data for each group-wise comparison. Note distinct expression 
profiles between astrocytic and oligodendroglia/oligoastrocytic tumors (A) as well as 1p/19q intact 
and co-deleted gliomas (B), with differential gene expression differences being more when tumors 
were stratified according to 1p/19q status. Comparison of WHO grade II versus WHO grade III 
gliomas revealed evidence for differential gene expression (C), however, the differences being less 
prominent as compared to those detected between 1p/19q intact versus co-deleted tumors. Lists of 
differentially expressed genes and associated gene ontology terms for each group-wise comparison are 
provided as Supplementary Tables 9-12. 
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